UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
 
Form 10-K
 
 
 
 
 
[X]
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the fiscal year ended December 31, 2018
 
 
or
 
 
[ ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the transition period from _____ to _____
Commission file number: 1-10864
__________________________________________________________ 
UHGLOGO1A10.JPG
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
 
Delaware
 
41-1321939
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota
 
55343
(Address of principal executive offices)
 
(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
______________________________________________________  
Securities registered pursuant to Section 12(b) of the Act:
COMMON STOCK, $.01 PAR VALUE
NEW YORK STOCK EXCHANGE, INC.
(Title of each class)
(Name of each exchange on which registered)
Securities registered pursuant to Section 12(g) of the Act: NONE
__________________________________________________________   
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes [X] No [ ]
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.     Yes [ ] No [X]
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.   [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)
Large accelerated filer
[X]
 
Accelerated filer
[ ]
 
Non-accelerated filer
[ ]
Smaller reporting company
[ ]
 
 
 
 
Emerging growth company
[ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes [ ] No [X]
The aggregate market value of voting stock held by non-affiliates of the registrant as of June 30, 2018 was $ 234,490,429,732 (based on the last reported sale price of $245.34 per share on June 30, 2018, on the New York Stock Exchange), excluding only shares of voting stock held beneficially by directors, executive officers and subsidiaries of the registrant.
As of January 31, 2019, there were 959,538,515 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
The information required by Part III of this report, to the extent not set forth herein, is incorporated by reference from the registrant’s definitive proxy statement relating to its 2019 Annual Meeting of Shareholders. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
 
 
 
 
 




UNITEDHEALTH GROUP
Table of Contents
 
 
 
Page
 
 
 
Part I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Part II
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Part III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Part IV
Item 15.
Item 16.









PART I
ITEM  1.
BUSINESS
INTRODUCTION
Overview
UnitedHealth Group is a diversified health care company dedicated to helping people live healthier lives and helping make the health system work better for everyone. The terms “we,” “our,” “us,” “its,” “UnitedHealth Group,” or the “Company” used in this report refer to UnitedHealth Group Incorporated and its subsidiaries.
Through our diversified family of businesses, we leverage core competencies in data and health information; advanced technology; and clinical expertise. These core competencies are deployed within our two distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
UnitedHealthcare provides health care benefits to an array of customers and markets. UnitedHealthcare Employer & Individual serves employers ranging from sole proprietorships to large, multi-site and national employers, public sector employers and individual consumers. UnitedHealthcare Medicare & Retirement delivers health and well-being benefits for Medicare beneficiaries and retirees. UnitedHealthcare Community & State manages health care benefit programs on behalf of state Medicaid and community programs and their participants. UnitedHealthcare Global includes the provision of health and dental benefits and hospital and clinical services to employer groups and individuals in South America, and other diversified global health businesses.
Optum is a health services business serving the broad health care marketplace, including payers, care providers, employers, governments, life sciences companies and consumers, through its OptumHealth, OptumInsight and OptumRx businesses. These businesses have dedicated units that help improve overall health system performance through optimizing care quality, reducing costs and improving consumer experience and care provider performance, leveraging distinctive capabilities in data and analytics, pharmacy care services, population health, health care delivery and health care operations.
Through UnitedHealthcare and Optum, in 2018, we processed more than three-quarters of a trillion dollars in gross billed charges and we managed more than $250 billion in aggregate health care spending on behalf of the customers and consumers we serve. Our revenues are derived from premiums on risk-based products; fees from management, administrative, technology and consulting services; sales of a wide variety of products and services related to the broad health care industry; and investment and other income. Our two business platforms have four reportable segments:
UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State and UnitedHealthcare Global;
OptumHealth;
OptumInsight; and
OptumRx.
UnitedHealthcare
Through its health benefits offerings, UnitedHealthcare is enabling better health, helping to control rising health care costs and creating a better health care experience for its customers. UnitedHealthcare’s market position is built on:
strong local-market relationships;
the breadth of product offerings, which are responsive to many distinct market segments in health care;
service and advanced technology, including digital consumer engagement;
competitive medical and operating cost positions;
effective clinical engagement;
extensive expertise in distinct market segments; and
innovation for customers and consumers.
UnitedHealthcare utilizes Optum’s capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively and create a simpler consumer experienc e.
In the United States, UnitedHealthcare arranges for discounted access to care through networks that include 1.3 million physicians and other health care professionals and more than 6,000 hospitals and other facilities.

1

Table of Contents


UnitedHealthcare is subject to extensive government regulation. See further discussion of our regulatory environment below under “Government Regulation” and in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
UnitedHealthcare Employer & Individual
UnitedHealthcare Employer & Individual offers an array of consumer-oriented health benefit plans and services nationwide for large national employers, public sector employers, mid-sized employers, small businesses, and individual consumers. UnitedHealthcare Employer & Individual provides access to medical services for 27 million people on behalf of our customers and alliance partners, including employer customers serving people across all 50 states, the District of Columbia and most U.S. territories. Products are offered through affiliates that are licensed as insurance companies, health maintenance organizations (HMOs), or third-party administrators (TPAs). Large employer groups typically use self-funded arrangements where UnitedHealthcare Employer & Individual earns a service fee. Smaller employer groups and individuals are more likely to purchase risk-based products because they are less willing or unable to bear a greater potential liability for health care expenditures.
Through its risk-based product offerings, UnitedHealthcare Employer & Individual assumes the risk of both medical and administrative costs for its customers in return for a monthly premium, which is typically a fixed rate per individual served for a one-year period. When providing administrative and other management services to customers that elect to self-fund the health care costs of their employees and employees’ dependents, UnitedHealthcare Employer & Individual receives a fixed monthly service fee per individual served. These customers retain the risk of financing medical benefits for their employees and employees’ dependents, while UnitedHealthcare Employer & Individual provides services such as coordination and facilitation of medical and related services to customers, consumers and health care professionals, administration of transaction processing and access to a contracted network of physicians, hospitals and other health care professionals, including dental and vision.
The consolidated purchasing capacity represented by the individuals served by UnitedHealth Group makes it possible for UnitedHealthcare Employer & Individual to contract for cost-effective access to a large number of conveniently located care professionals and facilities. UnitedHealthcare Employer & Individual has relationships with network care providers that integrate data and analytics, implement value-based payments and care management programs, and enable us to jointly better manage health care and improve quality across populations.
UnitedHealthcare Employer & Individual typically distributes its products through consultants or direct sales in the larger employer and public sector segments. In the smaller group segment of the commercial marketplace, UnitedHealthcare Employer & Individual’s distribution system consists primarily of direct sales and sales through collaboration with brokers and agents. UnitedHealthcare Employer & Individual also distributes products through wholesale agents or agencies that contract with health insurance carriers to distribute individual or group benefits and provide other related services to their customers. In addition, UnitedHealthcare Employer & Individual distributes its products through professional employer organizations, associations and through both multi-carrier and its own proprietary private exchange marketplaces.
UnitedHealthcare Employer & Individual’s diverse product portfolio offers employers a continuum of benefit designs, price points and approaches to consumer engagement, which provides the flexibility to meet a full spectrum of their coverage needs.
UnitedHealthcare Employer & Individual’s major product families include:
Traditional Products. Traditional products include a full range of medical benefits and network options, and offer a spectrum of covered services, including preventive care, direct access to specialists and catastrophic protection.
Consumer Engagement Products. Consumer engagement products couple plan design with financial accounts to increase individuals’ responsibility for their health and well-being. This suite of products includes high-deductible consumer-driven benefit plans, which include health reimbursement accounts (HRAs), health savings accounts (HSAs) and consumer engagement services such as personalized behavioral incentive programs, consumer education and other digital offerings.
Clinical and Pharmacy Products. UnitedHealthcare Employer & Individual offers a comprehensive suite of clinical and pharmacy care services products, which complement its service offerings by improving quality of care, engaging consumers and providing cost-saving options. Consumers served by UnitedHealthcare Employer & Individual can access clinical products that help them make better health care decisions and better use of their medical benefits, which contribute to improved health and lowered medical expenses.
Each medical plan has a core set of clinical programs embedded in the offering, with additional services available depending on offering type (risk-based or self-funded), line of business (e.g., small business, key accounts, public sector, national accounts or individual consumers) and clinical need. UnitedHealthcare Employer & Individual’s clinical programs include:
wellness programs;
decision support;

2

Table of Contents


utilization management;
case and disease management;
complex condition management;
on-site programs, including biometrics and flu shots;
incentives to reinforce positive behavior change;
mental health/substance use disorder management; and
employee assistance programs.
UnitedHealthcare Employer & Individual’s comprehensive and integrated pharmacy care services promote lower costs by using formulary programs to produce better unit costs, encouraging consumers to use drugs that offer improved value and outcomes, helping consumers take actions to improve their health and supporting the appropriate use of drugs based on clinical evidence through physician and consumer education programs.
Specialty Offerings . Through its broad network, UnitedHealthcare Employer & Individual delivers dental, vision, hearing, life, transportation, critical illness and disability product offerings using an integrated approach in private and retail settings.
UnitedHealthcare Medicare & Retirement
UnitedHealthcare Medicare & Retirement provides health and well-being services to individuals age 50 and older, addressing their unique needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues common among older people. UnitedHealthcare Medicare & Retirement is fully dedicated to serving this growing senior market segment, providing products and services in all 50 states, the District of Columbia and most U.S. territories. UnitedHealthcare Medicare & Retirement has distinct pricing, underwriting, clinical program management and marketing capabilities dedicated to health products and services in this market.
UnitedHealthcare Medicare & Retirement offers a selection of products that allow people to obtain the health coverage and services they need as their circumstances change. UnitedHealthcare Medicare & Retirement is positioned to serve seniors who find that affordable, network-based care provided through Medicare Advantage plans meets their unique health care needs. For those who prefer traditional fee-for-service Medicare, UnitedHealthcare Medicare & Retirement offers both Medicare Supplement and Medicare Prescription Drug Benefit (Medicare Part D) prescription drug programs that supplement their government-sponsored Medicare by providing additional benefits and coverage options. UnitedHealthcare Medicare & Retirement services include care management and clinical management programs, a nurse health line service, 24-hour access to health care information, access to discounted health services from a network of care providers and administrative services.
UnitedHealthcare Medicare & Retirement has extensive distribution capabilities and experience, including direct marketing to consumers on behalf of its key clients, including AARP, the nation’s largest membership organization dedicated to the needs of people age 50 and over, and state and U.S. government agencies. Products are also offered through employer groups and agent channels.
UnitedHealthcare Medicare & Retirement’s major product categories include:
Medicare Advantage. UnitedHealthcare Medicare & Retirement provides health care coverage for seniors and other eligible Medicare beneficiaries primarily through the Medicare Advantage program administered by the Centers for Medicare & Medicaid Services (CMS), including Medicare Advantage HMO plans, preferred provider organization (PPO) plans, Point-of-Service plans, Private-Fee-for-Service plans and Special Needs Plans (SNPs). Under the Medicare Advantage program, UnitedHealthcare Medicare & Retirement provides health insurance coverage in exchange for a fixed monthly premium per member from CMS plus, in some cases, monthly consumer premiums. Premium amounts received from CMS vary based on the geographic areas in which individuals reside; demographic factors such as age, gender and institutionalized status; and the health status of the individual. Medicare Advantage plans are designed to compete at the local level, taking into account consumer and care provider preferences, competitor offerings, our quality and cost initiatives, our historical financial results and the long-term payment rate outlook for each geographic area. UnitedHealthcare Medicare & Retirement served 4.9 million people through its Medicare Advantage products as of December 31, 2018.
Built on more than 20 years of experience, UnitedHealthcare Medicare & Retirement’s senior-focused care management model operates at a medical cost level below that of traditional Medicare, while helping seniors live healthier lives. Through our HouseCalls program, nurse practitioners performed 1.5 million in-home preventive care visits in 2018 to address unmet care opportunities and close gaps in care. Our Navigate4Me program provides a single point of contact and a direct line of support for individuals as they go through their health care experiences. For high-risk patients in certain care settings and programs, UnitedHealthcare Medicare & Retirement uses proprietary, automated medical record software that enables clinical care teams

3

Table of Contents


to capture and track patient data and clinical encounters, creating a comprehensive set of care information that bridges across home, hospital and nursing home care settings. Proprietary predictive modeling tools help identify people at high risk and enable care managers to create individualized care plans that help them obtain the right care, in the right place, at the right time.
Medicare Part D. UnitedHealthcare Medicare & Retirement provides Medicare Part D benefits to beneficiaries throughout the United States and its territories through its Medicare Advantage and stand-alone Medicare Part D plans. The stand-alone Medicare Part D plans address a large spectrum of people’s needs and preferences for their prescription drug coverage, including low-cost prescription options. Each of the plans includes the majority of the drugs covered by Medicare and provides varying levels of coverage to meet the diverse needs of Medicare beneficiaries. As of December 31, 2018, UnitedHealthcare enrolled 9.0 million people in the Medicare Part D programs, including 4.7 million individuals in the stand-alone Medicare Part D plans, with the remainder in Medicare Advantage plans incorporating Medicare Part D coverage.
Medicare Supplement. UnitedHealthcare Medicare & Retirement is currently serving 4.9 million seniors nationwide through various Medicare Supplement products in association with AARP. UnitedHealthcare Medicare & Retirement offers a full range of supplemental products at a diversity of price points. These products cover various levels of coinsurance and deductible gaps that seniors are exposed to in the traditional Medicare program.
Premium revenues from CMS represented 30% of UnitedHealth Group’s total consolidated revenues for the year ended December 31, 2018, most of which were generated by UnitedHealthcare Medicare & Retirement.
UnitedHealthcare Community & State
UnitedHealthcare Community & State is dedicated to serving state programs that care for the economically disadvantaged, the medically underserved and people without the benefit of employer-funded health care coverage, in exchange for a monthly premium per member from the state program. In some cases, these premiums are subject to experience or risk adjustments. UnitedHealthcare Community & State’s primary customers oversee Medicaid plans, including Temporary Assistance to Needy Families (TANF), Children’s Health Insurance Programs (CHIP), Dual SNPs (DSNPs), Aged, Blind and Disabled and other federal, state and community health care programs. As of December 31, 2018, UnitedHealthcare Community & State participated in programs in 30 states and the District of Columbia, and served 6.5 million people; including 1 million people through Medicaid expansion programs in 15 states under the Patient Protection and Affordable Care Act (ACA).
States using managed care services for Medicaid beneficiaries select health plans by using a formal bid process or by awarding individual contracts. A number of factors are considered by UnitedHealthcare Community & State when choosing programs for participation, including the state’s commitment and consistency of support for its Medicaid managed care program in terms of service, innovation and funding; the eligible population base, both immediate and long term; and the structure of the projected program. UnitedHealthcare Community & State works with its state customers to advocate for actuarially sound rates, commensurate with medical cost trends.
These health plans and care programs are designed to address the complex needs of the populations they serve, including the chronically ill, people with disabilities and people with a higher risk of medical, behavioral and social conditions. UnitedHealthcare Community & State administers benefits for the unique needs of children, pregnant women, adults, seniors and those who are institutionalized or are nursing home eligible. These individuals often live in areas that are medically underserved and are less likely to have a consistent relationship with the medical community or a care provider. They also often face significant social and economic challenges.
UnitedHealthcare Community & State leverages the national capabilities of UnitedHealth Group locally, supporting effective care management, strong regulatory partnerships, greater administrative efficiency, improved clinical outcomes and the ability to adapt to a changing national and local market environment. UnitedHealthcare Community & State coordinates resources among family, physicians, other health care providers, and government and community-based agencies and organizations to facilitate continuous and effective care and often addresses other social determinants that can affect people’s health status and health system usage.
Approximately 75% of the people in state Medicaid programs are served by managed care, but this population represents only 50% of total Medicaid spending. UnitedHealthcare Community & State’s business development opportunities include entering fee-for-service markets converting to managed care, which represents a population of nearly 8 million people; and growing in existing managed care markets, including state expansions to populations with more complex needs requiring more sophisticated models of care. This expansion includes integrated care management of physical, behavioral, long-term care services and supports, and social services by applying strong data analytics and community-based collaboration.
UnitedHealthcare Community & State continues to evolve its clinical model to enhance quality and the clinical experience for the people it serves. The model enables UnitedHealthcare Community & State to quickly identify the people who could benefit most from more highly coordinated care; typically, the 5% who are most at risk drive over 50% of states’ medical costs.

4

Table of Contents


UnitedHealthcare Global
UnitedHealthcare Global serves 6.2 million people with medical benefits, residing principally in Brazil, Chile, Colombia and Peru but also in more than 130 other countries. UnitedHealthcare Global owns and operates more than 300 hospitals, specialty centers, primary care and emergency services clinics in South America and Portugal. UnitedHealthcare Global provides a comprehensive range of health and mobilization capabilities and supports the health systems of individual nations with support for improving health care financing and delivery. Clients include multi-national and local businesses, governments and individual consumers around the world.
Global Markets. UnitedHealthcare Global serves local populations in select markets around the world, primarily in Brazil; Chile; Colombia; Peru; and Portugal, by touching nearly every aspect of health care and leveraging expertise in clinical care management and health care data to improve outcomes, raise quality and constrain costs.
In Brazil, Amil provides health benefits to 4.1 million people through a broad network of owned and affiliated clinics, hospitals and care providers. Dental benefits are also provided to 2.2 million people. Amil’s members have access to a provider network of physicians and other health care professionals, hospitals, laboratories and diagnostic imaging centers. Americas Serviços Médicos offers health care delivery in Brazil through hospitals, ambulatory clinics and surgery centers to Amil members and consumers served by the external payer market.
Empresas Banmédica provides health benefits and health care services to 2.1 million people in Chile, Colombia and Peru through a network of owned and affiliated clinics, hospitals and care providers. Empresas Banmédica owns and operates hospitals, clinics and outpatient centers.
Lusíadas Saúde provides clinical services to people in Portugal through an owned network of hospitals and outpatient clinics.
Global Solutions . UnitedHealthcare Global includes other diversified global health services with a variety of offerings for international customers.
Optum
Optum is a technology-enabled health services business serving the broad health care marketplace, including:
Those who need care: the consumers who need the right support, information, resources and products to achieve their health goals.
Those who provide care: pharmacies, hospitals, physicians, practices and other health care facilities seeking to modernize the health system and support the best possible patient care and experiences.
Those who pay for care: employers, health plans, and state, federal and municipal agencies devoted to ensuring the populations they sponsor receive high-quality care, administered and delivered efficiently and effectively.
Those who innovate for care: global life sciences organizations dedicated to developing more effective approaches to care, enabling technologies and medicines that improve care delivery and health outcomes.
Optum operates three business segments leveraging distinctive capabilities in data and analytics, pharmacy care services, population health, health care delivery and health care operations:
OptumHealth focuses on care delivery, care management, wellness and consumer engagement, and health financial services;
OptumInsight specializes in data and analytics and other health care information technology services, and delivers operational services and support; and
OptumRx provides pharmacy care services.
OptumHealth
OptumHealth is a diversified health and wellness business serving the physical, emotional and health-related financial needs of 93 million unique individuals. OptumHealth enables population health through programs offered by employers, payers, government entities and directly with the care delivery system. OptumHealth products and services deliver value by improving quality and patient satisfaction while lowering cost. OptumHealth builds high-performing networks and centers of excellence across the care continuum, by working directly with physicians to advance population health and by coordinating care for the most medically complex patients.
OptumHealth serves patients and care providers through its local ambulatory care services business and delivers care through a physician-led, patient-centric and data-driven organization comprised of more than 35,000 employed, managed or contracted physicians. OptumHealth also enables care providers’ transition from traditional, fee-for-service care delivery to performance-based delivery and payment models that improve the focus on patient health and outcomes, such as those emerging through

5

Table of Contents


accountable care organizations (ACOs) and local care provider partnerships. Through strategic partnerships, alliances and ownership arrangements, OptumHealth helps care providers adopt new approaches and technologies that improve the coordination of care across all providers involved in patient care. MedExpress’ neighborhood care centers provide urgent and walk-in care services with a consumer-friendly approach and Surgical Care Affiliates’ independent ambulatory surgical centers and surgical hospitals provide high-value surgical services at a substantially lower cost than a traditional in-patient hospital setting.
OptumServe provides a wide range of health services specifically tailored to active military and veterans and the agencies that support them.
OptumHealth serves people through population health services that meet both the preventive care and health intervention needs of consumers across the care continuum - physical health and wellness, mental health, complex medical conditions, disease management, hospitalization and post-acute care. This includes offering access to proprietary networks of provider specialists in many clinical specialties, including behavioral health, organ transplant, chiropractic and physical therapy. OptumHealth engages consumers in managing their health, including guidance, tools and programs that help them achieve their health goals and maintain healthy lifestyles.
Optum Financial Services, through Optum Bank, a wholly-owned subsidiary, serves consumers through 5.2 million health savings and other accounts approaching $10 billion in assets under management as of December 31, 2018. During 2018, Optum Bank processed nearly $160 billion in digital medical payments to physicians and other health care providers. Organizations across the health system rely on Optum to manage and improve payment flows through its highly automated, scalable, digital payment systems.
OptumHealth offers its products on a risk basis, where it assumes responsibility for health care costs in exchange for a monthly premium per individual served, on an administrative fee basis, under which it manages or administers delivery of the products or services in exchange for a fixed monthly fee per individual served, or on a fee-for-service basis, where it delivers medical services to patients in exchange for a contracted fee. For its financial services offerings, OptumHealth charges fees and earns investment income on managed funds.
OptumHealth sells its products primarily through its direct sales force, strategic collaborations and external producers in three markets: employers (which includes the sub-markets of large, mid-sized and small employers), payers (which includes the sub-markets of health plans, TPAs, underwriter/stop-loss carriers and individual market intermediaries) and government entities (which includes states, CMS, the Department of Defense, the Veterans Administration and other federal procurement agencies).
OptumInsight
OptumInsight provides services, technology and health care expertise to major participants in the health care industry. OptumInsight’s capabilities are focused on technology, research and consulting and managed services that help improve the quality of care and drive greater efficiency in the health care system. Technology includes population health and risk analytics, administrative and clinical technology for claims editing, risk adjustment and payment integrity, health information and electronic data exchange and technology strategy and management. Research and consulting helps organizations reduce administrative costs and implement best practices to improve clinical performance. Managed services provides solutions such as revenue cycle management, risk analytics, payment integrity outsourcing and state Medicaid data and technology management. Hospital systems, physicians, health plans, governments, life sciences companies and other organizations that comprise the health care industry depend on OptumInsight to help them improve performance, achieve efficiency, reduce costs, advance quality, meet compliance mandates and modernize their core operating systems to meet the changing needs of the health system.
Many of OptumInsight’s software and information products and professional services are delivered over extended periods, often several years. OptumInsight maintains an order backlog to track unearned revenues under these long-term arrangements. The backlog consists of estimated revenue from signed contracts, other legally binding agreements and anticipated contract renewals based on historical experience with OptumInsight’s customers. OptumInsight’s aggregate backlog at December 31, 2018 was $17.0 billion, of which $8.6 billion is expected to be realized within the next 12 months. The aggregate backlog includes $6.2 billion related to intersegment agreements. OptumInsight’s aggregate backlog at December 31, 2017, was $15.0 billion. OptumInsight cannot provide any assurance that it will be able to realize all of the revenues included in the backlog due to uncertainties with regard to the timing and scope of services and the potential for cancellation, non-renewal or early termination of service arrangements.
OptumInsight’s products and services are sold primarily through a direct sales force. OptumInsight’s products are also supported and distributed through an array of alliances and business partnerships with other technology vendors, who integrate and interface OptumInsight’s products with their applications.

6

Table of Contents


OptumInsight believes it is well positioned to address the needs of four primary market segments: care providers (e.g., physicians and hospital systems), health plans, governments and life sciences companies.
Care Providers. Serving more than four out of five U.S. hospitals and more than 100,000 physicians, OptumInsight assists care providers in meeting their challenge to improve patient outcomes and care amid changing payment models and pressures. OptumInsight brings a broad array of solutions to help care providers meet these challenges, with particular focus on clinical performance and quality improvement, population health, data management and analytics, revenue management, cost containment, compliance, cloud-enabled collaboration and consumer engagement.
Health Plans. OptumInsight serves three out of four U.S. health plans through cost-effective, technology-enabled solutions that help them improve efficiency, understand and optimize growth while managing risk, deliver on clinical performance and compliance goals, and build and manage strong networks of care.
Governments. OptumInsight provides services tailored to government payers, including data and analytics technology, claims management and payment accuracy services, and strategic consulting.
Life Sciences. OptumInsight provides services to global life sciences companies. These companies look to OptumInsight for data, analytics and expertise in core areas of health economics and outcomes research, market access consulting, integrated clinical and health care claims data and informatics services, epidemiology and drug safety, and patient reported outcomes.
OptumRx
OptumRx provides a full spectrum of pharmacy care services to 65 million people in the United States through its network of more than 67,000 retail pharmacies, multiple home delivery, specialty and compounding pharmacies and through the provision of home infusion services. In 2018, OptumRx added capabilities in managing limited and ultra-limited distribution drugs in oncology, HIV, pain management and ophthalmology as well as capabilities to serve the growing pharmacy needs of people with behavioral health and substance use disorders, particularly Medicare and Medicaid beneficiaries.
OptumRx’s comprehensive whole-person approach to pharmacy care services integrates demographic, medical, laboratory, pharmaceutical and other clinical data and applies analytics to drive clinical care insight to support care treatments and compliance, benefiting clients and individual consumers through enhanced services, elevated clinical quality and cost trend management.
In 2018, OptumRx managed $91 billion in pharmaceutical spending, including $40 billion in specialty pharmaceutical spending.
OptumRx provides pharmacy care services to a number of health plans, including a substantial majority of UnitedHealthcare members, large national employer plans, unions and trusts and government entities. OptumRx’s distribution system consists primarily of health insurance brokers and other health care consultants and direct sales.
OptumRx offers multiple clinical programs and services to help clients manage overall pharmacy and health care costs in a clinically appropriate manner, which are designed to promote good health outcomes, and to help target inappropriate utilization and non-adherence to medication, each of which may result in adverse medical events that affect member health and client pharmacy and medical spend. OptumRx provides various utilization management, medication management, quality assurance, adherence and counseling programs to complement the client’s plan design and clinical strategies. OptumRx offers a distinctive approach to integrating the management of medical and pharmaceutical care, using data and advanced analytics to help improve comprehensive decision-making, elevate quality, close gaps in care and reduce costs for customers and members.
As of December 31, 2018, OptumRx operated four home delivery pharmacies in the United States, which provide patients with access to maintenance medications and enables OptumRx to manage clients’ drug costs through operating efficiencies and economies of scale. As of December 31, 2018, OptumRx’s specialty pharmacy operations included more than 70 specialty and infusion pharmacies located throughout the United States that are used for delivery of advanced medications to people with chronic or genetic diseases and disorders. OptumRx also operates community mental health facility pharmacies, which help align benefits, care management and pharmacy services for those living with complex, chronic medical and behavioral health issues.

7

Table of Contents


GOVERNMENT REGULATION
Our businesses are subject to comprehensive federal, state and international laws and regulations. We are regulated by federal, state and international regulatory agencies that generally have discretion to issue regulations and interpret and enforce laws and rules. The regulations can vary significantly from jurisdiction to jurisdiction and the interpretation of existing laws and rules also may change periodically. Domestic and international governments continue to enact and consider various legislative and regulatory proposals that could materially impact certain aspects of the health care system. New laws, regulations and rules, or changes in the interpretation of existing laws, regulations and rules, including as a result of changes in the political climate, could adversely affect our business.
If we fail to comply with, or fail to respond quickly and appropriately to changes in, applicable laws, regulations and rules, our business, results of operations, financial position and cash flows could be materially and adversely affected. See Part I, Item 1A, “Risk Factors” for a discussion of the risks related to our compliance with federal, state and international laws and regulations.

Federal Laws and Regulation
We are subject to various levels of U.S. federal regulation. For example, when we contract with the federal government, we are subject to federal laws and regulations relating to the award, administration and performance of U.S. government contracts. CMS regulates our UnitedHealthcare businesses and certain aspects of our Optum businesses. Payments by CMS to our businesses are subject to regulations, including those governing fee-for-service and the submission of information relating to the health status of enrollees for purposes of determining the amounts of certain payments to us. CMS also has the right to audit our performance to determine our compliance with CMS contracts and regulations and the quality of care we provide to Medicare beneficiaries. Our commercial business is further subject to CMS audits related to medical loss ratios (MLRs) and risk adjustment data.
UnitedHealthcare Community & State has Medicaid and CHIP contracts that are subject to federal regulations regarding services to be provided to Medicaid enrollees, payment for those services and other aspects of these programs. There are many regulations affecting Medicare and Medicaid compliance and the regulatory environment with respect to these programs is complex. We are also subject to federal law and regulations relating to the administration of contracts with federal agencies. In addition, our business is subject to laws and regulations relating to consumer protection, anti-fraud and abuse, anti-kickbacks, false claims, prohibited referrals, inappropriately reducing or limiting health care services, anti-money laundering, securities and antitrust compliance.
The Tax Cuts and Jobs Act . In December 2017, the U.S. federal government enacted a tax bill (Tax Cuts and Jobs Act or Tax Reform). The Tax Cuts and Jobs Act changed existing United States tax law and included numerous provisions that affected our results of operations, financial position and cash flows. For instance, Tax Reform reduced the U.S. corporate income tax rate and changed business-related exclusions and deductions and credits.
Privacy, Security and Data Standards Regulation. The administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996, as amended (HIPAA), apply to both the group and individual health insurance markets, including self-funded employee benefit plans. Federal regulations related to HIPAA contain minimum standards for electronic transactions and code sets and for the privacy and security of protected health information.
The Health Information Technology for Economic and Clinical Health Act (HITECH) imposed requirements on uses and disclosures of health information; included contracting requirements for HIPAA business associate agreements; extended parts of HIPAA privacy and security provisions to business associates; added federal data breach notification requirements for covered entities and business associates and reporting requirements to the U.S. Department of Health and Human Services (HHS) and the Federal Trade Commission (FTC) and, in some cases, to the local media; strengthened enforcement and imposed higher financial penalties for HIPAA violations and, in certain cases, imposed criminal penalties for individuals, including employees. In the conduct of our business, depending on the circumstances, we may act as either a covered entity or a business associate. Federal consumer protection laws may also apply in some instances to privacy and security practices related to personally identifiable information.
The use and disclosure of individually identifiable health data by our businesses is also regulated in some instances by other federal laws, including the Gramm-Leach-Bliley Act (GLBA) or state statutes implementing GLBA. These federal laws and state statutes generally require insurers to provide customers with notice regarding how their non-public personal health and financial information is used and the opportunity to “opt out” of certain disclosures before the insurer shares such information with a third party, and generally prescribe safeguards for the protection of personal information. Neither the GLBA nor HIPAA privacy regulations preempt more stringent state laws and regulations that may apply to us, as discussed below.

8

Table of Contents


ERISA. The Employee Retirement Income Security Act of 1974, as amended (ERISA), regulates how our services are provided to or through certain types of employer-sponsored health benefit plans. ERISA is a set of laws and regulations that is subject to periodic interpretation by the U.S. Department of Labor (DOL) as well as the federal courts. ERISA sets forth standards on how our business units may do business with employers who sponsor employee health benefit plans, particularly those that maintain self-funded plans. Regulations established by the DOL subject us to additional requirements for administration of benefits, claims payment and member appeals under health care plans governed by ERISA.
State Laws and Regulation
Health Care Regulation. Our insurance and HMO subsidiaries must be licensed by the jurisdictions in which they conduct business. All of the states in which our subsidiaries offer insurance and HMO products regulate those products and operations. The states require periodic financial reports and establish minimum capital or restricted cash reserve requirements. The National Association of Insurance Commissioners (NAIC) has adopted model regulations that, where adopted by states, require expanded governance practices and risk and solvency assessment reporting. Most states have adopted these or similar measures to expand the scope of regulations relating to corporate governance and internal control activities of HMOs and insurance companies. We are required to maintain a risk management framework and file a confidential self-assessment report with state insurance regulators. We file reports annually with Connecticut, our lead regulator, and with New York, as required by that state’s regulation. Certain states have also adopted their own regulations for minimum MLRs with which health plans must comply. In addition, a number of state legislatures have enacted or are contemplating significant reforms of their health insurance markets, either independent of or to comply with or be eligible for grants or other incentives in connection with the ACA, which may affect our operations and our financial results.
Health plans and insurance companies are regulated under state insurance holding company regulations. Such regulations generally require registration with applicable state departments of insurance and the filing of reports that describe capital structure, ownership, financial condition, certain intercompany transactions and general business operations. Most state insurance holding company laws and regulations require prior regulatory approval of acquisitions and material intercompany transfers of assets, as well as transactions between the regulated companies and their parent holding companies or affiliates. These laws may restrict the ability of our regulated subsidiaries to pay dividends to our holding companies.
Some of our business activity is subject to other health care-related regulations and requirements, including PPO, Managed Care Organization (MCO), utilization review (UR), TPA, pharmacy care services, durable medical equipment or care provider-related regulations and licensure requirements. These regulations differ from state to state and may contain network, contracting, product and rate, licensing and financial and reporting requirements. There are laws and regulations that set specific standards for delivery of services, appeals, grievances and payment of claims, adequacy of health care professional networks, fraud prevention, protection of consumer health information, pricing and underwriting practices and covered benefits and services. State health care anti-fraud and abuse prohibitions encompass a wide range of activities, including kickbacks for referral of members, billing for unnecessary medical services and improper marketing. Certain of our businesses are subject to state general agent, broker and sales distribution laws and regulations. UnitedHealthcare Community & State and certain of our Optum businesses are subject to regulation by state Medicaid agencies that oversee the provision of benefits to our Medicaid and CHIP beneficiaries and to our dually eligible (for Medicare and Medicaid) beneficiaries. We also contract with state governmental entities and are subject to state laws and regulations relating to the award, administration and performance of state government contracts.
State Privacy and Security Regulations. A number of states have adopted laws and regulations that may affect our privacy and security practices, such as state laws that govern the use, disclosure and protection of social security numbers and protected health information or that are designed to implement GLBA or protect credit card account data. State and local authorities increasingly focus on the importance of protecting individuals from identity theft, with a significant number of states enacting laws requiring businesses to meet minimum cyber-security standards and notify individuals of security breaches involving personal information. State consumer protection laws may also apply to privacy and security practices related to personally identifiable information, including information related to consumers and care providers. Different approaches to state privacy and insurance regulation and varying enforcement philosophies in the different states may materially and adversely affect our ability to standardize our products and services across state lines. See Part I, Item 1A, “Risk Factors” for a discussion of the risks related to compliance with state privacy and security regulations.
Corporate Practice of Medicine and Fee-Splitting Laws. Certain of our businesses function as direct medical service providers and, as such, are subject to additional laws and regulations. Some states have corporate practice of medicine laws that prohibit specific types of entities from practicing medicine or employing physicians to practice medicine. Moreover, some states prohibit certain entities from engaging in fee-splitting practices that involve sharing in the fees or revenues of a professional practice. These prohibitions may be statutory or regulatory, or may be imposed through judicial or regulatory interpretation.

9

Table of Contents


The laws, regulations and interpretations in certain states have been subject to limited judicial and regulatory interpretation and are subject to change.
Pharmacy and Pharmacy Benefits Management (PBM) Regulations
OptumRx’s businesses include home delivery, specialty and compounding pharmacies, as well as clinic-based pharmacies that must be licensed as pharmacies in the states in which they are located. Certain of our home delivery, specialty and compounding pharmacies must also register with the U.S. Drug Enforcement Administration (DEA) and individual state controlled substance authorities to dispense controlled substances. In addition to adhering to the laws and regulations in the states where our home delivery, specialty and compounding pharmacies are located, we also are required to comply with laws and regulations in some non-resident states where we deliver pharmaceuticals, including those requiring us to register with the board of pharmacy in the non-resident state. These non-resident states generally expect our home delivery, specialty and compounding pharmacies to follow the laws of the state in which the pharmacies are located, but some states also require us to comply with the laws of that non-resident state when pharmaceuticals are delivered there. Additionally, certain of our pharmacies that participate in programs for Medicare and state Medicaid providers are required to comply with the applicable Medicare and Medicaid provider rules and regulations. Other laws and regulations affecting our home delivery and specialty pharmacies include federal and state statutes and regulations governing the labeling, packaging, advertising and adulteration of prescription drugs and dispensing of controlled substances. See Part I, Item 1A, “Risk Factors” for a discussion of the risks related to our pharmacy care services businesses.
Federal and state legislation of PBM activities affect both our ability to limit access to a pharmacy provider network or remove network providers. Additionally, many states limit our ability to manage and establish maximum allowable costs for generic prescription drugs. With respect to formulary services, a number of government entities, including CMS, HHS and state departments of insurance, regulate the administration of prescription drug benefits offered through federal or state exchanges. Many states also regulate the scope of prescription drug coverage, as well as the delivery channels to receive such prescriptions, for insurers, MCOs and Medicaid managed care plans. These regulations could limit or preclude (i) certain plan designs, (ii) limited networks, (iii) requirements to use particular care providers or distribution channel, (iv) copayment differentials among providers and (v) formulary tiering practices.
Legislation seeking to regulate PBM activities introduced or enacted at the federal or state level could impact our business practices with others in the pharmacy supply chain, including pharmaceutical manufacturers and network providers. Additionally, organizations like the NAIC periodically issue model regulations and credentialing organizations, like the National Committee for Quality Assurance (NCQA) and the Utilization Review Accreditation Commission (URAC), may establish standards that impact PBM pharmacy activities. While these model regulations and standards do not have the force of law, they may influence states to adopt their recommendations and impact the services we deliver to our clients.
Consumer Protection Laws
Certain of our businesses participate in direct-to-consumer activities and are subject to regulations applicable to on-line communications and other general consumer protection laws and regulations such as the Federal Tort Claims Act, the Federal Postal Service Act and the FTC’s Telemarketing Sales Rule. Most states also have similar consumer protection laws.
Certain laws, such as the Telephone Consumer Protection Act, give the FTC, Federal Communications Commission (“FCC”) and state attorneys general the ability to regulate, and bring enforcement actions relating to, telemarketing practices and certain automated outbound contacts such as phone calls, texts or emails. Under certain circumstances, these laws may provide consumers with a private right of action. Violations of these laws could result in substantial statutory penalties and other sanctions.
Banking Regulation
Optum Bank is subject to regulation by federal banking regulators, including the Federal Deposit Insurance Corporation, which performs annual examinations to ensure that the bank is operating in accordance with federal safety and soundness requirements, and the Consumer Financial Protection Bureau, which may perform periodic examinations to ensure that the bank is in compliance with applicable consumer protection statutes, regulations and agency guidelines. Optum Bank is also subject to supervision and regulation by the Utah State Department of Financial Institutions, which carries out annual examinations to ensure that the bank is operating in accordance with state safety and soundness requirements and performs periodic examinations of the bank’s compliance with applicable state banking statutes, regulations and agency guidelines. In the event of unfavorable examination results from any of these agencies, the bank could become subject to increased operational expenses and capital requirements, enhanced governmental oversight and monetary penalties.

10

Table of Contents


International Regulation
Certain of our businesses operate internationally and are subject to regulation in the jurisdictions in which they are organized or conduct business. These regulatory regimes vary from jurisdiction to jurisdiction. In addition, our non-U.S. businesses and operations are subject to U.S. laws that regulate the conduct and activities of U.S.-based businesses operating abroad, such as the Foreign Corrupt Practices Act (FCPA), which prohibits offering, promising, providing or authorizing others to give anything of value to a foreign government official to obtain or retain business or otherwise secure a business advantage.
COMPETITION
As a diversified health care company, we operate in highly competitive markets across the full expanse of health care benefits and services, including organizations ranging from startups to highly sophisticated Fortune 50 global enterprises, for-profit and non-profit companies, and private and government-sponsored entities. New entrants and business combinations also contribute to a dynamic and competitive environment. We compete fundamentally on the quality and value we provide to those we serve, which can include elements such as product and service innovation; use of technology; consumer and provider engagement and satisfaction; sales, marketing and pricing. See Part I, Item 1A, “Risk Factors” for additional discussion of our risks related to competition.
 
INTELLECTUAL PROPERTY RIGHTS
We have obtained trademark registration for the UnitedHealth Group, UnitedHealthcare and Optum names and logos. We own registrations for certain of our other trademarks in the United States and abroad. We hold a portfolio of patents and have patent applications pending from time to time. We are not substantially dependent on any single patent or group of related patents.
Unless otherwise noted, trademarks appearing in this report are trademarks owned by us. We disclaim any proprietary interest in the marks and names of others.
EMPLOYEES
As of December 31, 2018 , we employed 300,000 individuals.
EXECUTIVE OFFICERS OF THE REGISTRANT
The following sets forth certain information regarding our executive officers as of February 12, 2019 , including the business experience of each executive officer during the past five years:
Name
 
Age
 
Position
Stephen J. Hemsley
 
66
 
Executive Chair of the Board
David S. Wichmann
 
56
 
Chief Executive Officer
Steven H. Nelson
 
59
 
Executive Vice President; Chief Executive Officer of UnitedHealthcare
Andrew P. Witty
 
54
 
Executive Vice President; Chief Executive Officer of Optum
John F. Rex
 
56
 
Executive Vice President; Chief Financial Officer
Thomas E. Roos
 
46
 
Senior Vice President; Chief Accounting Officer
Marianne D. Short
 
67
 
Executive Vice President; Chief Legal Officer
D. Ellen Wilson
 
61
 
Executive Vice President; Chief Human Resources Officer
Our Board of Directors elects executive officers annually. Our executive officers serve until their successors are duly elected and qualified, or until their earlier death, resignation, removal or disqualification.
Mr. Hemsley is Executive Chair of the Board of UnitedHealth Group and has served in that capacity since September 2017. Mr. Hemsley previously served as Chief Executive Officer from 2006 to August 2017. He has been a member of the Board of Directors since 2000.
Mr. Wichmann is Chief Executive Officer of UnitedHealth Group and a member of the Board of Directors and has served in that capacity since September 2017. Mr. Wichmann previously served as President of UnitedHealth Group from November 2014 to August 2017. Mr. Wichmann also served as Chief Financial Officer of UnitedHealth Group from January 2011 to June

11

Table of Contents


2016. From April 2008 to November 2014, Mr. Wichmann served as Executive Vice President of UnitedHealth Group and President of UnitedHealth Group Operations.
Mr. Nelson is Executive Vice President of UnitedHealth Group and Chief Executive Officer of UnitedHealthcare and has served in that capacity since August 2017. Mr. Nelson served as Chief Executive Officer of UnitedHealthcare’s Medicare & Retirement, from March 2014 to August 2017. He served as Chief Executive Officer of UnitedHealthcare Community & State from August 2012 to March 2014. From January 2008 to July 2012 he served as President of UnitedHealthcare Community & State and then as Chief Executive Officer of UnitedHealthcare Employer & Individual’s West Region business.
Mr. Witty is Executive Vice President of UnitedHealth Group and Chief Executive Officer of Optum and has served in that capacity since July 2018. He previously served as a UnitedHealth Group director from August 2017 to March 2018. Prior to joining UnitedHealth Group, Mr. Witty was CEO and a board member of GlaxoSmithKline, a global pharmaceutical company, from 2008 to April 2017.
Mr. Rex is Executive Vice President and Chief Financial Officer of UnitedHealth Group and has served in that capacity since June 2016. From March 2012 to June 2016, Mr. Rex served as Executive Vice President and Chief Financial Officer of Optum. Prior to joining Optum in 2012, Mr. Rex spent over a decade at JP Morgan, a global financial services firm, and its predecessors, concluding his tenure as a Managing Director.
Mr. Roos is Senior Vice President and Chief Accounting Officer of UnitedHealth Group and has served in that capacity since August 2015. Prior to joining UnitedHealth Group, Mr. Roos was a Partner at Deloitte & Touche LLP, an independent registered public accounting firm, from September 2007 to August 2015.
Ms. Short is Executive Vice President and Chief Legal Officer of UnitedHealth Group and has served in that capacity since January 2013. Prior to joining UnitedHealth Group, Ms. Short served as the Managing Partner at Dorsey & Whitney LLP, an international law firm, from January 2007 to December 2012.
Ms. Wilson is Executive Vice President and Chief Human Resources Officer of UnitedHealth Group and has served in that capacity since June 2013. From January 2012 to May 2013, Ms. Wilson served as Chief Administrative Officer of Optum. Prior to joining Optum, Ms. Wilson served for 17 years at Fidelity Investments, concluding her tenure there as head of Human Resources.
Additional Information
UnitedHealth Group Incorporated was incorporated in January 1977 in Minnesota. On July 1, 2015, UnitedHealth Group Incorporated changed its state of incorporation from Minnesota to Delaware pursuant to a plan of conversion. Our executive offices are located at UnitedHealth Group Center, 9900 Bren Road East, Minnetonka, Minnesota 55343; our telephone number is (952) 936-1300.
You can access our website at www.unitedhealthgroup.com to learn more about our company. From that site, you can download and print copies of our annual reports to shareholders, annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with amendments to those reports. You can also download from our website our certificate of incorporation, bylaws and corporate governance policies, including our Principles of Governance, Board of Directors Committee Charters and Code of Conduct. We make periodic reports and amendments available, free of charge, on our website, as soon as reasonably practicable after we file or furnish these reports to the Securities and Exchange Commission (SEC). We will also provide a copy of any of our corporate governance policies published on our website free of charge, upon request. To request a copy of any of these documents, please submit your request to: UnitedHealth Group Incorporated, 9900 Bren Road East, Minnetonka, MN 55343, Attn: Corporate Secretary. Information on or linked to our website is neither part of nor incorporated by reference into this Annual Report on Form 10-K or any other SEC filings.
Our transfer agent, Equiniti (EQ), can help you with a variety of shareholder-related services, including change of address, lost stock certificates, transfer of stock to another person and other administrative services. You can write to our transfer agent at: EQ Shareowner Services, P.O. Box 64854, St. Paul, Minnesota 55164-0854, or telephone (800) 401-1957 or (651) 450-4064.
ITEM 1A.
RISK FACTORS
CAUTIONARY STATEMENTS
The statements, estimates, projections or outlook contained in this Annual Report on Form 10-K include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). When used in this Annual Report on Form 10-K and in future filings by us with the SEC, in our news releases, presentations to securities analysts or investors, and in oral statements made by or with the approval of one of our executive officers, the words “believe,” “expect,”

12

Table of Contents


“intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” or similar words or phrases are intended to identify such forward-looking statements. These statements are intended to take advantage of the “safe harbor” provisions of the PSLRA. These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations expressed or implied in the forward-looking statements. Any forward-looking statement in this report speaks only as of the date of this report and, except as required by law; we undertake no obligation to update any forward-looking statement to reflect events or circumstances, including unanticipated events, after the date of this report.
The following discussion contains cautionary statements regarding our business that investors and others should consider. We do not undertake to address in future filings or communications regarding our business or results of operations how any of these factors may have caused our results to differ from discussions or information contained in previous filings or communications. In addition, any of the matters discussed below may have affected past, as well as current, forward-looking statements about future results. Any or all forward-looking statements in this Annual Report on Form 10-K and in any other public filings or statements we make may turn out to be wrong. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors discussed below will be important in determining our future results. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.
If we fail to estimate, price for and manage our medical costs in an effective manner, the profitability of our risk-based products and services could decline and could materially and adversely affect our results of operations, financial position and cash flows.
Through our risk-based benefit products, we assume the risk of both medical and administrative costs for our customers in return for monthly premiums. Premium revenues from risk-based benefits products comprise nearly 80% of our total consolidated revenues. We generally use approximately 80% to 85% of our premium revenues to pay the costs of health care services delivered to these customers. The profitability of our products depends in large part on our ability to predict, price for and effectively manage medical costs. In addition, our OptumHealth business negotiates capitation arrangements with commercial third-party payers. Under the typical capitation arrangement, the health care provider receives a fixed percentage of a third-party payer’s premiums to cover all or a defined portion of the medical costs provided to the capitated member. If we fail to predict accurately, or effectively price for or manage the costs of providing care to our capitated members, our results of operations could be materially and adversely affected.
We manage medical costs through underwriting criteria, product design, negotiation of favorable provider contracts and care management programs. Total medical costs are affected by the number of individual services rendered, the cost of each service and the type of service rendered. Our premium revenue on commercial policies and Medicaid contracts are typically based on a fixed monthly rate per individual served for a 12-month period and is generally priced one to six months before the contract commences. Our revenue on Medicare policies is based on bids submitted to CMS in June the year before the contract year. Although we base the commercial and Medicaid premiums we charge and our Medicare bids on our estimates of future medical costs over the fixed contract period, many factors may cause actual costs to exceed those estimated and reflected in premiums or bids. These factors may include medical cost inflation, increased use of services, increased cost of individual services, large-scale medical emergencies, the introduction of new or costly drugs, treatments and technology, new treatment guidelines, new mandated benefits (such as the expansion of essential benefits coverage) or other regulatory changes and insured population characteristics. Relatively small differences between predicted and actual medical costs or utilization rates as a percentage of revenues can result in significant changes in our financial results. For example, if our 2018 medical costs for commercial insured products had been 1% higher than our actual medical costs, without proportionally higher revenues from such products, our annual net earnings for 2018 would have been reduced by approximately $305 million, excluding any offsetting impact from risk adjustment or from reduced premium rebates due to minimum MLRs.
In addition, the financial results we report for any particular period include estimates of costs that have been incurred for which claims are still outstanding. These estimates involve an extensive degree of judgment. If these estimates prove inaccurate, our results of operations could be materially and adversely affected.
Our business activities are highly regulated and new laws or regulations or changes in existing laws or regulations or their enforcement or application could materially and adversely affect our business.
We are regulated by federal, state and local governments in the United States and other countries where we do business. Our insurance and HMO subsidiaries must be licensed by and are subject to regulation in the jurisdictions in which they conduct business. For example, states require periodic financial reports and enforce minimum capital or restricted cash reserve requirements. Health plans and insurance companies are also regulated under state insurance holding company regulations and some of our activities may be subject to other health care-related regulations and requirements, including those relating to PPOs, MCOs, UR and TPA-related regulations and licensure requirements. Under state guaranty association laws, certain insurance companies can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of impaired or insolvent insurance companies that write the same line or similar lines of business. Any such assessment could

13

Table of Contents


expose our insurance entities and other insurers to the risk that they would be required to pay a portion of an impaired or insolvent insurance company’s claims through state guaranty associations.
Certain of our businesses provide products or services to various government agencies. For example, some of our UnitedHealthcare and Optum businesses hold government contracts or provide services related to government contracts and are subject to U.S. federal and state and non U.S. self-referral, anti-kickback, medical necessity, risk adjustment, false claims and other laws and regulations governing government contractors and the use of government funds. Our relationships with these government agencies are subject to the terms of contracts that we hold with the agencies and to laws and regulations regarding government contracts. Among others, certain laws and regulations restrict or prohibit companies from performing work for government agencies that might be viewed as an actual or potential conflict of interest. These laws may limit our ability to pursue and perform certain types of work, thereby materially and adversely affecting our results of operations, financial position and cash flows.
Certain of our Optum businesses are also subject to regulations that are distinct from those faced by our insurance and HMO subsidiaries, including, for example, state telemedicine regulations; debt collection laws; banking regulations; distributor and producer licensing requirements; state corporate practice of medicine doctrines; fee-splitting rules; and health care facility licensure and certificate of need requirements, some of which could impact our relationships with physicians, hospitals and customers. These risks and uncertainties may materially and adversely affect our ability to market or provide our products and services, or to do so at targeted operating margins, or may increase the regulatory burdens under which we operate.
The laws and rules governing our businesses and interpretations of those laws and rules are subject to frequent change. For example, legislative, administrative and public policy changes to the ACA are being considered, and we cannot predict if the ACA will be further modified or repealed or replaced. Litigation challenges have been brought seeking to invalidate the ACA in whole or in part; and a federal district court struck down the ACA in its entirety as unconstitutional in 2018. That opinion has been stayed and appealed. Further, the integration into our businesses of entities that we acquire may affect the way in which existing laws and rules apply to us, including by subjecting us to laws and rules that did not previously apply to us. The broad latitude given to the agencies administering, interpreting and enforcing current and future regulations governing our businesses could force us to change how we do business, restrict revenue and enrollment growth, increase our health care and administrative costs and capital requirements, or expose us to increased liability in courts for coverage determinations, contract interpretation and other actions.
We also must obtain and maintain regulatory approvals to market many of our products and services, increase prices for certain regulated products and services and complete certain acquisitions and dispositions or integrate certain acquisitions. For example, premium rates for our health insurance and managed care products are subject to regulatory review or approval in many states and by the federal government. Additionally, we must submit data on all proposed rate increases on many of our products to HHS for monitoring purposes. Geographic and product expansions may be subject to state and federal regulatory approvals. Delays in obtaining necessary approvals or our failure to obtain or maintain adequate approvals could materially and adversely affect our results of operations, financial position and cash flows.
Certain of our businesses operate internationally and are subject to regulation in the jurisdictions in which they are organized or conduct business. These regulatory regimes encompass, among other matters, local and cross-border taxation, licensing, tariffs, intellectual property, investment, capital (including minimum solvency margin and reserve requirements), management control, labor, anti-fraud, anti-corruption and privacy and data protection regulations (including requirements for cross-border data transfers) that vary by jurisdiction. We currently operate outside of the United States and in the future may acquire or commence additional businesses based outside of the United States, increasing our exposure to non-U.S. regulatory regimes. For example, our UnitedHealthcare Global business subjects us to Brazilian laws and regulations affecting hospitals, managed care and insurance industries and to regulation by Brazilian regulators, including the national regulatory agency for private health insurance and plans, the Agência Nacional de Saúde Suplementar, while the Banmédica business is subject to Chilean, Colombian and Peruvian laws, regulations and regulators applicable to hospitals and private insurance. Any international regulator may take an approach to the interpretation, implementation and enforcement of industry regulations that could differ from the approach taken by U.S. regulators. In addition, our non-U.S. businesses and operations are subject to U.S. laws that regulate the conduct and activities of U.S.-based businesses operating abroad, such as the FCPA, which prohibits offering, promising, providing or authorizing others to give anything of value to a foreign government official to obtain or retain business or otherwise secure a business advantage. Our failure to comply with U.S. or non-U.S. laws and regulations governing our conduct outside the United States or to establish constructive relations with non-U.S. regulators could adversely affect our ability to market our products and services, or to do so at targeted operating margins, which may have a material adverse effect on our business, financial condition and results of operations.
The health care industry is regularly subject to negative publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding industry regulation. Negative publicity may adversely affect our stock price and damage our reputation in various markets.

14

Table of Contents


As a result of our participation in various government health care programs, both as a payer and as a service provider to payers, we are exposed to additional risks associated with program funding, enrollments, payment adjustments, audits and government investigations that could materially and adversely affect our business, results of operations, financial position and cash flows.
We participate in various federal, state and local government health care benefit programs, including as a payer in Medicare Advantage, Medicare Part D, various Medicaid programs and CHIP, and receive substantial revenues from these programs. Certain of our Optum businesses also provide services to payers participating in government health care programs. A reduction or less than expected increase, or a protracted delay, in government funding for these programs or change in allocation methodologies, or termination of the contract at the option of the government, may materially and adversely affect our results of operations, financial position and cash flows.
The government health care programs in which we participate generally are subject to frequent changes, including changes that may reduce the number of persons enrolled or eligible for coverage, reduce the amount of reimbursement or payment levels, reduce our participation in certain service areas or markets, or increase our administrative or medical costs under such programs. Revenues for these programs depend on periodic funding from the federal government or applicable state governments and allocation of the funding through various payment mechanisms. Funding for these government programs depends on many factors outside of our control, including general economic conditions and budgetary constraints at the federal or applicable state level. For example, CMS has in the past reduced or frozen Medicare Advantage benchmarks, and additional cuts to Medicare Advantage benchmarks are possible. In addition, from time to time, CMS makes changes to the way it calculates Medicare Advantage risk adjustment payments. Although we have adjusted members’ benefits and premiums on a selective basis, ceased to offer benefit plans in certain counties, and intensified both our medical and operating cost management in response to the benchmark reductions and other funding pressures, these or other strategies may not fully address the funding pressures in the Medicare Advantage program. In addition, payers in the Medicare Advantage program may be subject to reductions in payments from CMS as a result of decreased funding or recoupment pursuant to government audit.
Under the Medicaid managed care program, state Medicaid agencies seek bids from eligible health plans to continue their participation in the acute care Medicaid health programs. If we are not successful in obtaining renewals of state Medicaid managed care contracts, we risk losing the members that were enrolled in those Medicaid plans. Under the Medicare Part D program, to qualify for automatic enrollment of low income members, our bids must result in an enrollee premium below a regional benchmark, which is calculated by the government after all regional bids are submitted. If the enrollee premium is not below the government benchmark, we risk losing the members who were auto-assigned to us and will not have additional members auto-assigned to us. In general, our bids are based upon certain assumptions regarding enrollment, utilization, medical costs and other factors. If any of these assumptions is materially incorrect, either as a result of unforeseen changes to the programs on which we bid, or submission by our competitors at lower rates than our bids, our results of operations, financial position and cash flows could be materially and adversely affected.
Many of the government health care coverage programs in which we participate are subject to the prior satisfaction of certain conditions or performance standards or benchmarks. For example, as part of the ACA, CMS has a system that provides various quality bonus payments to Medicare Advantage plans that meet certain quality star ratings at the individual plan or local contract level. The star rating system considers various measures adopted by CMS, including, among others, quality of care, preventive services, chronic illness management and customer satisfaction. Plans must have a rating of four stars or higher to qualify for bonus payments. If we do not maintain or continue to improve our star ratings, our plans may not be eligible for quality bonuses and we may experience a negative impact on our revenues and the benefits that our plans can offer, which could materially and adversely affect the marketability of our plans, our membership levels, results of operations, financial position and cash flows. Any changes in standards or care delivery models that apply to government health care programs, including Medicare and Medicaid, or our inability to improve our quality scores and star ratings to meet government performance requirements or to match the performance of our competitors could result in limitations to our participation in or exclusion from these or other government programs, which in turn could materially and adversely affect our results of operations, financial position and cash flows.
CMS uses various payment mechanisms to allocate funding for Medicare programs, including adjustment of monthly capitation payments to Medicare Advantage plans and Medicare Part D plans according to the predicted health status of each beneficiary as supported by data from health care providers for Medicare Advantage plans, as well as, for Medicare Part D plans, risk-sharing provisions based on a comparison of costs predicted in our annual bids to actual prescription drug costs. Some state Medicaid programs utilize a similar process. For example, our UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State businesses submit information relating to the health status of enrollees to CMS or state agencies for purposes of determining the amount of certain payments to us. CMS and the Office of Inspector General for HHS periodically perform risk adjustment data validation (RADV) audits of selected Medicare health plans to validate the coding practices of and supporting documentation maintained by health care providers. Certain of our local plans have been selected for such audits, which have in the past resulted and could in the future result in retrospective adjustments to payments made to our health plans, fines, corrective action plans or other adverse action by CMS.

15

Table of Contents


We have been and may in the future become involved in routine, regular and special governmental investigations, audits, reviews and assessments. For example, various governmental agencies have conducted investigations into certain PBM practices, which have resulted in other PBMs agreeing to civil penalties, including the payment of money and corporate integrity agreements. Additionally, such investigations, audits or reviews sometimes arise out of, or prompt claims by private litigants or whistleblowers that, among other allegations, we failed to disclose certain business practices or, as a government contractor, submitted false or erroneous claims to the government. Governmental investigations, audits, reviews and assessments could lead to government actions, which could result in adverse publicity, the assessment of damages, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way we conduct business, loss of licensure or exclusion from participation in government programs, any of which could have a material adverse effect on our business, results of operations, financial position and cash flows.
If we sustain cyber-attacks or other privacy or data security incidents that result in security breaches that disrupt our operations or result in the unintended dissemination of protected personal information or proprietary or confidential information, we could suffer a loss of revenue and increased costs, exposure to significant liability, reputational harm and other serious negative consequences.
We routinely process, store and transmit large amounts of data in our operations, including protected personal information as well as proprietary or confidential information relating to our business or third parties. Some of the data we process, store and transmit may be outside of the United States due to our information technology systems and international business operations. We are regularly the target of attempted cyber-attacks and other security threats and may be subject to breaches of the information technology systems we use. We have programs in place that are intended to detect, contain and respond to data security incidents and that provide employee awareness training regarding phishing, malware and other cyber risks to protect against cyber risks and security breaches. However, because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect for long periods of time, we may be unable to anticipate these techniques or implement adequate preventive measures. Experienced computer programmers and hackers may be able to penetrate our security controls and access, misappropriate or otherwise compromise protected personal information or proprietary or confidential information or that of third-parties, create system disruptions or cause system shutdowns that could negatively affect our operations. They also may be able to develop and deploy viruses, worms and other malicious software programs that attack our systems or otherwise exploit any security vulnerabilities. Hardware, software, or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security. Our facilities and services may also be vulnerable to security incidents or security attacks; acts of vandalism or theft; coordinated attacks by activist entities; misplaced or lost data; human error; malicious social engineering; or other events that could negatively affect our systems, our customers’ data, proprietary or confidential information relating to our business or third parties, or our operations. In certain circumstances we may rely on third party vendors to process, store and transmit large amounts of data for our business whose operations are subject to similar risks.
The costs to eliminate or address the foregoing security threats and vulnerabilities before or after a cyber-incident could be material. Our remediation efforts may not be successful and could result in interruptions, delays, or cessation of service and loss of existing or potential customers. In addition, breaches of our security measures and the unauthorized dissemination of sensitive personal information, proprietary information or confidential information about us or our customers or other third-parties, could expose our customers’ private information and our customers to the risk of financial or medical identity theft, or expose us or other third-parties to a risk of loss or misuse of this information, result in litigation and potential liability, including regulatory penalties, for us, damage our brand and reputation, or otherwise harm our business.
If we fail to comply with applicable privacy, security and data laws, regulations and standards, including with respect to third-party service providers that utilize protected personal information on our behalf, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.
The collection, maintenance, protection, use, transmission, disclosure and disposal of protected personal information is regulated at the federal, state, international and industry levels and requirements are imposed on us by contracts with customers. These laws, rules and requirements are subject to change. Compliance with new privacy and security laws, regulations and requirements may result in increased operating costs, and may constrain or require us to alter our business model or operations. For example, the HITECH amendments to HIPAA imposed further restrictions on our ability to collect, disclose and use protected personal information and imposed additional compliance requirements on our business.
Internationally, many of the jurisdictions in which we operate have established their own data security and privacy legal framework with which we or our customers must comply. We expect that there will continue to be new proposed laws, regulations and industry standards concerning privacy, data protection and information security in the European Union, Brazil, Chile, India and other jurisdictions, and we cannot yet determine the impacts such future laws, regulations and standards may have on our businesses or the businesses of our customers. For example, effective May 2018, the European Union’s General Data Protection Regulation (GDPR) overhauled data protection laws in the European Union. The new regulation superseded

16

Table of Contents


prior European Union privacy and data protection legislation, imposed more stringent European Union data protection requirements on us or our customers, and prescribed greater penalties for noncompliance. Brazilian privacy legislation, similar in certain respects to GDPR, goes into effect in 2020.
Many of our businesses are also subject to the Payment Card Industry Data Security Standard, which is a multifaceted security standard that is designed to protect credit card account data.
HIPAA requires business associates as well as covered entities to comply with certain privacy and security requirements. While we provide for appropriate protections through our contracts with our third-party service providers and in certain cases assess their security controls, we have limited oversight or control over their actions and practices. Several of our businesses act as business associates to their covered entity customers and, as a result, collect, use, disclose and maintain protected personal information in order to provide services to these customers. HHS has announced that it will continue its audit program to assess HIPAA compliance efforts by covered entities and expand it to include business associates. An audit resulting in findings or allegations of noncompliance could have a material adverse effect on our results of operations, financial position and cash flows.
Through our Optum businesses, including our Optum Labs business, we maintain a database of administrative and clinical data that is statistically de-identified in accordance with HIPAA standards. Noncompliance or findings of noncompliance with applicable laws, regulations or requirements, or the occurrence of any privacy or security breach involving the misappropriation, loss or other unauthorized disclosure of protected personal information, whether by us or by one of our third-party service providers, could have a material adverse effect on our reputation and business and, among other consequences, could subject us to mandatory disclosure to the media, loss of existing or new customers, significant increases in the cost of managing and remediating privacy or security incidents and material fines, penalties and litigation awards. Any of these consequences could have a material and adverse effect on our results of operations, financial position and cash flows.
Our businesses providing pharmacy care services face regulatory and operational risks and uncertainties that may differ from the risks of our other businesses.
We provide pharmacy care services through our OptumRx and UnitedHealthcare businesses. Each business is subject to federal and state anti-kickback, beneficiary inducement and other laws that govern the relationships of the business with pharmaceutical manufacturers, physicians, pharmacies, customers and consumers. As a provider of pharmacy benefit management services, OptumRx is also subject to an increasing number of licensure, registration and other laws and accreditation standards that impact the business practices of a pharmacy benefit manager. OptumRx also conducts business through home delivery, specialty and compounding pharmacies, pharmacies located in community mental health centers and home infusion, which subjects it to extensive federal, state and local laws and regulations, including those of the DEA and individual state controlled substance authorities, the FDA and Boards of Pharmacy. In addition, federal and state legislatures regularly consider new regulations for the industry that could materially affect current industry practices, including potential new legislation and regulations regarding the receipt or disclosure of rebates and other fees from pharmaceutical companies, the development and use of formularies and other utilization management tools, the use of average wholesale prices or other pricing benchmarks, pricing for specialty pharmaceuticals, limited access to networks and pharmacy network reimbursement methodologies.
We could face potential claims in connection with purported errors by our home delivery, specialty or compounding or clinic-based pharmacies or the provision of home infusion services, including as a result of the risks inherent in the packaging and distribution of pharmaceuticals and other health care products. Disruptions from any of our home delivery, specialty pharmacy or home infusion services could materially and adversely affect our results of operations, financial position and cash flows.
In addition, our pharmacy care services businesses provide services to sponsors of health benefit plans that are subject to ERISA. A private party or the DOL, which is the agency that enforces ERISA, could assert that the fiduciary obligations imposed by the statute apply to some or all of the services provided by our pharmacy care services businesses even where those businesses are not contractually obligated to assume fiduciary obligations. If a court were to determine that fiduciary obligations apply, we could be subject to claims for breaches of fiduciary obligations or claims that we entered into certain prohibited transactions.
If we fail to compete effectively to maintain or increase our market share, including maintaining or increasing enrollments in businesses providing health benefits, our results of operations, financial position and cash flows could be materially and adversely affected.
Our businesses compete throughout the United States, South America and other foreign markets and face significant competition in all of the geographic markets in which we operate. In particular markets, our competitors, compared to us, may have greater capabilities, resources or market share; a more established reputation; superior supplier or health care professional arrangements; better existing business relationships; lower profit margin or financial return expectations; or other factors that give such competitors a competitive advantage. Our competitive position may also be adversely affected by significant merger

17

Table of Contents


and acquisition activity that has occurred in the industries in which we operate, both among our competitors and suppliers (including hospitals, physician groups and other health care professionals). Consolidation may make it more difficult for us to retain or increase our customer base, improve the terms on which we do business with our suppliers, or maintain or increase profitability.
In addition, our success in the health care marketplace will depend on our ability to develop and deliver innovative and potentially disruptive products and services to satisfy evolving market demands. If we do not continue to innovate and provide products and services that are useful and relevant to consumers, we may not remain competitive, and we risk losing market share to existing competitors and disruptive new market entrants. For example, new direct-to-consumer business models from competing businesses may make it more difficult for us to directly engage consumers in the selection and management of their health care benefits and health care usage, and we may face challenges from new technologies and market entrants that could affect our existing relationship with health plan enrollees in these areas. Our business, results of operations, financial position and cash flows could be materially and adversely affected if we do not compete effectively in our markets, if we set rates too high or too low in highly competitive markets, if we do not design and price our products properly and competitively, if we are unable to innovate and deliver products and services that demonstrate value to our customers, if we do not provide a satisfactory level of services, if membership or demand for other services does not increase as we expect or declines, or if we lose accounts with more profitable products while retaining or increasing membership in accounts with less profitable products.
If we fail to develop and maintain satisfactory relationships with physicians, hospitals and other service providers, our business could be materially and adversely affected.
Our results of operations and prospects are substantially dependent on our continued ability to contract with physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers and other service providers at competitive prices. Any failure by us to develop and maintain satisfactory relationships with health care providers, whether in-network or out-of-network, could materially and adversely affect our business, results of operations, financial position and cash flows. In addition, certain activities related to network design, provider participation in networks and provider payments could result in disputes that may be costly, divert management’s attention from our operations and result in negative publicity.
In any particular market, physicians and health care providers could refuse to contract, demand higher payments, or take other actions that could result in higher medical costs, less desirable products for customers or difficulty meeting regulatory or accreditation requirements. In some markets, certain health care providers, particularly hospitals, physician and hospital organizations or multi-specialty physician groups, may have significant market positions or near monopolies that could result in diminished bargaining power on our part. In addition, ACOs; practice management companies (which aggregate physician practices for administrative efficiency); and other organizational structures adopted by physicians, hospitals and other care providers may change the way in which these providers do business with us and may change the competitive landscape. Such organizations or groups of physicians may compete directly with us, which could adversely affect our business, and our results of operations, financial position and cash flows by impacting our relationships with these providers or affecting the way that we price our products and estimate our costs, which might require us to incur costs to change our operations. In addition, if these providers refuse to contract with us, use their market position to negotiate favorable contracts or place us at a competitive disadvantage, our ability to market products or to be profitable in those areas could be materially and adversely affected.
Our health care benefits businesses have capitation arrangements with some physicians, hospitals and other health care providers. Capitation arrangements limit our exposure to the risk of increasing medical costs, but expose us to risk related to the adequacy of the financial and medical care resources of the health care provider. To the extent that a capitated health care provider organization faces financial difficulties or otherwise is unable to perform its obligations under the capitation arrangement, we may be held responsible for unpaid health care claims that should have been the responsibility of the capitated health care provider and for which we have already paid the provider, under the capitation arrangement. Further, payment or other disputes between a primary care provider and specialists with whom the primary care provider contracts could result in a disruption in the provision of services to our members or a reduction in the services available to our members. Health care providers with which we contract may not properly manage the costs of services, maintain financial solvency or avoid disputes with other providers. Any of these events could have a material adverse effect on the provision of services to our members and our operations.
Some providers that render services to our members do not have contracts with us. In those cases, we do not have a pre-established understanding about the amount of compensation that is due to the provider for services rendered to our members. In some states, the amount of compensation due to these out-of-network providers is defined by law or regulation, but in most instances the amount is either not defined or is established by a standard that does not clearly specify dollar terms. In some instances, providers may believe that they are underpaid for their services and may either litigate or arbitrate their dispute with us or try to recover from our members the difference between what we have paid them and the amount they charged us.
The success of some of our businesses, including OptumHealth and UnitedHealthcare Global, depend on maintaining satisfactory relationships with physicians as our employees, independent contractors or joint venture partners. The physicians that practice medicine or contract with our affiliated physician organizations could terminate their provider contracts or

18

Table of Contents


otherwise become unable or unwilling to continue practicing medicine or contracting with us. There is and will likely be heightened competition in the markets where we operate to acquire or manage physician practices or to employ or contract with individual physicians. If we are unable to maintain or grow satisfactory relationships with physicians, or to acquire, recruit or, in some instances, employ physicians, or to retain enrollees following the departure of a physician, our revenues could be materially and adversely affected. In addition, our affiliated physician organizations contract with competitors of UnitedHealthcare. Our businesses could suffer if our affiliated physician organizations fail to maintain relationships with these companies, or fail to adequately price their contracts with these third-party payers.
In addition, physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers and certain health care providers are customers of our Optum businesses. Physicians also provide medical services at facilities owned by our Optum businesses. Given the importance of health care providers and other constituents to our businesses, failure to maintain satisfactory relationships with them could materially and adversely affect our results of operations, financial position and cash flows.
We are routinely subject to various legal actions due to the nature of our business, which could damage our reputation and, if resolved unfavorably, could result in substantial penalties or monetary damages and materially and adversely affect our results of operations, financial position and cash flows.
We are routinely made party to a variety of legal actions related to, among other matters, the design, management and delivery of our product and service offerings. These matters have included or could in the future include matters related to health care benefits coverage and payment claims (including disputes with enrollees, customers and contracted and non-contracted physicians, hospitals and other health care professionals), tort claims (including claims related to the delivery of health care services, such as medical malpractice by staff at our affiliates’ facilities, or by health care practitioners who are employed by us, have contractual relationships with us, or serve as providers to our managed care networks), whistleblower claims (including claims under the False Claims Act or similar statutes), contract and labor disputes, tax claims and claims related to disclosure of certain business practices. We are also party to certain class action lawsuits brought by health care professional groups and consumers. In addition, we operate in jurisdictions outside of the United States where contractual rights, tax positions and applicable regulations may be subject to interpretation or uncertainty to a greater degree than in the United States, and therefore subject to dispute by customers, government authorities or others. We are largely self-insured with regard to litigation risks. While we maintain excess liability insurance with outside insurance carriers for claims in excess of our self-insurance, certain types of damages, such as punitive damages in some circumstances, are not covered by insurance. Although we record liabilities for our estimates of the probable costs resulting from self-insured matters, it is possible that the level of actual losses will significantly exceed the liabilities recorded.
We cannot predict the outcome of significant legal actions in which we are involved and are incurring expenses in resolving these matters. The legal actions we face or may face in the future could further increase our cost of doing business and materially and adversely affect our results of operations, financial position and cash flows. In addition, certain legal actions could result in adverse publicity, which could damage our reputation and materially and adversely affect our ability to retain our current business or grow our market share in some markets and businesses.
Any failure by us to manage successfully our strategic alliances or complete, manage or integrate acquisitions and other significant strategic transactions or relationships domestically or outside the United States could materially and adversely affect our business, prospects, results of operations, financial position and cash flows.
As part of our business strategy, we frequently engage in discussions with third parties regarding possible investments, acquisitions, divestitures, strategic alliances, joint ventures and outsourcing transactions and often enter into agreements relating to such transactions. For example, we have a strategic alliance with AARP under which we provide AARP-branded Medicare Supplement insurance to AARP members and other AARP-branded products and services to Medicare beneficiaries. If we fail to meet the needs of our alliance or joint venture partners, including by developing additional products and services, providing high levels of service, pricing our products and services competitively or responding effectively to applicable federal and state regulatory changes, our alliances and joint ventures could be damaged or terminated, which in turn could adversely impact our reputation, business and results of operations. Further, if we fail to identify and successfully complete transactions that further our strategic objectives, we may be required to expend resources to develop products and technology internally, we may be placed at a competitive disadvantage or we may be adversely affected by negative market perceptions, any of which may have a material adverse effect on our results of operations, financial position or cash flows.
Success in completing acquisitions is also dependent on efficiently integrating the acquired business into our existing operations, including our internal control environment, or otherwise leveraging its operations, which may present challenges that are different from those presented by organic growth and that may be difficult for us to manage. If we cannot successfully integrate these acquisitions and realize contemplated revenue growth opportunities and cost savings, our business, prospects, results of operations, financial position and cash flows could be materially and adversely affected.

19

Table of Contents


As we expand and operate our business outside of the United States, we are presented with challenges that differ from those presented by acquisitions of domestic businesses, including challenges in adapting to new markets, languages, business, labor and cultural practices and regulatory environments. Adapting to these challenges could require us to devote significant senior management and other resources to the acquired businesses before we realize anticipated synergies or other benefits from the acquired businesses. These challenges vary widely by country and may include political instability, government intervention, discriminatory regulation and currency exchange controls or other restrictions that could prevent us from transferring funds from these operations out of the countries in which our acquired businesses operate, or converting local currencies that we hold into U.S. dollars or other currencies. If we are unable to manage successfully our non-U.S. acquisitions, our business, prospects, results of operations and financial position could be materially and adversely affected.
Foreign currency exchange rates and fluctuations may have an impact on our shareholders’ equity from period to period, which could adversely affect our debt to debt-plus-equity ratio, and our future revenues, costs and cash flows from international operations. Any measures we may implement to reduce the effect of volatile currencies may be costly or ineffective.
Our sales performance will suffer if we do not adequately attract, retain and provide support to a network of independent producers and consultants.
Our products and services are sold in part through nonexclusive producers and consultants for whose services and allegiance we must compete. Our sales would be materially and adversely affected if we are unable to attract, retain and support such independent producers and consultants or if our sales strategy is not appropriately aligned across distribution channels. Our relationships with producers could be materially and adversely impacted by changes in our business practices and the nature of our relationships to address these pressures, including potential reductions in commission levels.
A number of investigations have been conducted regarding the marketing practices of producers selling health care products and the payments they receive and have resulted in enforcement actions against companies in our industry and producers marketing and selling those companies’ products. If we were subjected to similar investigations and enforcement actions, such actions could result in penalties and the imposition of corrective action plans, which could materially and adversely impact our ability to market our products.
Unfavorable economic conditions could materially and adversely affect our revenues and our results of operations.
Unfavorable economic conditions may impact demand for certain of our products and services. For example, high unemployment can cause lower enrollment or lower rates of renewal in our employer group plans. Unfavorable economic conditions also have caused and could continue to cause employers to stop offering certain health care coverage as an employee benefit or elect to offer this coverage on a voluntary, employee-funded basis as a means to reduce their operating costs. In addition, unfavorable economic conditions could adversely impact our ability to increase premiums or result in the cancellation by certain customers of our products and services. These conditions could lead to a decrease in our membership levels and premium and fee revenues and could materially and adversely affect our results of operations, financial position and cash flows.
During a prolonged unfavorable economic environment, state and federal budgets could be materially and adversely affected, resulting in reduced reimbursements or payments in our federal and state government health care coverage programs, including Medicare, Medicaid and CHIP. A reduction in state Medicaid reimbursement rates could be implemented retrospectively to apply to payments already negotiated or received from the government and could materially and adversely affect our results of operations, financial position and cash flows. In addition, state and federal budgetary pressures could cause the affected governments to impose new or a higher level of taxes or assessments for our commercial programs, such as premium taxes on health insurance and surcharges or fees on select fee-for-service and capitated medical claims. Any of these developments or actions could materially and adversely affect our results of operations, financial position and cash flows.
A prolonged unfavorable economic environment also could adversely impact the financial position of hospitals and other care providers, which could materially and adversely affect our contracted rates with these parties and increase our medical costs or materially and adversely affect their ability to purchase our service offerings. Further, unfavorable economic conditions could adversely impact the customers of our Optum businesses, including health plans, hospitals, care providers, employers and others, which could, in turn, materially and adversely affect Optum’s financial results.
Our investment portfolio may suffer losses, which could adversely affect our results of operations, financial position and cash flows.
Market fluctuations could impair our profitability and capital position. Volatility in interest rates affects our interest income and the market value of our investments in debt securities of varying maturities, which constitute the vast majority of the fair value of our investments as of December 31, 2018 . Relatively low interest rates on investments, such as those experienced during recent years, have adversely impacted our investment income. In addition, a delay in payment of principal or interest by issuers, or defaults by issuers (primarily issuers of our investments in corporate and municipal bonds), could reduce our investment income and require us to write down the value of our investments, which could adversely affect our profitability and equity.

20

Table of Contents


There can be no assurance that our investments will produce total positive returns or that we will not sell investments at prices that are less than their carrying values. Changes in the value of our investment assets, as a result of interest rate fluctuations, changes in issuer financial conditions, illiquidity or otherwise, could have an adverse effect on our equity. In addition, if it became necessary for us to liquidate our investment portfolio on an accelerated basis, such an action could have an adverse effect on our results of operations and the capital position of our regulated subsidiaries.
If the value of our intangible assets is materially impaired, our results of operations, equity and credit ratings could be materially and adversely affected.
As of December 31, 2018 , our goodwill and other intangible assets had a carrying value of $68 billion , representing 45% of our total consolidated assets. We periodically evaluate our goodwill and other intangible assets to determine whether all or a portion of their carrying values may be impaired, in which case a charge to earnings may be necessary. The value of our goodwill may be materially and adversely impacted if businesses that we acquire perform in a manner that is inconsistent with our assumptions. In addition, from time to time we divest businesses, and any such divestiture could result in significant asset impairment and disposition charges, including those related to goodwill and other intangible assets. Any future evaluations requiring an impairment of our goodwill and other intangible assets could materially and adversely affect our results of operations and equity in the period in which the impairment occurs. A material decrease in equity could, in turn, adversely impact our credit ratings and potentially impact our compliance with the financial covenants in our bank credit facilities.
If we fail to maintain properly the integrity or availability of our data or successfully consolidate, integrate, upgrade or expand our existing information systems, or if our technology products do not operate as intended, our business could be materially and adversely affected.
Our ability to price adequately our products and services, to provide effective service to our customers in an efficient and uninterrupted fashion, and to report accurately our results of operations depends on the integrity of the data in our information systems. We periodically consolidate, integrate, upgrade and expand our information systems’ capabilities as a result of technology initiatives and recently enacted regulations, changes in our system platforms and integration of new business acquisitions. In addition, recent trends toward greater consumer engagement in health care require new and enhanced technologies, including more sophisticated applications for mobile devices. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards and changing customer preferences. If the information we rely upon to run our businesses is found to be inaccurate or unreliable or if we fail to maintain or protect our information systems and data integrity effectively, we could lose existing customers, have difficulty attracting new customers, experience problems in determining medical cost estimates and establishing appropriate pricing, have difficulty preventing, detecting and controlling fraud, have disputes with customers, physicians and other health care professionals, become subject to regulatory sanctions or penalties, incur increases in operating expenses or suffer other adverse consequences. Our process of consolidating the number of systems we operate, upgrading and expanding our information systems’ capabilities, enhancing our systems and developing new systems to keep pace with continuing changes in information processing technology may not be successful. Failure to protect, consolidate and integrate our systems successfully could result in higher than expected costs and diversion of management’s time and energy, which could materially and adversely affect our results of operations, financial position and cash flows.
Certain of our businesses sell and install software products that may contain unexpected design defects or may encounter unexpected complications during installation or when used with other technologies utilized by the customer. Connectivity among competing technologies is becoming increasingly important in the health care industry. A failure of our technology products to operate as intended and in a seamless fashion with other products could materially and adversely affect our results of operations, financial position and cash flows.
Uncertain and rapidly evolving U.S. federal and state, non-U.S. and international laws and regulations related to the health information technology market may present compliance challenges and could materially and adversely affect the configuration of our information systems and platforms, and our ability to compete in this market.
If we are not able to protect our proprietary rights to our databases, software and related products, our ability to market our knowledge and information-related businesses could be hindered and our results of operations, financial position and cash flows could be materially and adversely affected.
We rely on our agreements with customers, confidentiality agreements with employees and third parties, and our trademarks, trade secrets, copyrights and patents to protect our proprietary rights. These legal protections and precautions may not prevent misappropriation of our proprietary information. In addition, substantial litigation regarding intellectual property rights exists in the software industry, and we expect software products to be increasingly subject to third-party infringement claims as the number of products and competitors in this industry segment grows. Such litigation and misappropriation of our proprietary

21

Table of Contents


information could hinder our ability to market and sell products and services and our results of operations, financial position and cash flows could be materially and adversely affected.
Restrictions on our ability to obtain funds from our regulated subsidiaries could materially and adversely affect our results of operations, financial position and cash flows.
Because we operate as a holding company, we are dependent on dividends and administrative expense reimbursements from our subsidiaries to fund our obligations. Many of these subsidiaries are regulated by departments of insurance or similar regulatory authorities. We are also required by law or regulation to maintain specific prescribed minimum amounts of capital in these subsidiaries. The levels of capitalization required depend primarily on the volume of premium revenues generated by the applicable subsidiary. In most states, we are required to seek approval by state regulatory authorities before we transfer money or pay dividends from our regulated subsidiaries that exceed specified amounts. An inability of our regulated subsidiaries to pay dividends to their parent companies in the desired amounts or at the time of our choosing could adversely affect our ability to reinvest in our business through capital expenditures or business acquisitions, as well as our ability to maintain our corporate quarterly dividend payment, repurchase shares of our common stock and repay our debt. If we are unable to obtain sufficient funds from our subsidiaries to fund our obligations, our results of operations, financial position and cash flows could be materially and adversely affected.
Any downgrades in our credit ratings could adversely affect our business, financial condition and results of operations.
Claims paying ability, financial strength and debt ratings by Nationally Recognized Statistical Rating Organizations are important factors in establishing the competitive position of insurance companies. Ratings information is broadly disseminated and generally used by customers and creditors. We believe our claims paying ability and financial strength ratings are important factors in marketing our products to certain of our customers. Our credit ratings impact both the cost and availability of future borrowings. Each of the credit rating agencies reviews its ratings periodically. Our ratings reflect each credit rating agency’s opinion of our financial strength, operating performance and ability to meet our debt obligations or obligations to policyholders. There can be no assurance that our current credit ratings will be maintained in the future. Any downgrades in our credit ratings could materially increase our costs of or ability to access funds in the debt capital markets and otherwise materially increase our operating costs.
ITEM 1B.
UNRESOLVED STAFF COMMENTS
None.
ITEM 2.
PROPERTIES
To support our business operations in the United States and other countries we own and lease real properties. Our various reportable segments use these facilities for their respective business purposes, and we believe these current facilities are suitable for their respective uses and are adequate for our anticipated future needs.
ITEM 3.
LEGAL PROCEEDINGS
The information required by this Item 3 is incorporated herein by reference to the information set forth under the captions “Legal Matters” and “Governmental Investigations, Audits and Reviews” in Note 12 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”
ITEM 4.
MINE SAFETY DISCLOSURES
Not Applicable.
PART II
ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
MARKET AND HOLDERS
Our common stock is traded on the New York Stock Exchange (NYSE) under the symbol UNH. On January 31, 2019, there were 11,948 registered holders of record of our common stock.
DIVIDEND POLICY
In June 2018, our Board of Directors increased the Company’s annual cash dividend rate to shareholders to $3.60 per share compared to $3.00 per share, which the Company had paid since June 2017. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.

22

Table of Contents


ISSUER PURCHASES OF EQUITY SECURITIES
In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates periodically. There is no established expiration date for the program. During the fourth quarter of 2018, we repurchased 3.3 million shares at an average price of $256.15 per share. As of December 31, 2018, we had Board authorization to purchase up to 94 million shares of our common stock.
PERFORMANCE GRAPH
The following performance graph compares the cumulative five-year total return to shareholders on our common stock relative to the cumulative total returns of the S&P 500 index, the S&P Health Care Index and the Dow Jones US Industrial Average Index for the five-year period ended December 31, 2018 . We have also included the customized peer group of certain Fortune 50 companies that we have compared ourselves to in prior years. We believe that these indices provide a more meaningful comparison than the previous subset of the Fortune 50 given our diverse businesses. The comparisons assume the investment of $100 on December 31, 2013 in our common stock and in each index, and that dividends were reinvested when paid.
The Fortune 50 Group consists of the following companies: American International Group, Inc., Berkshire Hathaway Inc., Cardinal Health, Inc., Citigroup Inc., General Electric Company, International Business Machines Corporation and Johnson & Johnson. We are not included in this Fortune 50 Group index. In calculating the cumulative total shareholder return of the indexes, the shareholder returns of the Fortune 50 Group companies are weighted according to the stock market capitalizations of the companies at January 1 of each year.
A2018PERFORMANCEGRAPH2.JPG




23

Table of Contents


 
12/13
 
12/14
 
12/15
 
12/16
 
12/17
 
12/18
UnitedHealth Group
$
100.00

 
$
136.46

 
$
161.37

 
$
223.35

 
$
312.29

 
$
357.64

S&P Health Care Index
100.00

 
125.34

 
133.97

 
130.37

 
159.15

 
169.44

Dow Jones US Industrial Average
100.00

 
110.04

 
110.28

 
128.47

 
164.58

 
158.85

S&P 500 Index
100.00

 
113.69

 
115.26

 
129.05

 
157.22

 
150.33

Fortune 50 Group
100.00

 
105.33

 
108.75

 
123.33

 
126.45

 
103.96

The stock price performance included in this graph is not necessarily indicative of future stock price performance.

ITEM 6.
SELECTED FINANCIAL DATA
 
 
For the Years Ended December 31,
(in millions, except percentages and per share data)
 
2018
 
2017 (a)
 
2016
 
2015 (b)
 
2014
Consolidated operating results
 
 
 
 
 
 
 
 
 
 
Revenues
 
$
226,247

 
$
201,159

 
$
184,840

 
$
157,107

 
$
130,474

Earnings from operations
 
17,344

 
15,209

 
12,930

 
11,021

 
10,274

Net earnings attributable to UnitedHealth Group common shareholders
 
11,986

 
10,558

 
7,017

 
5,813

 
5,619

Return on equity (c)
 
24.4
%
 
24.4
%
 
19.4
%
 
17.7
%
 
17.3
%
Basic earnings per share attributable to UnitedHealth Group common shareholders
 
$
12.45

 
$
10.95

 
$
7.37

 
$
6.10

 
$
5.78

Diluted earnings per share attributable to UnitedHealth Group common shareholders
 
12.19

 
10.72

 
7.25

 
6.01

 
5.70

Cash dividends declared per common share
 
3.45

 
2.875

 
2.375

 
1.875

 
1.405

 
 
 
 
 
 
 
 
 
 
 
Consolidated cash flows from (used for)
 
 
 
 
 
 
 
 
 
 
Operating activities
 
$
15,713

 
$
13,596

 
$
9,795

 
$
9,740

 
$
8,051

Investing activities
 
(12,385
)
 
(8,599
)
 
(9,355
)
 
(18,395
)
 
(2,534
)
Financing activities
 
(4,365
)
 
(3,441
)
 
(1,011
)
 
12,239

 
(5,293
)
 
 
 
 
 
 
 
 
 
 
 
Consolidated financial condition
 
 
 
 
 
 
 
 
 
 
(as of December 31)
 
 
 
 
 
 
 
 
 
 
Cash and investments
 
$
46,834

 
$
43,831

 
$
37,143

 
$
31,703

 
$
28,063

Total assets
 
152,221

 
139,058

 
122,810

 
111,254

 
86,300

Total commercial paper and long-term debt
 
36,554

 
31,692

 
32,970

 
31,965

 
17,324

Redeemable noncontrolling interests
 
1,908

 
2,189

 
2,012

 
1,736

 
1,388

Total equity
 
54,319

 
49,833

 
38,177

 
33,725

 
32,454

               
(a)
Includes the impact of the revaluation of our net deferred tax liabilities due to Tax Reform enacted in December 2017.
(b)
Includes the effects of the July 2015 acquisition of Catamaran Corporation (Catamaran) and related debt issuances.
(c)
Return on equity is calculated as net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the four quarters of the year presented.
This selected financial data should be read with the accompanying “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 and the Consolidated Financial Statements and Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”

ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Consolidated Financial Statements and Notes to the Consolidated Financial Statements thereto included in Item 8, “Financial Statements and Supplementary Data.” Readers are cautioned that the statements, estimates, projections or outlook contained in this report, including discussions regarding

24

Table of Contents


financial prospects, economic conditions, trends and uncertainties contained in this Item 7, may constitute forward-looking statements within the meaning of the PSLRA. These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations expressed or implied in the forward-looking statements. A description of some of the risks and uncertainties can be found further below in this Item 7 and in Part I, Item 1A, “Risk Factors.”
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a diversified health care company dedicated to helping people live healthier lives and helping make the health system work better for everyone. Through our diversified family of businesses, we leverage core competencies in data analytics and health information; advanced technology; and clinical expertise. These core competencies are deployed within our two distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
We have four reportable segments across our two business platforms, UnitedHealthcare and Optum:
UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State and UnitedHealthcare Global;
OptumHealth;
OptumInsight; and
OptumRx.
Further information on our business and reportable segments is presented in Part I, Item 1, “Business” and in Note 13 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”
Business Trends
Our businesses participate in the United States, South America and certain other international health markets. In the United States, health care spending has grown consistently for many years and comprises 18% of gross domestic product (GDP). We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macro-economic conditions and regulatory changes, which have impacted and could further impact our results of operations.
Pricing Trends . To price our health care benefit products, we start with our view of expected future costs. We frequently evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum MLR thresholds. We will continue seeking to balance growth and profitability across all of these dimensions.
The commercial risk market remains highly competitive in both the small group and large group segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs amid reform changes. The ACA included an annual, nondeductible insurance industry tax (Health Insurance Industry Tax) to be levied proportionally across the insurance industry for risk-based health insurance products. A provision in the 2018 federal budget imposed a one year moratorium for 2019 on the collection of the Health Insurance Industry Tax. Pricing for contracts that cover a portion of calendar year 2019 reflected the impact of the moratorium. The industry has continued to experience favorable medical cost trends due to moderated utilization, which has impacted the competitive pricing environment.
Medicare Advantage funding continues to be pressured, as discussed below in “Regulatory Trends and Uncertainties.”
We expect continued Medicaid revenue growth due to anticipated changes in mix and increases in the number of people we serve; we also believe that the payment rate environment creates the risk of downward pressure on Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships. We continue to advocate for actuarially sound rates that are commensurate with our medical cost trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization and prescription drug costs. We endeavor to mitigate those increases by engaging physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care.

25

Table of Contents


Delivery System and Payment Modernization. The health care market continues to change based on demographic shifts, new regulations, political forces and both payer and patient expectations. Health plans and care providers are being called upon to work together to close gaps in care and improve overall care quality, improve the health of populations and reduce costs. We continue to see a greater number of people enrolled in plans with underlying incentive-based care provider payment models that reward high-quality, affordable care and foster collaboration. We work together with clinicians to leverage our data and analytics to provide the necessary information to close gaps in care and improve overall health outcomes for patients.
We are increasingly rewarding care providers for delivering improvements in quality and cost-efficiency. As of December 31, 2018, we served nearly 17 million people through some form of aligned contractual arrangement, including full-risk, shared-risk and bundled episode-of-care and performance incentive payment approaches. As of December 31, 2018, our contracts with value-based elements totaled $74 billion in annual spending, including $18 billion through risk-transfer agreements.
This trend is creating needs for health management services that can coordinate care around the primary care physician, including new primary care channels, and for investments in new clinical and administrative information and management systems, which we believe provide growth opportunities for our Optum business platform.
Regulatory Trends and Uncertainties
Following is a summary of management’s view of the trends and uncertainties related to some of the key provisions of the ACA and other regulatory matters. For additional information regarding the ACA and regulatory trends and uncertainties, see Part I, Item 1 “Business - Government Regulation” and Item 1A, “Risk Factors.”
Medicare Advantage Rates. Final 2019 Medicare Advantage rates resulted in an increase in industry base rates of 3.4%, short of the industry forward medical cost trend, which creates continued pressure in the Medicare Advantage program.
The ongoing pressure on Medicare Advantage funding places continued importance on effective medical management and ongoing improvements in administrative efficiency. There are a number of adjustments we have made to partially offset these rate pressures and reductions. In some years, these adjustments will impact the majority of the seniors we serve through Medicare Advantage. For example, we seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust members' benefits and implement or increase the member premiums that supplement the monthly payments we receive from the government. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans.
As Medicare Advantage payments change, other products may become relatively more attractive to Medicare beneficiaries and increase the demand for other senior health benefits products, such as our market-leading Medicare Supplement and stand-alone Medicare Part D insurance offerings.
Our Medicare Advantage rates are currently enhanced by CMS quality bonuses in certain counties based on our local plans’ Star ratings. The level of Star ratings from CMS, based upon specified clinical and operational performance standards, will impact future quality bonuses.
Tax Reform. Tax Reform was enacted by the U.S federal government in December 2017, changing existing United States tax law, including reducing the U.S. corporate income tax rate. In 2018, the impact of Tax Reform was partially offset by the return of the nondeductible Health Insurance Industry Tax.
Health Insurance Industry Tax. After a moratorium in 2017, the industry-wide amount of the Health Insurance Industry Tax in 2018 was $14.3 billion, with our portion being $2.6 billion. The return of the tax impacted year-over-year comparability of our financial results, including revenues, the medical care ratio (MCR), operating cost ratio and effective tax rate. A one year moratorium is imposed on the collection of the Health Insurance Industry Tax in 2019.
SELECTED OPERATING PERFORMANCE ITEMS
The following represents a summary of select 2018 year-over-year operating comparisons to 2017 .
Consolidated revenues increased by 12% , UnitedHealthcare revenues increased 12% and Optum revenues grew 11% .
UnitedHealthcare’s addition of 2.2 million people through acquisition and 250,000 through organic growth was offset by 2.9 million fewer people served as a result of completion of its commitment under the TRICARE military health care program.
Earnings from operations increased by 14% , including increases of 7% at UnitedHealthcare and 23% at Optum.
Diluted earnings per common share increased 14% to $12.19 .
Cash flows from operations were $15.7 billion , an increase of 16% .

26

Table of Contents


RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data)
 
For the Years Ended December 31,
 
Change
 
Change
 
2018
 
2017
 
2016
 
2018 vs. 2017
 
2017 vs. 2016
Revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
178,087

 
$
158,453

 
$
144,118

 
$
19,634

 
12
%
 
$
14,335

 
10
%
Products
 
29,601

 
26,366

 
26,658

 
3,235

 
12

 
(292
)
 
(1
)
Services
 
17,183

 
15,317

 
13,236

 
1,866

 
12

 
2,081

 
16

Investment and other income
 
1,376

 
1,023

 
828

 
353

 
35

 
195

 
24

Total revenues
 
226,247

 
201,159

 
184,840

 
25,088

 
12

 
16,319

 
9

Operating costs:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical costs
 
145,403

 
130,036

 
117,038

 
15,367

 
12

 
12,998

 
11

Operating costs
 
34,074

 
29,557

 
28,401

 
4,517

 
15

 
1,156

 
4

Cost of products sold
 
26,998

 
24,112

 
24,416

 
2,886

 
12

 
(304
)
 
(1
)
Depreciation and amortization
 
2,428

 
2,245

 
2,055

 
183

 
8

 
190

 
9

Total operating costs
 
208,903

 
185,950

 
171,910

 
22,953

 
12

 
14,040

 
8

Earnings from operations
 
17,344

 
15,209

 
12,930

 
2,135

 
14

 
2,279

 
18

Interest expense
 
(1,400
)
 
(1,186
)
 
(1,067
)
 
(214
)
 
18

 
(119
)
 
11

Earnings before income taxes
 
15,944

 
14,023

 
11,863

 
1,921

 
14

 
2,160

 
18

Provision for income taxes
 
(3,562
)
 
(3,200
)
 
(4,790
)
 
(362
)
 
11

 
1,590

 
(33
)
Net earnings
 
12,382

 
10,823

 
7,073

 
1,559

 
14

 
3,750

 
53

Earnings attributable to noncontrolling interests
 
(396
)
 
(265
)
 
(56
)
 
(131
)
 
49

 
(209
)
 
373

Net earnings attributable to UnitedHealth Group common shareholders
 
$
11,986

 
$
10,558

 
$
7,017

 
$
1,428

 
14
%
 
$
3,541

 
50
 %
Diluted earnings per share attributable to UnitedHealth Group common shareholders
 
$
12.19

 
$
10.72

 
$
7.25

 
$
1.47

 
14
%
 
$
3.47

 
48
 %
Medical care ratio (a)
 
81.6
%
 
82.1
%
 
81.2
%
 
(0.5
)%
 
 
 
0.9
 %
 
 
Operating cost ratio
 
15.1

 
14.7

 
15.4

 
0.4

 
 
 
(0.7
)
 
 
Operating margin
 
7.7

 
7.6

 
7.0

 
0.1

 
 
 
0.6

 
 
Tax rate
 
22.3

 
22.8

 
40.4

 
(0.5
)
 
 
 
(17.6
)
 
 
Net earnings margin (b)
 
5.3

 
5.2

 
3.8

 
0.1

 
 
 
1.4

 
 
Return on equity (c)
 
24.4
%
 
24.4
%
 
19.4
%
 
 %
 
 
 
5.0
 %
 
 
               
(a)
Medical care ratio is calculated as medical costs divided by premium revenue.
(b)
Net earnings margin attributable to UnitedHealth Group shareholders.
(c)
Return on equity is calculated as net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the four quarters of the year presented.
2018 RESULTS OF OPERATIONS COMPARED TO 2017 RESULTS
Consolidated Financial Results
Revenue
The increase in revenue was primarily driven by the increase in the number of individuals served through risk-based products across our UnitedHealthcare benefits businesses; pricing trends, including the Health Insurance Industry Tax in 2018; and growth across the Optum business, primarily due to expansion and growth in care delivery, pharmacy care services, managed services and advisory services.
Medical Costs and MCR
Medical costs increased due to growth in people served through risk-based products and medical cost trends. The MCR decreased due to the revenue effects of the Health Insurance Industry Tax, which more than offset business mix changes and a lower level of favorable reserve development.

27



Reportable Segments
See Note 13 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for more information on our segments. The following table presents a summary of the reportable segment financial information:
 
 
For the Years Ended December 31,
 
Change
 
Change
(in millions, except percentages)
 
2018
 
2017
 
2016
 
2018 vs. 2017
 
2016 vs. 2015
Revenues
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UnitedHealthcare
 
$
183,476

 
$
163,257

 
$
148,581

 
$
20,219

 
12
%
 
$
14,676

 
10
%
OptumHealth
 
24,145

 
20,570

 
16,908

 
3,575

 
17

 
3,662

 
22

OptumInsight
 
9,008

 
8,087

 
7,333

 
921

 
11

 
754

 
10

OptumRx
 
69,536

 
63,755

 
60,440

 
5,781

 
9

 
3,315

 
5

Optum eliminations
 
(1,409
)
 
(1,227
)
 
(1,088
)
 
(182
)
 
15

 
(139
)
 
13

Optum
 
101,280

 
91,185

 
83,593

 
10,095

 
11

 
7,592

 
9

Eliminations
 
(58,509
)
 
(53,283
)
 
(47,334
)
 
(5,226
)
 
10

 
(5,949
)
 
13

Consolidated revenues
 
$
226,247

 
$
201,159

 
$
184,840

 
$
25,088

 
12
%
 
$
16,319

 
9
%
Earnings from operations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UnitedHealthcare
 
$
9,113

 
$
8,498

 
$
7,307

 
$
615

 
7
%
 
$
1,191

 
16
%
OptumHealth
 
2,430

 
1,823

 
1,428

 
607

 
33

 
395

 
28

OptumInsight
 
2,243

 
1,770

 
1,513

 
473

 
27

 
257

 
17

OptumRx
 
3,558

 
3,118

 
2,682

 
440

 
14

 
436

 
16

Optum
 
8,231

 
6,711

 
5,623

 
1,520

 
23

 
1,088

 
19

Consolidated earnings from operations
 
$
17,344

 
$
15,209

 
$
12,930

 
$
2,135

 
14
%
 
$
2,279

 
18
%
Operating margin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UnitedHealthcare
 
5.0
%
 
5.2
%
 
4.9
%
 
(0.2
)%
 
 
 
0.3
%
 
 
OptumHealth
 
10.1

 
8.9

 
8.4

 
1.2

 
 
 
0.5

 
 
OptumInsight
 
24.9

 
21.9

 
20.6

 
3.0

 
 
 
1.3

 
 
OptumRx
 
5.1

 
4.9

 
4.4

 
0.2

 
 
 
0.5

 
 
Optum
 
8.1

 
7.4

 
6.7

 
0.7

 
 
 
0.7

 
 
Consolidated operating margin
 
7.7
%
 
7.6
%
 
7.0
%
 
0.1
 %
 
 
 
0.6
%
 
 
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
 
 
For the Years Ended December 31,
 
Change
 
Change
(in millions, except percentages)
 
2018
 
2017
 
2016
 
2018 vs. 2017
 
2017 vs. 2016
UnitedHealthcare Employer & Individual
 
$
54,761

 
$
52,066

 
$
53,084

 
$
2,695

 
5
%
 
$
(1,018
)
 
(2
)%
UnitedHealthcare Medicare & Retirement
 
75,473

 
65,995

 
56,329

 
9,478

 
14

 
9,666

 
17

UnitedHealthcare Community & State
 
43,426

 
37,443

 
32,945

 
5,983

 
16

 
4,498

 
14

UnitedHealthcare Global
 
9,816

 
7,753

 
6,223

 
2,063

 
27

 
1,530

 
25

Total UnitedHealthcare revenues
 
$
183,476

 
$
163,257

 
$
148,581

 
$
20,219

 
12
%
 
$
14,676

 
10
 %

28



The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
 
 
December 31,
 
Change
 
Change
(in thousands, except percentages)
 
2018
 
2017
 
2016
 
2018 vs. 2017
 
2017 vs. 2016
Commercial:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk-based
 
8,495

 
8,420

 
8,820

 
75

 
1
 %
 
(400
)
 
(5
)%
Fee-based
 
18,420

 
18,595

 
18,900

 
(175
)
 
(1
)
 
(305
)
 
(2
)
Fee-based TRICARE
 

 
2,850

 
2,860

 
(2,850
)
 
(100
)
 
(10
)
 

Total commercial
 
26,915

 
29,865

 
30,580

 
(2,950
)
 
(10
)
 
(715
)
 
(2
)
Medicare Advantage
 
4,945

 
4,430

 
3,630

 
515

 
12

 
800

 
22

Medicaid
 
6,450

 
6,705

 
5,890

 
(255
)
 
(4
)
 
815

 
14

Medicare Supplement (Standardized)
 
4,545

 
4,445

 
4,265

 
100

 
2

 
180

 
4

Total public and senior
 
15,940

 
15,580

 
13,785

 
360

 
2

 
1,795

 
13

Total UnitedHealthcare - domestic medical
 
42,855

 
45,445

 
44,365

 
(2,590
)
 
(6
)
 
1,080

 
2

International
 
6,220

 
4,080

 
4,220

 
2,140

 
52

 
(140
)
 
(3
)
Total UnitedHealthcare - medical
 
49,075

 
49,525

 
48,585

 
(450
)
 
(1
)%
 
940

 
2
 %
Supplemental Data:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medicare Part D stand-alone
 
4,710

 
4,940

 
4,930

 
(230
)
 
(5
)%
 
10

 
 %
The overall increase in people served through risk-based benefit plans in the commercial group market was due to growth in services to small groups. Fee-based commercial group business declined primarily due to customers converting their retirees to Medicare Advantage plans, as well as certain customers expanding the number of carriers and reconfiguring geographies served. Medicare Advantage increased year-over-year due to growth in people served through individual and employer-sponsored group Medicare Advantage plans. The decrease in people served through Medicaid was primarily driven by states adding new carriers to existing programs, reduced enrollment from state efforts to manage eligibility status and the sale of our New Mexico Medicaid plan. Medicare Supplement growth reflected strong customer retention and new sales. International growth was primarily driven by an acquisition in the first quarter.
UnitedHealthcare’s revenue and earnings from operations increased due to growth in the number of individuals served across its risk-based businesses, a higher revenue membership mix, rate increases for underlying medical cost trends and the impact of the return of the Health Insurance Industry Tax. UnitedHealthcare’s operating margin decreased slightly due to the performance of our traditional community-based TANF Medicaid business.
Optum
Total revenues and earnings from operations increased as each segment reported increased revenues and earnings from operations as a result of the factors discussed below, as well as productivity and overall cost management initiatives.
The results by segment were as follows:
OptumHealth
Revenue and earnings from operations increased at OptumHealth primarily due to organic and acquisition-related growth in care delivery and behavioral health, digital consumer engagement and health financial services.
OptumInsight
Revenue and earnings from operations at OptumInsight increased primarily due to growth in data analytics product and service offerings and managed services as well as organic and acquisition-related growth in advisory services.
OptumRx
Revenue and earnings from operations at OptumRx increased primarily due to growth in specialty pharmacy, home delivery services, and overall prescription growth. OptumRx fulfilled 1,343 million and 1,298 million adjusted scripts in 2018 and 2017, respectively.

29



2017 RESULTS OF OPERATIONS COMPARED TO 2016 RESULTS
Consolidated Financial Results
Revenue
The increase in revenue was primarily driven by organic growth in the number of individuals served across our UnitedHealthcare benefits businesses and growth across the Optum business. The increase was partially offset by revenue decreases due to the withdrawals of the ACA-compliant products in the individual market and the effects of the Health Insurance Industry Tax moratorium.
Medical Costs and MCR
Medical costs increased due to risk-based membership growth and medical cost trends. The MCR increased due to the effects of the Health Insurance Industry Tax moratorium, offset primarily by the reduction in individual ACA business, medical management initiatives and an increase in favorable medical cost reserve development.
Income Tax Rate
Our effective tax rate decreased primarily due to the impact of Tax Reform and the Health Insurance Tax moratorium. The provision for income taxes included a $1.2 billion benefit from the revaluation of net deferred tax liabilities.
Reportable Segments
UnitedHealthcare
UnitedHealthcare’s revenue increase was due to growth in the number of individuals served across its businesses and price increases for underlying medical cost trends, which were partially offset by the reduction of people served in ACA-compliant individual products and the impact of the Health Insurance Industry Tax moratorium.
The increase in UnitedHealthcare’s earnings from operations was led by diversified growth and increased operating margin. The 2016 results included losses in ACA-compliant individual products and guaranty fund assessments.
Optum
Total revenues and earnings from operations increased as each segment reported increased revenues and earnings from operations as a result of the factors discussed below.
The results by segment were as follows:
OptumHealth
Revenue and earnings from operations increased at OptumHealth primarily due to organic and acquisition-related growth in care delivery.
OptumInsight
Revenue and earnings from operations at OptumInsight increased primarily due to growth in revenue management services and business process services.
OptumRx
Revenue and earnings from operations at OptumRx increased primarily due to client and consumer growth. In 2017, OptumRx fulfilled 1.3 billion adjusted scripts compared to 1.2 billion in 2016.

LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Introduction
We manage our liquidity and financial position in the context of our overall business strategy. We continually forecast and manage our cash, investments, working capital balances and capital structure to meet the short-term and long-term obligations of our businesses while seeking to maintain liquidity and financial flexibility. Cash flows generated from operating activities are principally from earnings before noncash expenses.
Our regulated subsidiaries generate significant cash flows from operations and are subject to financial regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of

30



statutory capital, as defined by each jurisdiction, and restrict the timing and amount of dividends and other distributions that may be paid to their parent companies.
In both 2018 and 2017, our U.S. regulated subsidiaries paid their parent companies dividends of $3.7 billion. See Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for further detail concerning our regulated subsidiary dividends.
Our nonregulated businesses also generate significant cash flows from operations that are available for general corporate use. Cash flows generated by these entities, combined with dividends from our regulated entities and financing through the issuance of long-term debt as well as issuance of commercial paper or the ability to draw under our committed credit facilities, further strengthen our operating and financial flexibility. We use these cash flows to expand our businesses through acquisitions, reinvest in our businesses through capital expenditures, repay debt and return capital to our shareholders through shareholder dividends and/or repurchases of our common stock, depending on market conditions.
Summary of our Major Sources and Uses of Cash and Cash Equivalents
 
 
For the Years Ended December 31,
 
Change
 
Change
(in millions)
 
2018
 
2017
 
2016
 
2018 vs. 2017
 
2017 vs. 2016
Sources of cash:
 
 
 
 
 
 
 
 
 
 
Cash provided by operating activities
 
$
15,713

 
$
13,596

 
$
9,795

 
$
2,117

 
$
3,801

Issuances of long-term debt and commercial paper, net of repayments
 
4,134

 

 
990

 
4,134

 
(990
)
Proceeds from common share issuances
 
838

 
688

 
429

 
150

 
259

Customer funds administered
 

 
3,172

 
1,692

 
(3,172
)
 
1,480

Other
 

 

 
37

 

 
(37
)
Total sources of cash
 
20,685

 
17,456

 
12,943

 
 
 
 
Uses of cash:
 
 
 
 
 
 
 
 
 
 
Cash paid for acquisitions, net of cash assumed
 
(5,997
)
 
(2,131
)
 
(1,760
)
 
(3,866
)
 
(371
)
Cash dividends paid
 
(3,320
)
 
(2,773
)
 
(2,261
)
 
(547
)
 
(512
)
Common share repurchases
 
(4,500
)
 
(1,500
)
 
(1,280
)
 
(3,000
)
 
(220
)
Repayments of long-term debt and commercial paper, net of issuances
 

 
(2,615
)
 

 
2,615

 
(2,615
)
Purchases of property, equipment and capitalized software
 
(2,063
)
 
(2,023
)
 
(1,705
)
 
(40
)
 
(318
)
Purchases of investments, net of sales and maturities
 
(4,099
)
 
(4,319
)
 
(5,927
)
 
220

 
1,608

Other
 
(1,743
)
 
(539
)
 
(581
)
 
(1,204
)
 
42

Total uses of cash
 
(21,722
)
 
(15,900
)
 
(13,514
)
 
 
 
 
Effect of exchange rate changes on cash and cash equivalents
 
(78
)
 
(5
)
 
78

 
(73
)
 
(83
)
Net (decrease) increase in cash and cash equivalents
 
$
(1,115
)
 
$
1,551

 
$
(493
)
 
$
(2,666
)
 
$
2,044

2018 Cash Flows Compared to 2017 Cash Flows
Increased cash flows provided by operating activities were primarily driven by higher net earnings in 2018 and the impact to 2017 cash flows from operating activities due to a change in net deferred tax liabilities from Tax Reform, partially offset by changes in working capital accounts.
Other significant changes in sources or uses of cash year-over-year included net issuances of debt in 2018 compared to net repayments in 2017, an increase in cash paid for acquisitions, increased share repurchases and a decrease in customer funds administered due to the timing of government payments.
2017 Cash Flows Compared to 2016 Cash Flows
Increased cash flows provided by operating activities were primarily driven by higher net earnings and changes in working capital accounts, partially offset by the change in net deferred tax liabilities driven by tax reform.

31



Other significant changes in sources or uses of cash year-over-year included net repayments of debt compared to 2016 net proceeds from debt issuances, which were partially offset by lower net purchases of investments.
Financial Condition
As of December 31, 2018 , our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $44.7 billion included $10.9 billion of cash and cash equivalents (of which $925 million was available for general corporate use), $31.9 billion of debt securities and $2.0 billion of investments in equity securities. Given the significant portion of our portfolio held in cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Other sources of liquidity, primarily from operating cash flows and our commercial paper program, which is supported by our bank credit facilities, reduce the need to sell investments during adverse market conditions. See Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for further detail concerning our fair value measurements.
Our available-for-sale debt portfolio had a weighted-average duration of 3.3 years and a weighted-average credit rating of “Double A” as of December 31, 2018 . When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:
Commercial Paper and Bank Credit Facilities. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of senior unsecured debt through third-party broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of December 31, 2018, our debt to debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was 38%.
Long-Term Debt. Periodically, we access capital markets to issue long-term debt for general corporate purposes, such as, to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8 “Financial Statements and Supplementary Data.”
Credit Ratings. Our credit ratings as of December 31, 2018 were as follows:
   
Moody’s
 
S&P Global
 
Fitch
 
A.M. Best
 
Ratings
 
Outlook
 
Ratings
 
Outlook
 
Ratings
 
Outlook
 
Ratings
 
Outlook
Senior unsecured debt
A3
 
Stable
 
A+
 
Stable
 
A-
 
Stable
 
A-
 
Stable
Commercial paper
P-2
 
n/a
 
A-1
 
n/a
 
F1
 
n/a
 
AMB-1
 
n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. For example, a significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. As of December 31, 2018 , we had Board authorization to purchase up to 94 million shares of our common stock. For more information on our share repurchase program, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”
Dividends. In June 2018, our Board increased our annual cash dividend rate to shareholders to $3.60 per share from $3.00 per share. For more information on our dividend, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”

32



CONTRACTUAL OBLIGATIONS AND COMMITMENTS
The following table summarizes future obligations due by period as of December 31, 2018, under our various contractual obligations and commitments:
(in millions)
 
2019
 
2020 to 2021
 
2022 to 2023
 
Thereafter
 
Total
Debt (a)
 
$
3,463

 
$
8,970

 
$
7,396

 
$
37,988

 
$
57,817

Operating leases
 
669

 
1,103

 
761

 
1,343

 
3,876

Purchase and other obligations (b)
 
1,216

 
2,205

 
808

 
175

 
4,404

Other liabilities (c)
 
1,206

 
260

 
257

 
5,213

 
6,936

Redeemable noncontrolling interests (d)
 
1,276

 
380

 
25

 
227

 
1,908

Total contractual obligations
 
$
7,830

 
$
12,918

 
$
9,247

 
$
44,946

 
$
74,941

               
(a)
Includes interest coupon payments and maturities at par or put values. The table also assumes amounts are outstanding through their contractual term. See Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for more detail.
(b)
Includes fixed or minimum commitments under existing purchase obligations for goods and services, including agreements that are cancelable with the payment of an early termination penalty and remaining capital commitments for venture capital funds and other funding commitments. Excludes agreements that are cancelable without penalty and excludes liabilities to the extent recorded in our Consolidated Balance Sheets as of December 31, 2018 .
(c)
Includes obligations associated with contingent consideration and payments related to business acquisitions, certain employee benefit programs, amounts accrued for guaranty fund assessments, unrecognized tax benefits, and various long-term liabilities. Due to uncertainty regarding payment timing, obligations for employee benefit programs, charitable contributions, future settlements, unrecognized tax benefits and other liabilities have been classified as “Thereafter.”
(d)
Includes commitments for redeemable shares of our subsidiaries. When the timing of the redemption is indeterminable, the commitment has been classified as “Thereafter.”
Pending Acquisitions. In December 2017, we entered into an agreement to acquire a company in the health care sector for a total of approximately $4.3 billion, which is not reflected in the table above.
We do not have other significant contractual obligations or commitments that require cash resources. However, we continually evaluate opportunities to expand our operations, which include internal development of new products, programs and technology applications and may include acquisitions.
OFF-BALANCE SHEET ARRANGEMENTS
As of December 31, 2018, we were not involved in any off-balance sheet arrangements, which have or are reasonably likely to have a material effect on our financial condition, results of operations or liquidity.
RECENTLY ISSUED ACCOUNTING STANDARDS
See Note 2 of Notes to the Consolidated Financial Statements in Part II, Item 8 “Financial Statements and Supplementary Data” for a discussion of new accounting pronouncements that affect us.
CRITICAL ACCOUNTING ESTIMATES
Critical accounting estimates are those estimates that require management to make challenging, subjective or complex judgments, often because they must estimate the effects of matters that are inherently uncertain and may change in subsequent periods. Critical accounting estimates involve judgments and uncertainties that are sufficiently sensitive and may result in materially different results under different assumptions and conditions.
Medical Costs Payable
Medical costs and medical costs payable include estimates of our obligations for medical care services that have been rendered on behalf of insured consumers, but for which claims have either not yet been received or processed. Depending on the health care professional and type of service, the typical billing lag for services can be up to 90 days from the date of service. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months. As of December 31, 2018 , our days outstanding in medical payables was 50 days, calculated as total medical payables divided by total medical costs times the number of days in the period.

33



In each reporting period, our operating results include the effects of more completely developed medical costs payable estimates associated with previously reported periods. If the revised estimate of prior period medical costs is less than the previous estimate, we will decrease reported medical costs in the current period (favorable development). If the revised estimate of prior period medical costs is more than the previous estimate, we will increase reported medical costs in the current period (unfavorable development). Medical costs in 2018, 2017 and 2016 included favorable medical cost development related to prior years of $320 million , $690 million and $220 million , respectively.
In developing our medical costs payable estimates, we apply different estimation methods depending on the month for which incurred claims are being estimated. For example, for the most recent two months, we estimate claim costs incurred by applying observed medical cost trend factors to the average per member per month (PMPM) medical costs incurred in prior months for which more complete claim data is available, supplemented by a review of near-term completion factors.
Completion Factors. A completion factor is an actuarial estimate, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period that have been adjudicated by us at the date of estimation. Completion factors are the most significant factors we use in developing our medical costs payable estimates for periods prior to the most recent two months. Completion factors include judgments in relation to claim submissions such as the time from date of service to claim receipt, claim inventory levels and claim processing backlogs, as well as other factors. If actual claims submission rates from providers (which can be influenced by a number of factors, including provider mix and electronic versus manual submissions) or our claim processing patterns are different than estimated, our reserve estimates may be significantly impacted.
The following table illustrates the sensitivity of these factors and the estimated potential impact on our medical costs payable estimates for those periods as of December 31, 2018 :  
Completion Factors
(Decrease) Increase in Factors
 
Increase (Decrease)
In Medical Costs Payable
 
 
(in millions)
(0.75)%
 
$
550

(0.50)
 
366

(0.25)
 
182

0.25
 
(181
)
0.50
 
(362
)
0.75
 
(541
)
Medical Cost Per Member Per Month Trend Factors. Medical cost PMPM trend factors are significant factors we use in developing our medical costs payable estimates for the most recent two months. Medical cost trend factors are developed through a comprehensive analysis of claims incurred in prior months, provider contracting and expected unit costs, benefit design and a review of a broad set of health care utilization indicators, including but not limited to, pharmacy utilization trends, inpatient hospital authorization data and influenza incidence data from the National Centers for Disease Control. We also consider macroeconomic variables such as GDP growth, employment and disposable income. A large number of factors can cause the medical cost trend to vary from our estimates, including: our ability and practices to manage medical and pharmaceutical costs, changes in level and mix of services utilized, mix of benefits offered, including the impact of co-pays and deductibles, changes in medical practices, catastrophes and epidemics.
The following table illustrates the sensitivity of these factors and the estimated potential impact on our medical costs payable estimates for the most recent two months as of December 31, 2018 :
Medical Cost PMPM Quarterly Trend
Increase (Decrease) in Factors
 
Increase (Decrease)
In Medical Costs Payable
 
 
(in millions)
3%
 
$
703

2
 
469

1
 
234

(1)
 
(234
)
(2)
 
(469
)
(3)
 
(703
)

34



The completion factors and medical costs PMPM trend factors analyses above include outcomes that are considered reasonably likely based on our historical experience estimating liabilities for incurred but not reported benefit claims.
Management believes the amount of medical costs payable is reasonable and adequate to cover our liability for unpaid claims as of December 31, 2018 ; however, actual claim payments may differ from established estimates as discussed above. Assuming a hypothetical 1% difference between our December 31, 2018 estimates of medical costs payable and actual medical costs payable, excluding AARP Medicare Supplement Insurance and any potential offsetting impact from premium rebates, 2018 net earnings would have increased or decreased by approximately $140 million.
For more detail related to our medical cost estimates, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”
Revenues
We derive a substantial portion of our revenues from health care insurance premiums. We recognize premium revenues in the period eligible individuals are entitled to receive health care services. Customers are typically billed monthly at a contracted rate per eligible person multiplied by the total number of people eligible to receive services.
Our Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under the CMS risk adjustment payment methodology. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. We estimate risk adjustment revenues based upon the data submitted and expected to be submitted to CMS. As a result of the variability of factors that determine such estimations, the actual amount of CMS’ retroactive payments could be materially more or less than our estimates. This may result in favorable or unfavorable adjustments to our Medicare premium revenue and, accordingly, our profitability. For more detail on premium revenues, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” Risk adjustment data for our plans is subject to review by the federal and state governments, including audit by regulators. See Note 12 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” for additional information regarding these audits. Our estimates of premiums to be recognized are reduced by any expected premium minimum MLR rebates payable by us.
Goodwill and Intangible Assets
Goodwill. We evaluate goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. When testing goodwill for impairment, we may first assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. During a qualitative analysis, we consider the impact of changes, if any, to the following factors: macroeconomic, industry and market factors, cost factors, changes in overall financial performance, and any other relevant events and uncertainties impacting a reporting unit. If our qualitative assessment indicates that goodwill impairment is more likely than not, we perform additional quantitative analyses. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing. For reporting units where a quantitative analysis is performed, we perform a multi-step test measuring the fair values of the reporting units and comparing them to their aggregate carrying values, including goodwill. If the fair value is less than the carrying value of the reporting unit, then the implied value of goodwill would be calculated and compared to the carrying amount of goodwill to determine whether goodwill is impaired.
We estimate the fair values of our reporting units using discounted cash flows, which include assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods and discount rates. For each reporting unit, comparative market multiples are used to corroborate the results of our discounted cash flow test.
Forecasts and long-term growth rates used for our reporting units are consistent with, and use inputs from, our internal long-term business plan and strategies. Key assumptions used in these forecasts include:
Revenue trends. Key revenue drivers for each reporting unit are determined and assessed. Significant factors include: customer and/or membership growth, medical trends and the impact and expectations of regulatory environments. Additional macro-economic assumptions relating to unemployment, GDP growth, interest rates and inflation are also evaluated and incorporated, as appropriate.
Medical cost trends. For further discussion of medical cost trends, see the “Medical Cost Trend” section of Executive Overview- Business Trends and the “Medical Costs Payable” critical accounting estimate above. Similar factors, including historical and expected medical cost trend levels, are considered in estimating our long-term medical trends at the reporting unit level.

35



Operating productivity. We forecast expected operating cost levels based on historical levels and expectations of future operating cost levels.
Capital levels. The operating and long-term capital requirements for each business are considered.
Discount rates are determined for each reporting unit and include consideration of the implied risk inherent in their forecasts. Our most significant estimate in the discount rate determinations involves our adjustments to the peer company weighted average costs of capital that reflect reporting unit-specific factors. We have not made any adjustments to decrease a discount rate below the calculated peer company weighted average cost of capital for any reporting unit. Company-specific adjustments to discount rates are subjective and thus are difficult to measure with certainty. The passage of time and the availability of additional information regarding areas of uncertainty with respect to the reporting units’ operations could cause these assumptions to change in the future. As of October 1, 2018, we completed our annual impairment tests for goodwill with all of our reporting units having fair values substantially in excess of their carrying values.
Intangible Assets. Our finite-lived intangible assets are subject to impairment tests when events or circumstances indicate that an asset’s (or asset group’s) carrying value may exceed its estimated fair value. Consideration is given on a quarterly basis to a number of potential impairment indicators, including: changes in the use of the assets, changes in legal or other business factors that could affect value, experienced or expected operating cash-flow deterioration or losses, adverse changes in customer populations, adverse competitive or technological advances that could impact value and other factors.
Our indefinite-lived intangible assets are tested for impairment on an annual basis, or more frequently if impairment indicators exist. To determine if an indefinite-lived intangible asset is impaired, we compare its estimated fair value to its carrying value. If the carrying value exceeds its estimated fair value, an impairment would be recorded for the amount by which the carrying value exceeds its estimated fair value. Intangible assets were not impaired in 2018.
LEGAL MATTERS
A description of our legal proceedings is presented in Note 12 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”
CONCENTRATIONS OF CREDIT RISK
Investments in financial instruments such as marketable securities and accounts receivable may subject us to concentrations of credit risk. Our investments in marketable securities are managed under an investment policy authorized by our Board of Directors. This policy limits the amounts that may be invested in any one issuer and generally limits our investments to U.S. government and agency securities, state and municipal securities and corporate debt obligations that are investment grade. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of employer groups and other customers that constitute our client base. As of December 31, 2018 , there were no significant concentrations of credit risk.
ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our primary market risks are exposures to changes in interest rates that impact our investment income and interest expense and the fair value of certain of our fixed-rate investments and debt, as well as foreign currency exchange rate risk of the U.S. dollar primarily to the Brazilian real and Chilean peso.
As of December 31, 2018, we had $14 billion of financial assets on which the interest rates received vary with market interest rates, which may materially impact our investment income. Also as of December 31, 2018, $9 billion of our financial liabilities, which include commercial paper, debt and deposit liabilities, were at interest rates that vary with market rates, either directly or through the use of related interest rate swap contracts.
The fair value of certain of our fixed-rate investments and debt also varies with market interest rates. As of December 31, 2018, $30 billion of our investments were fixed-rate debt securities and $32 billion of our debt was non-swapped fixed-rate term debt. An increase in market interest rates decreases the market value of fixed-rate investments and fixed-rate debt. Conversely, a decrease in market interest rates increases the market value of fixed-rate investments and fixed-rate debt.
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by endeavoring to match our floating-rate assets and liabilities over time, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale securities are reported in comprehensive income.

36

Table of Contents


The following tables summarize the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of December 31, 2018 and 2017 on our investment income and interest expense per annum and the fair value of our investments and debt (in millions, except percentages):
 
 
December 31, 2018
Increase (Decrease) in Market Interest Rate
 
Investment
Income Per
Annum
 
Interest
Expense Per
Annum
 
Fair Value of
Financial Assets (b)
 
Fair Value of
Financial Liabilities
2 %
 
$
276

 
$
189

 
$
(2,242
)
 
$
(5,017
)
1
 
138

 
94

 
(1,140
)
 
(2,724
)
(1)
 
(138
)
 
(94
)
 
1,118

 
3,155

(2)
 
(276
)
 
(189
)
 
2,196

 
6,953

 
 
December 31, 2017
Increase (Decrease) in Market Interest Rate
 
Investment
Income Per
Annum (a)
 
Interest
Expense Per
Annum (a)
 
Fair Value of
Financial Assets (b)
 
Fair Value of
Financial Liabilities
2%
 
$
300

 
$
170

 
$
(1,958
)
 
$
(4,546
)
1
 
150

 
85

 
(933
)
 
(2,460
)
(1)
 
(150
)
 
(85
)
 
950

 
2,923

(2)
 
(197
)
 
(133
)
 
1,773

 
6,414

               
(a)
Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of December 31, 2017, the assumed hypothetical change in interest rates does not reflect the full 200 basis point reduction in interest income or interest expense in 2017, as the rate cannot fall below zero.
(b)
As of December 31, 2018 and 2017, some of our investments had interest rates below 2% so the assumed hypothetical change in the fair value of investments does not reflect the full 200 basis point reduction.
We have an exposure to changes in the value of foreign currencies, primarily the Brazilian real and the Chilean peso, to the U.S. dollar in translation of UnitedHealthcare Global’s operating results at the average exchange rate over the accounting period, and UnitedHealthcare Global’s assets and liabilities at the spot rate at the end of the accounting period. The gains or losses resulting from translating foreign assets and liabilities into U.S. dollars are included in equity and comprehensive income.
An appreciation of the U.S. dollar against the Brazilian real or Chilean peso reduces the carrying value of the net assets denominated in those currencies. For example, as of December 31, 2018, a hypothetical 10% and 25% increase in the value of the U.S. dollar against those currencies would have caused a reduction in net assets of approximately $600 million and $1.4 billion, respectively. We manage exposure to foreign currency earnings risk primarily by conducting our international business operations in their functional currencies.
As of December 31, 2018, we had $2.0 billion of investments in equity securities, consisting of investments in non-U.S. dollar fixed-income funds; employee savings plan related investments; and dividend paying stocks. Valuations in non-U.S. dollar funds are subject to foreign exchange rates. 

37

Table of Contents


ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
 
Page
 
 


38

Table of Contents


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of UnitedHealth Group Incorporated and Subsidiaries:
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of UnitedHealth Group Incorporated and subsidiaries (the "Company") as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive income, changes in equity and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.
We also have audited, in accordance with the standards of Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 12, 2019 expressed an unqualified opinion on the Company’s internal control over financial reporting.
Basis for Opinions
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
 
/ S / DELOITTE & TOUCHE LLP
 
Minneapolis, Minnesota
February 12, 2019

We have served as the Company's auditor since 2002.


39



UnitedHealth Group
Consolidated Balance Sheets
(in millions, except per share data)
 
December 31,
2018
 
December 31,
2017
Assets
 
 
 
 
Current assets:
 
 
 
 
Cash and cash equivalents
 
$
10,866

 
$
11,981

Short-term investments
 
3,458

 
3,509

Accounts receivable, net of allowances of $712 and $641
 
11,388

 
9,568

Other current receivables, net of allowances of $502 and $440
 
6,862

 
6,262

Assets under management
 
3,032

 
3,101

Prepaid expenses and other current assets
 
3,086

 
2,663

Total current assets
 
38,692

 
37,084

Long-term investments
 
32,510

 
28,341

Property, equipment and capitalized software, net of accumulated depreciation and amortization of $4,141 and $3,694
 
8,458

 
7,013

Goodwill
 
58,910

 
54,556

Other intangible assets, net of accumulated amortization of $4,592 and $4,309
 
9,325

 
8,489

Other assets
 
4,326

 
3,575

Total assets
 
$
152,221

 
$
139,058

Liabilities, redeemable noncontrolling interests and equity
 
 
 
 
Current liabilities:
 
 
 
 
Medical costs payable
 
$
19,891

 
$
17,871

Accounts payable and accrued liabilities
 
16,705

 
15,180

Commercial paper and current maturities of long-term debt
 
1,973

 
2,857

Unearned revenues
 
2,396

 
2,269

Other current liabilities
 
12,244

 
12,286

Total current liabilities
 
53,209

 
50,463

Long-term debt, less current maturities
 
34,581

 
28,835

Deferred income taxes
 
2,474

 
2,182

Other liabilities
 
5,730

 
5,556

Total liabilities
 
95,994

 
87,036

 
 
 


Redeemable noncontrolling interests
 
1,908

 
2,189

Equity:
 
 
 
 
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding
 

 

Common stock, $0.01 par value - 3,000 shares authorized; 960 and 969 issued and outstanding
 
10

 
10

Additional paid-in capital
 

 
1,703

Retained earnings
 
55,846

 
48,730

Accumulated other comprehensive loss
 
(4,160
)
 
(2,667
)
Nonredeemable noncontrolling interests
 
2,623

 
2,057

Total equity
 
54,319

 
49,833

Total liabilities, redeemable noncontrolling interests and equity
 
$
152,221

 
$
139,058


See Notes to the Consolidated Financial Statements


40

Table of Contents


UnitedHealth Group
Consolidated Statements of Operations
 
 
For the Years Ended December 31,
(in millions, except per share data)
 
2018
 
2017
 
2016
Revenues:
 
 
 
 
 
 
Premiums
 
$
178,087

 
$
158,453

 
$
144,118

Products
 
29,601

 
26,366

 
26,658

Services
 
17,183

 
15,317

 
13,236

Investment and other income
 
1,376

 
1,023

 
828

Total revenues
 
226,247

 
201,159

 
184,840

Operating costs:
 
 
 
 
 
 
Medical costs
 
145,403

 
130,036

 
117,038

Operating costs
 
34,074

 
29,557

 
28,401

Cost of products sold
 
26,998

 
24,112

 
24,416

Depreciation and amortization
 
2,428

 
2,245

 
2,055

Total operating costs
 
208,903

 
185,950

 
171,910

Earnings from operations
 
17,344

 
15,209

 
12,930

Interest expense
 
(1,400
)
 
(1,186
)
 
(1,067
)
Earnings before income taxes
 
15,944

 
14,023

 
11,863

Provision for income taxes
 
(3,562
)
 
(3,200
)
 
(4,790
)
Net earnings
 
12,382

 
10,823

 
7,073

Earnings attributable to noncontrolling interests
 
(396
)
 
(265
)
 
(56
)
Net earnings attributable to UnitedHealth Group common shareholders
 
$
11,986

 
$
10,558

 
$
7,017

Earnings per share attributable to UnitedHealth Group common shareholders:
 
 
 
 
 
 
Basic
 
$
12.45

 
$
10.95

 
$
7.37

Diluted
 
$
12.19

 
$
10.72

 
$
7.25

Basic weighted-average number of common shares outstanding
 
963

 
964

 
952

Dilutive effect of common share equivalents
 
20

 
21

 
16

Diluted weighted-average number of common shares outstanding
 
983

 
985

 
968

Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents
 
6

 
5

 
3


See Notes to the Consolidated Financial Statements

41

Table of Contents



UnitedHealth Group
Consolidated Statements of Comprehensive Income

 
 
For the Years Ended December 31,
(in millions)
 
2018
 
2017
 
2016
Net earnings
 
$
12,382

 
$
10,823

 
$
7,073

Other comprehensive (loss) income:
 
 
 
 
 
 
Gross unrealized (losses) gains on investment securities during the period
 
(294
)
 
209

 
(73
)
Income tax effect
 
67

 
(72
)
 
26

Total unrealized (losses) gains, net of tax
 
(227
)
 
137

 
(47
)
Gross reclassification adjustment for net realized gains included in net earnings
 
(62
)
 
(83
)
 
(166
)
Income tax effect
 
14

 
30

 
60

Total reclassification adjustment, net of tax
 
(48
)
 
(53
)
 
(106
)
Total foreign currency translation (losses) gains
 
(1,242
)
 
(70
)
 
806

Other comprehensive (loss) income
 
(1,517
)
 
14

 
653

Comprehensive income
 
10,865

 
10,837

 
7,726

Comprehensive income attributable to noncontrolling interests
 
(396
)
 
(265
)
 
(56
)
Comprehensive income attributable to UnitedHealth Group common shareholders
 
$
10,469

 
$
10,572

 
$
7,670


See Notes to the Consolidated Financial Statements

42

Table of Contents


UnitedHealth Group
Consolidated Statements of Changes in Equity
 
 
Common Stock
 
Additional Paid-In Capital
 
Retained Earnings
 
Accumulated Other Comprehensive Income (Loss)
 
Nonredeemable
Noncontrolling
Interests
 
Total
Equity
(in millions)
 
Shares
 
Amount
 
 
 
Net Unrealized Gains (Losses) on Investments
 
Foreign Currency Translation (Losses) Gains
 
 
Balance at January 1, 2016
 
953

 
$
10

 
$
29

 
$
37,125

 
$
56

 
$
(3,390
)
 
$
(105
)
 
$
33,725

Adjustment to adopt ASU 2016-09
 
 
 
 
 
 
 
28

 
 
 
 
 
 
 
28

Net earnings
 
 
 
 
 
 
 
7,017

 
 
 
 
 
40

 
7,057

Other comprehensive (loss) income
 
 
 
 
 
 
 
 
 
(153
)
 
806

 
 
 
653

Issuances of common stock, and related tax effects
 
9

 

 
191

 
 
 
 
 
 
 
 
 
191

Share-based compensation
 
 
 
 
 
455

 
 
 
 
 
 
 
 
 
455

Common share repurchases
 
(10
)
 

 
(316
)
 
(964
)
 
 
 
 
 
 
 
(1,280
)
Cash dividends paid on common shares ($2.375 per share)
 
 
 
 
 
 
 
(2,261
)
 
 
 
 
 
 
 
(2,261
)
Acquisition of redeemable noncontrolling interest shares
 
 
 
 
 
(143
)
 
 
 
 
 
 
 
 
 
(143
)
Redeemable noncontrolling interest fair value and other adjustments
 
 
 
 
 
(216
)
 
 
 
 
 
 
 
 
 
(216
)
Distributions to nonredeemable noncontrolling interest
 
 
 
 
 
 
 
 
 
 
 
 
 
(32
)
 
(32
)
Balance at December 31, 2016
 
952

 
10

 

 
40,945

 
(97
)
 
(2,584
)
 
(97
)
 
38,177

Net earnings
 
 
 
 
 
 
 
10,558

 
 
 
 
 
194

 
10,752

Other comprehensive income (loss)
 
 
 
 
 
 
 
 
 
84

 
(70
)
 
 
 
14

Issuances of common stock, and related tax effects
 
26

 

 
2,225

 
 
 
 
 
 
 
 
 
2,225

Share-based compensation
 
 
 
 
 
582

 
 
 
 
 
 
 
 
 
582

Common share repurchases
 
(9
)
 

 
(1,500
)
 
 
 
 
 
 
 
 
 
(1,500
)
Cash dividends paid on common shares ($2.875 per share)
 
 
 
 
 
 
 
(2,773
)
 
 
 
 
 
 
 
(2,773
)
Acquisition of redeemable noncontrolling interest shares
 
 
 
 
 
283

 
 
 
 
 
 
 
 
 
283

Redeemable noncontrolling interest fair value and other adjustments
 
 
 
 
 
113

 
 
 
 
 
 
 
 
 
113

Acquisition of nonredeemable noncontrolling interests
 
 
 
 
 
 
 
 
 
 
 
 
 
2,112

 
2,112

Distributions to nonredeemable noncontrolling interest
 
 
 
 
 
 
 
 
 
 
 
 
 
(152
)
 
(152
)
Balance at December 31, 2017
 
969

 
10

 
1,703

 
48,730

 
(13
)
 
(2,654
)
 
2,057

 
49,833

Adjustment to adopt ASU 2016-01
 
 
 
 
 
 
 
(24
)
 
24

 
 
 
 
 

Net earnings
 
 
 
 
 
 
 
11,986

 
 
 
 
 
273

 
12,259

Other comprehensive loss
 
 
 
 
 
 
 
 
 
(275
)
 
(1,242
)
 
 
 
(1,517
)
Issuances of common stock, and related tax effects
 
10

 

 
814

 
 
 
 
 
 
 
 
 
814

Share-based compensation
 
 
 
 
 
620

 
 
 
 
 
 
 
 
 
620

Common share repurchases
 
(19
)
 

 
(2,974
)
 
(1,526
)
 
 
 
 
 
 
 
(4,500
)
Cash dividends paid on common shares ($3.45 per share)
 
 
 
 
 
 
 
(3,320
)
 
 
 
 
 
 
 
(3,320
)
Redeemable noncontrolling interests fair value and other adjustments
 
 
 
 
 
(163
)
 
 
 
 
 
 
 
 
 
(163
)
Acquisition of nonredeemable noncontrolling interests
 
 
 
 
 
 
 
 
 
 
 
 
 
521

 
521

Distributions to nonredeemable noncontrolling interests
 
 
 
 
 
 
 
 
 
 
 
 
 
(228
)
 
(228
)
Balance at December 31, 2018
 
960

 
$
10

 
$

 
$
55,846

 
$
(264
)
 
$
(3,896
)
 
$
2,623

 
$
54,319

See Notes to the Consolidated Financial Statements

43

Table of Contents


UnitedHealth Group
Consolidated Statements of Cash Flows
 
 
For the Years Ended December 31,
(in millions)
 
2018
 
2017
 
2016
Operating activities
 
 
 
 
 
 
Net earnings
 
$
12,382

 
$
10,823

 
$
7,073

Noncash items:
 
 
 
 
 
 
Depreciation and amortization
 
2,428

 
2,245

 
2,055

Deferred income taxes
 
42

 
(965
)
 
81

Share-based compensation
 
638

 
597

 
485

Other, net
 
(71
)
 
217

 
(82
)
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
 
 
 
 
 
 
Accounts receivable
 
(1,351
)
 
(1,062
)
 
(1,357
)
Other assets
 
(750
)
 
(630
)
 
(1,601
)
Medical costs payable
 
1,831

 
1,284

 
1,849

Accounts payable and other liabilities
 
526

 
930

 
1,494

Unearned revenues
 
38

 
157

 
(202
)
Cash flows from operating activities
 
15,713

 
13,596

 
9,795

Investing activities
 
 
 
 
 
 
Purchases of investments
 
(14,010
)
 
(14,588
)
 
(17,547
)
Sales of investments
 
3,641

 
4,623

 
7,339

Maturities of investments
 
6,270

 
5,646

 
4,281

Cash paid for acquisitions, net of cash assumed
 
(5,997
)
 
(2,131
)
 
(1,760
)
Purchases of property, equipment and capitalized software
 
(2,063
)
 
(2,023
)
 
(1,705
)
Other, net
 
(226
)
 
(126
)
 
37

Cash flows used for investing activities
 
(12,385
)
 
(8,599
)
 
(9,355
)
Financing activities
 
 
 
 
 
 
Common share repurchases
 
(4,500
)
 
(1,500
)
 
(1,280
)
Cash dividends paid
 
(3,320
)
 
(2,773
)
 
(2,261
)
Proceeds from common stock issuances
 
838

 
688

 
429

Repayments of long-term debt
 
(2,600
)
 
(4,398
)
 
(2,596
)
Repayments of commercial paper, net
 
(201
)
 
(3,508
)
 
(382
)
Proceeds from issuance of long-term debt
 
6,935

 
5,291

 
3,968

Customer funds administered
 
(131
)
 
3,172

 
1,692

Other, net
 
(1,386
)
 
(413
)
 
(581
)
Cash flows used for financing activities
 
(4,365
)
 
(3,441
)
 
(1,011
)
Effect of exchange rate changes on cash and cash equivalents
 
(78
)
 
(5
)
 
78

(Decrease) increase in cash and cash equivalents
 
(1,115
)
 
1,551

 
(493
)
Cash and cash equivalents, beginning of period
 
11,981

 
10,430

 
10,923

Cash and cash equivalents, end of period
 
$
10,866

 
$
11,981

 
$
10,430

 
 
 
 
 
 
 
Supplemental cash flow disclosures
 
 
 
 
 
 
Cash paid for interest
 
$
1,410

 
$
1,133

 
$
1,055

Cash paid for income taxes
 
3,257

 
4,004

 
4,726

Supplemental schedule of non-cash investing activities
 
 
 
 
 
 
Common stock issued for acquisitions
 
$

 
$
2,164

 
$


See Notes to the Consolidated Financial Statements

44

Table of Contents


UnitedHealth Group
Notes to the Consolidated Financial Statements
1.
Description of Business
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and “the Company”) is a diversified health care company dedicated to helping people live healthier lives and helping make the health system work better for everyone.
Through its diversified family of businesses, the Company leverages core competencies in data and health information; advanced technology; and clinical expertise. These core competencies are deployed within two distinct, but strategically aligned, business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
2.
Basis of Presentation, Use of Estimates and Significant Accounting Policies
Basis of Presentation
The Company has prepared the Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries.
Use of Estimates
These Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and revenues, valuation and impairment analysis of goodwill and other intangible assets and estimates of other current liabilities and other current receivables. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenues
Premiums
Premium revenues are primarily derived from risk-based health insurance arrangements in which the premium is typically at a fixed rate per individual served for a one-year period, and the Company assumes the economic risk of funding its customers’ health care and related administrative costs.
Premium revenues are recognized in the period in which eligible individuals are entitled to receive health care benefits. Health care premium payments received from the Company’s customers in advance of the service period are recorded as unearned revenues. Fully insured commercial products of U.S. health plans, Medicare Advantage and Medicare Prescription Drug Benefit (Medicare Part D) plans with medical loss ratios as calculated under the definitions in the Patient Protection and Affordable Care Act (ACA) and related federal and state regulations and implementing regulation, that fall below certain targets are required to rebate ratable portions of their premiums annually. Medicare Advantage premium revenue includes the impact of the Centers for Medicare & Medicaid Services (CMS) quality bonuses based on plans’ Star ratings.
Premium revenues are recognized based on the estimated premiums earned, net of projected rebates, because the Company is able to reasonably estimate the ultimate premiums of these contracts. The Company also records premium revenues from capitation arrangements at its OptumHealth businesses.
The Company’s Medicare Advantage and Medicare Part D premium revenues are subject to periodic adjustment under CMS’ risk adjustment payment methodology. CMS deploys a risk adjustment model that apportions premiums paid to all health plans according to health severity and certain demographic factors. The CMS risk adjustment model provides higher per member payments for enrollees diagnosed with certain conditions and lower payments for enrollees who are healthier. Under this risk adjustment methodology, CMS calculates the risk adjusted premium payment using diagnosis data from hospital inpatient, hospital outpatient and physician treatment settings. The Company and health care providers collect, capture and submit the necessary and available diagnosis data to CMS within prescribed deadlines. The Company estimates risk adjustment premium revenues based upon the diagnosis data submitted and expected to be submitted to CMS. Risk adjustment data for the Company’s plans are subject to review by the government, including audit by regulators. See Note 12 for additional information regarding these audits.
Products and Services
For the Company’s OptumRx pharmacy care services business, the majority of revenues are derived from products sold through a contracted network of retail pharmacies or home delivery, specialty and compounding pharmacy facilities. Product

45

Table of Contents


revenues include ingredient costs (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through the Company’s mail-service pharmacy. In retail pharmacy transactions, revenues recognized exclude the member’s applicable co-payment. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Product revenues are recognized when the prescriptions are dispensed through the retail network or received by consumers through the Company’s mail-service pharmacy. The Company has entered into contracts in which it is primarily obligated to pay its network pharmacy providers for benefits provided to their customers regardless of whether the Company is paid. The Company is also involved in establishing the prices charged by retail pharmacies, determining which drugs will be included in formulary listings and selecting which retail pharmacies will be included in the network offered to plan sponsors’ members and accordingly, are reported on a gross basis.
Services revenue consists of fees derived from services performed for customers that self-insure the health care costs of their employees and employees’ dependents. Under service fee contracts, the Company receives monthly, a fixed fee per employee, which is recognized as revenue as the Company performs, or makes available, the applicable services to the customer. The customers retain the risk of financing health care costs for their employees and employees’ dependents, and the Company administers the payment of customer funds to physicians and other health care professionals from customer-funded bank accounts. As the Company has neither the obligation for funding the health care costs, nor the primary responsibility for providing the medical care, the Company does not recognize premium revenue and medical costs for these contracts in its Consolidated Financial Statements. For these fee-based customer arrangements, the Company provides coordination and facilitation of medical services; transaction processing; customer, consumer and care professional services; and access to contracted networks of physicians, hospitals and other health care professionals. These services are performed throughout the contract period.
Revenues are also comprised of a number of services and products sold through Optum. OptumHealth’s service revenues include net patient service revenues that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For its financial services offerings, OptumHealth charges fees and earns investment income on managed funds. OptumInsight provides software and information products, advisory consulting arrangements and services outsourcing contracts, which may be delivered over several years. OptumInsight revenues are generally recognized over time and measured each period based on the progress to date as services are performed or made available to customers.
As of December 31, 2018 and 2017 , accounts receivables related to products and services were $3.9 billion and $3.7 billion , respectively. In 2018 and 2017 , the Company had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the Consolidated Balance Sheets as of December 31, 2018 or 2017 .
For the years ended December 31, 2018 and 2017 , revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price) was not material.
Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, is not material.
See Note 13 for disaggregation of revenue by segment and type.
Medical Costs and Medical Costs Payable
The Company’s estimate of medical costs payable represents management’s best estimate of its liability for unpaid medical costs as of December 31, 2018.
Each period, the Company re-examines previously established medical costs payable estimates based on actual claim submissions and other changes in facts and circumstances. As more complete claim information becomes available, the Company adjusts the amount of the estimates and includes the changes in estimates in medical costs in the period in which the change is identified. Approximately 90% of claims related to medical care services are known and settled within 90 days from the date of service and substantially all within twelve months.
Medical costs and medical costs payable include estimates of the Company’s obligations for medical care services that have been rendered on behalf of insured consumers, but for which claims have either not yet been received, processed, or paid. The Company develops estimates for medical care services incurred but not reported (IBNR), which includes estimates for claims that have not been received or fully processed, using an actuarial process that is consistently applied, centrally controlled and automated. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, medical care utilization and other medical cost

46

Table of Contents


trends, membership volume and demographics, the introduction of new technologies, benefit plan changes, and business mix changes related to products, customers and geography.
In developing its medical costs payable estimates, the Company applies different estimation methods depending on which incurred claims are being estimated. For the most recent two months, the Company estimates claim costs incurred by applying observed medical cost trend factors to the average per member per month (PMPM) medical costs incurred in prior months for which more complete claim data are available, supplemented by a review of near-term completion factors (actuarial estimates, based upon historical experience and analysis of current trends, of the percentage of incurred claims during a given period that have been adjudicated by the Company at the date of estimation). For months prior to the most recent two months, the Company applies the completion factors to actual claims adjudicated-to-date to estimate the expected amount of ultimate incurred claims for those months.
Cost of Products Sold
The Company’s cost of products sold includes the cost of pharmaceuticals dispensed to unaffiliated customers either directly at its home delivery and specialty pharmacy locations, or indirectly through its nationwide network of participating pharmacies. Rebates attributable to non-affiliated clients are accrued as rebates receivable and a reduction of cost of products sold, with a corresponding payable for the amounts of the rebates to be remitted to those non-affiliated clients in accordance with their contracts and recorded in the Consolidated Statements of Operations as a reduction of product revenue. Cost of products sold also includes the cost of personnel to support the Company’s transaction processing services, system sales, maintenance and professional services.
Cash, Cash Equivalents and Investments
Cash and cash equivalents are highly liquid investments that have an original maturity of three months or less. The fair value of cash and cash equivalents approximates their carrying value because of the short maturity of the instruments.
Investments with maturities of less than one year are classified as short-term. Because of regulatory requirements, certain investments are included in long-term investments regardless of their maturity date. The Company classifies these investments as held-to-maturity and reports them at amortized cost. Substantially all other investments are classified as available-for-sale and reported at fair value based on quoted market prices, where available. Equity investments, with certain exceptions, are measured at fair value with changes in fair value recognized in net earnings.
The Company excludes unrealized gains and losses on investments in available-for-sale debt securities from net earnings and reports them as comprehensive income and, net of income tax effects, as a separate component of equity. To calculate realized gains and losses on the sale of debt securities, the Company specifically identifies the cost of each investment sold.
The Company evaluates an investment for impairment by considering the length of time and extent to which market value has been less than cost or amortized cost, the financial condition and near-term prospects of the issuer as well as specific events or circumstances that may influence the operations of the issuer and the Company’s intent to sell the security or the likelihood that it will be required to sell the security before recovery of the entire amortized cost.
New information and the passage of time can change these judgments. The Company manages its investment portfolio to limit its exposure to any one issuer or market sector, and largely limits its investments to investment grade quality. Securities downgraded below policy minimums after purchase will be disposed of in accordance with the Company’s investment policy.
Assets Under Management
The Company provides health insurance products and services to members of AARP under a Supplemental Health Insurance Program (the AARP Program) and to AARP members and non-members under separate Medicare Advantage and Medicare Part D arrangements. The products and services under the AARP Program include supplemental Medicare benefits, hospital indemnity insurance, including insurance for individuals between 50 to 64 years of age, and other related products.
Pursuant to the Company’s agreement, AARP Program assets are managed separately from the Company’s general investment portfolio and are used to pay costs associated with the AARP Program. These assets are invested at the Company’s discretion, within investment guidelines approved by AARP. The Company does not guarantee any rates of return on these investments and, upon any transfer of the AARP Program contract to another entity, the Company would transfer cash equal in amount to the fair value of these investments at the date of transfer to that entity. Because the purpose of these assets is to fund the medical costs payable, the rate stabilization fund (RSF) liabilities and other related liabilities associated with this AARP contract, assets under management are classified as current assets, consistent with the classification of these liabilities.

47

Table of Contents


The effects of changes in other balance sheet amounts associated with the AARP Program also accrue to the overall benefit of the AARP policyholders through the RSF balance. Accordingly, the Company excludes the effect of such changes in its Consolidated Statements of Cash Flows.
Other Current Receivables
Other current receivables include amounts due from pharmaceutical manufacturers for rebates and other miscellaneous amounts due to the Company.
The Company’s pharmacy care services businesses contract with pharmaceutical manufacturers, some of which provide rebates based on use of the manufacturers’ products by its affiliated and non-affiliated clients. The Company accrues rebates as they are earned by its clients on a monthly basis based on the terms of the applicable contracts, historical data and current estimates. The pharmacy care services businesses bill these rebates to the manufacturers on a monthly or quarterly basis depending on the contractual terms and record rebates attributable to affiliated clients as a reduction to medical costs. The Company generally receives rebates two to five months after billing. As of December 31, 2018 and 2017, total pharmaceutical manufacturer rebates receivable included in other receivables in the Consolidated Balance Sheets amounted to $4.2 billion and $3.8 billion , respectively.
Property, Equipment and Capitalized Software
Property, equipment and capitalized software are stated at cost, net of accumulated depreciation and amortization. Capitalized software consists of certain costs incurred in the development of internal-use software, including external direct costs of materials and services and applicable payroll costs of employees devoted to specific software development.
The Company calculates depreciation and amortization using the straight-line method over the estimated useful lives of the assets. The useful lives for property, equipment and capitalized software are:
Furniture, fixtures and equipment
3 to 10 years
Buildings
35 to 40 years
Capitalized software
3 to 5 years
Leasehold improvements are depreciated over the shorter of the remaining lease term or their estimated useful economic life.
Goodwill
To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company may first assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. If the fair value is less than the carrying value of the reporting unit, then the implied value of goodwill would be calculated and compared to the carrying amount of goodwill to determine whether goodwill is impaired.
There was no impairment of goodwill during the year ended December 31, 2018 .
Intangible Assets
The Company’s intangible assets are subject to impairment tests when events or circumstances indicate that an intangible asset (or asset group) may be impaired. The Company’s indefinite-lived intangible assets are also tested for impairment annually. There was no impairment of intangible assets during the year ended December 31, 2018 .
Other Current Liabilities
Other current liabilities include health savings account deposits ( $7.5 billion and $6.4 billion as of December 31, 2018 and 2017 , respectively), deposits under the Medicare Part D program, the RSF associated with the AARP Program, accruals for premium rebate payments under the ACA, the current portion of future policy benefits and customer balances.
Policy Acquisition Costs
The Company’s short duration health insurance contracts typically have a one-year term and may be canceled by the customer with at least 30 days’ notice. Costs related to the acquisition and renewal of short duration customer contracts are primarily charged to expense as incurred.

48

Table of Contents


Redeemable Noncontrolling Interests
Redeemable noncontrolling interests in the Company’s subsidiaries whose redemption is outside the control of the Company are classified as temporary equity. The following table provides details of the Company's redeemable noncontrolling interests’ activity for the years ended December 31, 2018 and 2017 :
(in millions)
 
2018
 
2017
Redeemable noncontrolling interests, beginning of period
 
$
2,189

 
$
2,012

Net earnings
 
123

 
71

Acquisitions
 
102

 
565

Redemptions
 
(90
)
 
(309
)
Distributions
 
(53
)
 
(38
)
Fair value and other adjustments
 
(363
)
 
(112
)
Redeemable noncontrolling interests, end of period
 
$
1,908

 
$
2,189

Share-Based Compensation
The Company recognizes compensation expense for share-based awards, including stock options, stock-settled stock appreciation rights (SARs) and restricted stock and restricted stock units (collectively, restricted shares), on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. Restricted shares vest ratably, primarily over two to five years and compensation expense related to restricted shares is based on the share price on the date of grant. Stock options and SARs vest ratably primarily over four years and may be exercised up to 10 years from the date of grant. Compensation expense related to stock options and SARs is based on the fair value at the date of grant, which is estimated on the date of grant using a binomial option-pricing model. Under the Company’s Employee Stock Purchase Plan (ESPP), eligible employees are allowed to purchase the Company’s stock at a discounted price, which is 85% of the lower market price of the Company’s common stock at the beginning or at the end of the six-month purchase period. Share-based compensation expense for all programs is recognized in operating costs in the Consolidated Statements of Operations.
Net Earnings Per Common Share
The Company computes basic earnings per common share attributable to UnitedHealth Group common shareholders by dividing net earnings attributable to UnitedHealth Group common shareholders by the weighted-average number of common shares outstanding during the period. The Company determines diluted net earnings per common share attributable to UnitedHealth Group common shareholders using the weighted-average number of common shares outstanding during the period, adjusted for potentially dilutive shares associated with stock options, SARs, restricted shares and the ESPP (collectively, common stock equivalents), using the treasury stock method. The treasury stock method assumes a hypothetical issuance of shares to settle the share-based awards, with the assumed proceeds used to purchase common stock at the average market price for the period. Assumed proceeds include the amount the employee must pay upon exercise and the average unrecognized compensation cost. The difference between the number of shares assumed issued and number of shares assumed purchased represents the dilutive shares.
Health Insurance Industry Tax
The ACA includes an annual, nondeductible insurance industry tax (Health Insurance Industry Tax) to be levied proportionally across the insurance industry for risk-based health insurance products. A one year moratorium on the collection of the Health Insurance Industry Tax will occur in 2019.
The Company estimates its liability for the Health Insurance Industry Tax based on a ratio of the Company’s applicable net premiums written compared to the U.S. health insurance industry total applicable net premiums, both for the previous calendar year. The Company records in full the estimated liability for the Health Insurance Industry Tax at the beginning of the calendar year with a corresponding deferred cost that is amortized to operating costs on the Consolidated Statements of Operations using a straight-line method over the calendar year. The liability is recorded in accounts payable and accrued liabilities and the corresponding deferred cost is recorded in prepaid expenses and other current assets on the Consolidated Balance Sheets.
Recently Issued Accounting Standards
In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) No. 2016-02, “Leases (Topic 842)” as modified by ASUs 2018-01, 2018-10, 2018-11 and 2018-20 (collectively, ASU 2016-02). Under ASU 2016-02, an entity is required to recognize assets and liabilities for the rights and obligations created by leases on the entity’s balance sheet for both finance and operating leases. For leases with a term of 12 months or less, the Company elected to not

49

Table of Contents


recognize lease assets and lease liabilities and expense the leases over a straight-line basis for the term of those leases. ASU 2016-02 requires new disclosures that depict the amount, timing and uncertainty of cash flows pertaining to an entity’s leases. The Company adopted ASU 2016-02 on January 1, 2019, using the cumulative effect upon adoption approach. The adoption resulted in no material impact to the Company’s balance sheet, results of operations, equity or cash flows.
Recently Adopted Accounting Standards
In January 2016, the FASB issued ASU 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (ASU 2016-01). Most notably, the new guidance requires that equity investments, with certain exemptions, be measured at fair value with changes in fair value recognized in net income as opposed to other comprehensive income. The Company adopted ASU 2016-01 on a prospective basis effective January 1, 2018, as required, and reclassified $ 24 million from accumulated other comprehensive income to retained earnings.
The Company has determined that there have been no other recently adopted or issued accounting standards that had, or will have, a material impact on its Consolidated Financial Statements.
3.
Investments
A summary of debt securities by major security type is as follows:
(in millions)
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair
Value
December 31, 2018
 
 
 
 
 
 
 
 
Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
3,434

 
$
13

 
$
(42
)
 
$
3,405

State and municipal obligations
 
7,117

 
61

 
(57
)
 
7,121

Corporate obligations
 
15,366

 
14

 
(218
)
 
15,162

U.S. agency mortgage-backed securities
 
4,947

 
11

 
(106
)
 
4,852

Non-U.S. agency mortgage-backed securities
 
1,376

 
2

 
(20
)
 
1,358

Total debt securities - available-for-sale
 
32,240

 
101

 
(443
)
 
31,898

Debt securities - held-to-maturity:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
255

 
1

 
(2
)
 
254

State and municipal obligations
 
11

 

 

 
11

Corporate obligations
 
355

 

 

 
355

Total debt securities - held-to-maturity
 
621

 
1

 
(2
)
 
620

Total debt securities
 
$
32,861

 
$
102

 
$
(445
)
 
$
32,518

December 31, 2017
 
 
 
 
 
 
 
 
Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
2,673

 
$
1

 
$
(30
)
 
$
2,644

State and municipal obligations
 
7,596

 
99

 
(35
)
 
7,660

Corporate obligations
 
13,181

 
57

 
(44
)
 
13,194

U.S. agency mortgage-backed securities
 
3,942

 
7

 
(38
)
 
3,911

Non-U.S. agency mortgage-backed securities
 
1,018

 
3

 
(6
)
 
1,015

Total debt securities - available-for-sale
 
28,410

 
167

 
(153
)
 
28,424

Debt securities - held-to-maturity:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
254

 
1

 
(1
)
 
254

State and municipal obligations
 
2

 

 

 
2

Corporate obligations
 
280

 

 

 
280

Total debt securities - held-to-maturity
 
536

 
1

 
(1
)
 
536

Total debt securities
 
$
28,946

 
$
168

 
$
(154
)
 
$
28,960

Nearly all of the Company’s investments in mortgage-backed securities were rated AAA as of December 31, 2018 .
The Company held $2.0 billion of equity securities as of December 31, 2018 and December 31, 2017. The Company’s investments in equity securities primarily consist of employee savings plan related investments, Brazilian real denominated

50

Table of Contents


fixed-income funds and dividend paying stocks, with readily determinable fair values. Additionally, the Company’s investments included $ 1.5 billion and $ 0.9 billion of equity method investments in operating businesses in the health care sector, as of December 31, 2018 and 2017, respectively.
The amortized cost and fair value of debt securities as of December 31, 2018 , by contractual maturity, were as follows:
 
 
Available-for-Sale
 
Held-to-Maturity
(in millions)
 
Amortized
Cost
 
Fair
Value
 
Amortized
Cost
 
Fair
Value
Due in one year or less
 
$
3,560

 
$
3,551

 
$
150

 
$
150

Due after one year through five years
 
12,432

 
12,297

 
213

 
212

Due after five years through ten years
 
7,362

 
7,270

 
129

 
129

Due after ten years
 
2,563

 
2,570

 
129

 
129

U.S. agency mortgage-backed securities
 
4,947

 
4,852

 

 

Non-U.S. agency mortgage-backed securities
 
1,376

 
1,358

 

 

Total debt securities
 
$
32,240

 
$
31,898

 
$
621

 
$
620


The fair value of available-for-sale investments with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 
 
Less Than 12 Months
 
12 Months or Greater
 
 Total
(in millions)
 
Fair
Value
 
Gross
Unrealized
Losses
 
Fair
Value
 
Gross
Unrealized
Losses
 
Fair
Value
 
Gross
Unrealized
Losses
December 31, 2018
 
 
 
 
 
 
 
 
 
 
 
 
Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
998

 
$
(7
)
 
$
1,425

 
$
(35
)
 
$
2,423

 
$
(42
)
State and municipal obligations
 
1,334

 
(11
)
 
2,491

 
(46
)
 
3,825

 
(57
)
Corporate obligations
 
8,105

 
(109
)
 
4,239

 
(109
)
 
12,344

 
(218
)
U.S. agency mortgage-backed securities
 
1,296

 
(22
)
 
2,388

 
(84
)
 
3,684

 
(106
)
Non-U.S. agency mortgage-backed securities
 
622

 
(7
)
 
459

 
(13
)
 
1,081

 
(20
)
Total debt securities - available-for-sale
 
$
12,355

 
$
(156
)
 
$
11,002

 
$
(287
)
 
$
23,357

 
$
(443
)
December 31, 2017
 
 
 
 
 
 
 
 
 
 
 
 
Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
$
1,249

 
$
(8
)
 
$
1,027

 
$
(22
)
 
$
2,276

 
$
(30
)
State and municipal obligations
 
2,599

 
(21
)
 
866

 
(14
)
 
3,465

 
(35
)
Corporate obligations
 
5,901

 
(23
)
 
1,242

 
(21
)
 
7,143

 
(44
)
U.S. agency mortgage-backed securities
 
1,657

 
(12
)
 
1,162

 
(26
)
 
2,819

 
(38
)
Non-U.S. agency mortgage-backed securities
 
411

 
(3
)
 
144

 
(3
)
 
555

 
(6
)
Total debt securities - available-for-sale
 
$
11,817

 
$
(67
)
 
$
4,441

 
$
(86
)
 
$
16,258

 
$
(153
)
The Company’s unrealized losses from all securities as of December 31, 2018 were generated from approximately 19,000 positions out of a total of 31,000 positions. The Company believes that it will collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting no significant deterioration since purchase. As of December 31, 2018 , the Company did not have the intent to sell any of the securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary.

51

Table of Contents


4.
Fair Value
Certain assets and liabilities are measured at fair value in the Consolidated Financial Statements or have fair values disclosed in the Notes to the Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.
The fair value hierarchy is summarized as follows:
Level 1 — Quoted prices (unadjusted) for identical assets/liabilities in active markets.
Level 2 — Other observable inputs, either directly or indirectly, including:
Quoted prices for similar assets/liabilities in active markets;
Quoted prices for identical or similar assets/liabilities in inactive markets (e.g., few transactions, limited information, noncurrent prices, high variability over time);
Inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves, implied volatilities, credit spreads); and
Inputs that are corroborated by other observable market data.
Level 3 — Unobservable inputs that cannot be corroborated by observable market data.
There was no transfers in or out of Level 3 financial assets or liabilities during the year ended December 31, 2018 or 2017 .
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the year ended December 31, 2018 or 2017 .
The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the tables below:
Cash and Cash Equivalents. The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.
Debt and Equity Securities. Fair values of debt and equity securities are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (pricing service), which generally uses quoted or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, and, if necessary, makes adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and nonbinding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to prices reported by a secondary pricing source, such as its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company’s internal price verification procedures and reviews of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment in the prices obtained from the pricing service.
Fair values of debt securities that do not trade on a regular basis in active markets but are priced using other observable inputs are classified as Level 2.
Fair value estimates for Level 1 and Level 2 equity securities are based on quoted market prices for actively traded equity securities and/or other market data for the same or comparable instruments and transactions in establishing the prices.
The fair values of Level 3 investments in corporate bonds are estimated using valuation techniques that rely heavily on management assumptions and qualitative observations.
Throughout the procedures discussed above in relation to the Company’s processes for validating third-party pricing information, the Company validates the understanding of assumptions and inputs used in security pricing and determines the proper classification in the hierarchy based on that understanding.

52

Table of Contents


Assets Under Management. Assets under management consists of debt securities and other investments held to fund costs associated with the AARP Program and are priced and classified using the same methodologies as the Company’s investments in debt and equity securities.
Long-Term Debt. The fair values of the Company’s long-term debt are estimated and classified using the same methodologies as the Company’s investments in debt securities.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Consolidated Balance Sheets:
(in millions)
 
Quoted Prices
in Active
Markets
(Level 1)
 
Other
Observable
Inputs
(Level 2)
 
Unobservable
Inputs
(Level 3)
 
Total
Fair and Carrying
Value
December 31, 2018
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
10,757

 
$
109

 
$

 
$
10,866

Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
3,060

 
345

 

 
3,405

State and municipal obligations
 

 
7,121

 

 
7,121

Corporate obligations
 
39

 
14,950

 
173

 
15,162

U.S. agency mortgage-backed securities
 

 
4,852

 

 
4,852

Non-U.S. agency mortgage-backed securities
 

 
1,358

 

 
1,358

Total debt securities - available-for-sale
 
3,099

 
28,626

 
173

 
31,898

Equity securities
 
1,832

 
13

 

 
1,845

Assets under management
 
1,086

 
1,938

 
8

 
3,032

Total assets at fair value

$
16,774

 
$
30,686

 
$
181

 
$
47,641

Percentage of total assets at fair value
 
35
%
 
65
%
 
%
 
100
%
December 31, 2017
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
11,718

 
$
263

 
$

 
$
11,981

Debt securities - available-for-sale:
 
 
 
 
 
 
 
 
U.S. government and agency obligations
 
2,428

 
216

 

 
2,644

State and municipal obligations
 

 
7,660

 

 
7,660

Corporate obligations
 
65

 
12,989

 
140

 
13,194

U.S. agency mortgage-backed securities
 

 
3,911

 

 
3,911

Non-U.S. agency mortgage-backed securities
 

 
1,015

 

 
1,015

Total debt securities - available-for-sale
 
2,493

 
25,791

 
140

 
28,424

Equity securities
 
1,784

 
14

 
194

 
1,992

Assets under management
 
1,117

 
1,984

 

 
3,101

Total assets at fair value
 
$
17,112

 
$
28,052

 
$
334

 
$
45,498

Percentage of total assets at fair value
 
38
%
 
61
%
 
1
%
 
100
%

53

Table of Contents


The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Consolidated Balance Sheets:
(in millions)
 
Quoted Prices
in Active
Markets
(Level 1)
 
Other
Observable
Inputs
(Level 2)
 
Unobservable
Inputs
(Level 3)
 
Total
Fair
Value
 
Total Carrying Value
December 31, 2018
 
 
 
 
 
 
 
 
 
 
Debt securities - held-to-maturity
 
$
260

 
$
65

 
$
295

 
$
620

 
$
621

Long-term debt and other financing obligations
 
$

 
$
37,944

 
$

 
$
37,944

 
$
36,554

December 31, 2017
 
 
 
 
 
 
 
 
 
 
Debt securities - held-to-maturity
 
$
267

 
$
4

 
$
265

 
$
536

 
$
536

Long-term debt and other financing obligations
 
$

 
$
34,504

 
$

 
$
34,504

 
$
31,542

The carrying amounts reported on the Consolidated Balance Sheets for other current financial assets and liabilities approximate fair value because of their short-term nature. These assets and liabilities are not listed in the table above.
5.
Property, Equipment and Capitalized Software
A summary of property, equipment and capitalized software is as follows:
(in millions)
 
December 31, 2018
 
December 31, 2017
Land and improvements
 
$
566

 
$
405

Buildings and improvements
 
4,470

 
3,664

Computer equipment
 
1,984

 
1,829

Furniture and fixtures
 
1,525

 
1,208

Less accumulated depreciation
 
(2,787
)
 
(2,488
)
Property and equipment, net
 
5,758

 
4,618

Capitalized software
 
4,054

 
3,601

Less accumulated amortization
 
(1,354
)
 
(1,206
)
Capitalized software, net
 
2,700

 
2,395

Total property, equipment and capitalized software, net
 
$
8,458

 
$
7,013

 
Depreciation expense for property and equipment for the years ended December 31, 2018 , 2017 and 2016 was $924 million , $799 million and $698 million , respectively. Amortization expense for capitalized software for the years ended December 31, 2018 , 2017 and 2016 was $606 million , $550 million and $475 million , respectively.
6.
Goodwill and Other Intangible Assets
Changes in the carrying amount of goodwill, by reportable segment, were as follows:
(in millions)
 
UnitedHealthcare
 
OptumHealth
 
OptumInsight
 
OptumRx
 
Consolidated
Balance at January 1, 2017
 
$
23,854

 
$
6,322

 
$
4,449

 
$
12,959

 
$
47,584

Acquisitions
 
690

 
5,189

 
1,221

 

 
7,100

Foreign currency effects and adjustments, net
 
(60
)
 
(23
)
 
4

 
(49
)
 
(128
)
Balance at December 31, 2017
 
24,484

 
11,488

 
5,674

 
12,910

 
54,556

Acquisitions
 
2,723

 
471

 
106

 
1,881

 
5,181

Foreign currency effects and adjustments, net
 
(807
)
 
(12
)
 
(8
)
 

 
(827
)
Balance at December 31, 2018
 
$
26,400

 
$
11,947

 
$
5,772

 
$
14,791

 
$
58,910


54

Table of Contents


The gross carrying value, accumulated amortization and net carrying value of other intangible assets were as follows:
 
 
December 31, 2018
 
December 31, 2017
(in millions)
 
Gross Carrying Value
 
Accumulated Amortization
 
Net Carrying Value
 
Gross Carrying Value
 
Accumulated Amortization
 
Net Carrying Value
Customer-related
 
$
11,622

 
$
(3,908
)
 
$
7,714

 
$
10,832

 
$
(3,743
)
 
$
7,089

Trademarks and technology
 
1,122

 
(512
)
 
610

 
1,054

 
(432
)
 
622

Trademarks and other indefinite-lived
 
745

 

 
745

 
561

 

 
561

Other
 
428

 
(172
)
 
256

 
351

 
(134
)
 
217

Total
 
$
13,917

 
$
(4,592
)
 
$
9,325

 
$
12,798

 
$
(4,309
)
 
$
8,489

The acquisition date fair values and weighted-average useful lives assigned to finite-lived intangible assets acquired in business combinations consisted of the following by year of acquisition:
 
 
2018
 
2017
(in millions, except years)
 
Fair Value
 
Weighted-Average Useful Life
 
Fair Value
 
Weighted-Average Useful Life
Customer-related
 
$
1,355

 
17 years
 
$
324

 
13 years
Trademarks and technology
 
122

 
4 years
 
367

 
11 years
Other
 
97

 
9 years
 
82

 
6 years
Total acquired finite-lived intangible assets
 
$
1,574

 
16 years
 
$
773

 
11 years
  Estimated full year amortization expense relating to intangible assets for each of the next five years ending December 31 is as follows:
(in millions)
 
 
2019
 
$
889

2020
 
795

2021
 
724

2022
 
632

2023
 
593

Amortization expense relating to intangible assets for the years ended December 31, 2018 , 2017 and 2016 was $898 million , $896 million and $882 million , respectively.
7.
Medical Costs Payable
The following table shows the components of the change in medical costs payable for the years ended December 31:
(in millions)
 
2018
 
2017
 
2016
Medical costs payable, beginning of period
 
$
17,871

 
$
16,391

 
$
14,330

Acquisitions
 
339

 
83

 

Reported medical costs:
 
 
 
 
 
 
Current year
 
145,723

 
130,726

 
117,258

Prior years
 
(320
)
 
(690
)
 
(220
)
Total reported medical costs
 
145,403

 
130,036

 
117,038

Medical payments:
 
 
 
 
 
 
Payments for current year
 
(127,155
)
 
(113,811
)
 
(101,696
)
Payments for prior years
 
(16,567
)
 
(14,828
)
 
(13,281
)
Total medical payments
 
(143,722
)
 
(128,639
)
 
(114,977
)
Medical costs payable, end of period
 
$
19,891

 
$
17,871

 
$
16,391

For the years ended December 31, 2018 and 2016 , no individual factors significantly impacted medical cost reserve development . For the year ended December 31, 2017 , medical cost reserve development was primarily driven by lower than expected health system utilization levels.

55

Table of Contents


Medical costs payable included IBNR of $13.2 billion and $12.3 billion at December 31, 2018 and 2017 , respectively. Substantially all of the IBNR balance as of December 31, 2018 relates to the current year. The following is information about incurred and paid medical cost development as of December 31, 2018 :
 
 
Net Incurred Medical Costs
 (in millions)
 
For the Years ended December 31,
Year
 
2017
 
2018
2017
 
$
130,726

 
$
130,441

2018
 
 
 
145,723

Total
 
 
 
$
276,164

 
 
 
 
 
 
 
Net Cumulative Medical Payments
 (in millions)
 
For the Years ended December 31,
Year
 
2017
 
2018
2017
 
$
(113,811
)
 
$
(129,778
)
2018
 
 
 
(127,155
)
Total
 
 
 
(256,933
)
Net remaining outstanding liabilities prior to 2017
 
 
 
660

Total medical costs payable
 
 
 
$
19,891




56

Table of Contents


8.
Commercial Paper and Long-Term Debt
Commercial paper and senior unsecured long-term debt consisted of the following:
 
 
December 31, 2018
 
December 31, 2017
(in millions, except percentages)
 
Par
Value
 
Carrying
Value
 
Fair
Value
 
Par
Value
 
Carrying
Value
 
Fair
Value
Commercial paper
 
$

 
$

 
$

 
$
150

 
$
150

 
$
150

6.000% notes due February 2018
 

 

 

 
1,100

 
1,101

 
1,106

1.900% notes due July 2018
 

 

 

 
1,500

 
1,499

 
1,501

1.700% notes due February 2019
 
750

 
750

 
749

 
750

 
749

 
747

1.625% notes due March 2019
 
500

 
500

 
499

 
500

 
501

 
497

2.300% notes due December 2019
 
500

 
494

 
497

 
500

 
495

 
501

2.700% notes due July 2020
 
1,500

 
1,498

 
1,494

 
1,500

 
1,496

 
1,517

Floating rate notes due October 2020
 
300

 
299

 
298

 
300

 
299

 
300

3.875% notes due October 2020
 
450

 
443

 
456

 
450

 
446

 
467

1.950% notes due October 2020
 
900

 
897

 
884

 
900

 
895

 
892

4.700% notes due February 2021
 
400

 
398

 
412

 
400

 
403

 
425

2.125% notes due March 2021
 
750

 
747

 
734

 
750

 
746

 
744

Floating rate notes due June 2021
 
350

 
349

 
347

 

 

 

3.150% notes due June 2021
 
400

 
399

 
400

 

 

 

3.375% notes due November 2021
 
500

 
489

 
503

 
500

 
493

 
516

2.875% notes due December 2021
 
750

 
735

 
748

 
750

 
741

 
760

2.875% notes due March 2022
 
1,100

 
1,051

 
1,091

 
1,100

 
1,054

 
1,114

3.350% notes due July 2022
 
1,000

 
997

 
1,005

 
1,000

 
996

 
1,033

2.375% notes due October 2022
 
900

 
894

 
872

 
900

 
893

 
891

0.000% notes due November 2022
 
15

 
12

 
13

 
15

 
12

 
12

2.750% notes due February 2023
 
625

 
602

 
611

 
625

 
606

 
626

2.875% notes due March 2023
 
750

 
750

 
739

 
750

 
762

 
759

3.500% notes due June 2023
 
750

 
746

 
756

 

 

 

3.500% notes due February 2024
 
750

 
745

 
755

 

 

 

3.750% notes due July 2025
 
2,000

 
1,989

 
2,025

 
2,000

 
1,987

 
2,108

3.700% notes due December 2025
 
300

 
298

 
303

 

 

 

3.100% notes due March 2026
 
1,000

 
995

 
965

 
1,000

 
995

 
1,007

3.450% notes due January 2027
 
750

 
746

 
742

 
750

 
745

 
776

3.375% notes due April 2027
 
625

 
619

 
611

 
625

 
618

 
642

2.950% notes due October 2027
 
950

 
938

 
898

 
950

 
937

 
947

3.850% notes due June 2028
 
1,150

 
1,142

 
1,163

 

 

 

3.875% notes due December 2028
 
850

 
842

 
861

 

 

 

4.625% notes due July 2035
 
1,000

 
992

 
1,060

 
1,000

 
991

 
1,165

5.800% notes due March 2036
 
850

 
838

 
1,003

 
850

 
837

 
1,105

6.500% notes due June 2037
 
500

 
492

 
638

 
500

 
491

 
698

6.625% notes due November 2037
 
650

 
641

 
841

 
650

 
641

 
923

6.875% notes due February 2038
 
1,100

 
1,076

 
1,437

 
1,100

 
1,075

 
1,596

5.700% notes due October 2040
 
300

 
296

 
355

 
300

 
296

 
389

5.950% notes due February 2041
 
350

 
345

 
426

 
350

 
345

 
466

4.625% notes due November 2041
 
600

 
588

 
627

 
600

 
588

 
685

4.375% notes due March 2042
 
502

 
484

 
503

 
502

 
483

 
555

3.950% notes due October 2042
 
625

 
607

 
596

 
625

 
607

 
650

4.250% notes due March 2043
 
750

 
734

 
744

 
750

 
734

 
822

4.750% notes due July 2045
 
2,000

 
1,973

 
2,116

 
2,000

 
1,972

 
2,362

4.200% notes due January 2047
 
750

 
738

 
745

 
750

 
738

 
808

4.250% notes due April 2047
 
725

 
717

 
719

 
725

 
717

 
798

3.750% notes due October 2047
 
950

 
933

 
869

 
950

 
933

 
969

4.250% notes due June 2048
 
1,350

 
1,329

 
1,349

 

 

 

4.450% notes due December 2048
 
1,100

 
1,087

 
1,132

 

 

 

Total commercial paper and long-term debt
 
$
35,667

 
$
35,234

 
$
36,591

 
$
31,417

 
$
31,067

 
$
34,029



57

Table of Contents


The Company’s long-term debt obligations also included $1.3 billion and $625 million of other financing obligations, of which $229 million and $107 million were current as of December 31, 2018 and 2017 , respectively.
Maturities of long-term debt for the years ending December 31 are as follows:
(in millions)
 
 
2019
 
$
1,973

2020
 
3,350

2021
 
3,350

2022
 
3,215

2023
 
2,325

Thereafter
 
22,775

Commercial Paper and Revolving Bank Credit Facilities
Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers.
The Company has $3.5 billion five-year, $3.5 billion three-year and $3.0 billion 364-day revolving bank credit facilities with 26 banks, which mature in December 2023 , December 2021 and December 2019 , respectively. These facilities provide liquidity support for the Company’s commercial paper program and are available for general corporate purposes. As of December 31, 2018 , no amounts had been drawn on any of the bank credit facilities. The annual interest rates, which are variable based on term, are calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company’s senior unsecured credit ratings. If amounts had been drawn on the bank credit facilities as of December 31, 2018 , annual interest rates would have ranged from 3.2% to 3.6% .
Debt Covenants
The Company’s bank credit facilities contain various covenants, including requiring the Company to maintain a debt to debt-plus-shareholders’ equity ratio of not more than 60% . The Company was in compliance with its debt covenants as of December 31, 2018 .
9.
Income Taxes
The current income tax provision reflects the tax consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported. The deferred income tax provision or benefit generally reflects the net change in deferred income tax assets and liabilities during the year, excluding any deferred income tax assets and liabilities of acquired businesses. The components of the provision for income taxes for the years ended December 31 are as follows:
(in millions)
 
2018
 
2017
 
2016
Current Provision:
 
 
 
 
 
 
Federal
 
$
2,897

 
$
3,597

 
$
4,302

State and local
 
219

 
314

 
312

Foreign
 
404

 
254

 
95

Total current provision
 
3,520

 
4,165

 
4,709

Deferred provision (benefit)
 
42

 
(965
)
 
81

Total provision for income taxes
 
$
3,562

 
$
3,200

 
$
4,790



58

Table of Contents


The reconciliation of the tax provision at the U.S. federal statutory rate to the provision for income taxes and the effective tax rate for the years ended December 31 is as follows:
(in millions, except percentages)
 
2018
 
2017
 
2016
Tax provision at the U.S. federal statutory rate
 
$
3,348

 
21.0
 %
 
$
4,908

 
35.0
 %
 
$
4,152

 
35.0
 %
Change in tax law
 

 

 
(1,199
)
 
(8.6
)
 

 

State income taxes, net of federal benefit
 
168

 
1.0

 
197

 
1.4

 
205

 
1.7

Share-based awards - excess tax benefit
 
(161
)
 
(1.0
)
 
(319
)
 
(2.3
)
 
(158
)
 
(1.3
)
Non-deductible compensation
 
117

 
0.7

 
175

 
1.3

 
128

 
1.1

Health insurance industry tax
 
552

 
3.5

 

 

 
645

 
5.4

Foreign rate differential
 
(203
)
 
(1.3
)
 
(282
)
 
(2.0
)
 
(105
)
 
(0.9
)
Other, net
 
(259
)
 
(1.6
)
 
(280
)
 
(2.0
)
 
(77
)
 
(0.6
)
Provision for income taxes
 
$
3,562

 
22.3
 %
 
$
3,200

 
22.8
 %
 
$
4,790

 
40.4
 %
Deferred income tax assets and liabilities are recognized for the differences between the financial and income tax reporting bases of assets and liabilities based on enacted tax rates and laws. The components of deferred income tax assets and liabilities as of December 31 are as follows:
(in millions)
 
2018
 
2017
Deferred income tax assets:
 
 
 
 
Accrued expenses and allowances
 
$
551

 
$
544

U.S. federal and state net operating loss carryforwards
 
190

 
216

Share-based compensation
 
91

 
97

Nondeductible liabilities
 
184

 
169

Non-U.S. tax loss carryforwards
 
426

 
445

Other-domestic
 
306

 
167

Other-non-U.S.
 
337

 
198

Subtotal
 
2,085

 
1,836

Less: valuation allowances
 
(84
)
 
(64
)
Total deferred income tax assets
 
2,001

 
1,772

Deferred income tax liabilities:
 
 
 
 
U.S. federal and state intangible assets
 
(2,131
)
 
(1,998
)
Non-U.S. goodwill and intangible assets
 
(709
)
 
(602
)
Capitalized software
 
(603
)
 
(530
)
Depreciation and amortization
 
(266
)
 
(236
)
Prepaid expenses
 
(152
)
 
(223
)
Outside basis in partnerships
 
(300
)
 
(279
)
Other-non-U.S.
 
(314
)
 
(86
)
Total deferred income tax liabilities
 
(4,475
)
 
(3,954
)
Net deferred income tax liabilities
 
$
(2,474
)
 
$
(2,182
)
Valuation allowances are provided when it is considered more likely than not that deferred tax assets will not be realized. The valuation allowances primarily relate to future tax benefits on certain federal, state and non-U.S. net operating loss carryforwards. Federal net operating loss carryforwards of $99 million expire beginning in 2022 through 2037 and $17 million have an indefinite carryforward period; state net operating loss carryforwards expire beginning in 2019 through 2038. Substantially all of the non-U.S. tax loss carryforwards have indefinite carryforward periods.
As of December 31, 2018 , the Company’s undistributed earnings from non-U.S. subsidiaries are intended to be indefinitely reinvested in non-U.S. operations, and therefore no U.S. deferred taxes have been recorded. Taxes payable on the remittance of such earnings would be minimal.

59

Table of Contents


A reconciliation of the beginning and ending amount of unrecognized tax benefits as of December 31 is as follows:
(in millions)
 
2018
 
2017
 
2016
Gross unrecognized tax benefits, beginning of period
 
$
598

 
$
263

 
$
224

Gross increases:
 
 

 
 

 
 

Current year tax positions
 
487

 
356

 
37

Prior year tax positions
 
87

 
40

 
24

Gross decreases:
 
 

 
 

 
 

Prior year tax positions
 
(84
)
 
(33
)
 
(4
)
Settlements
 
(20
)
 
(24
)
 
(6
)
Statute of limitations lapses
 
(12
)
 
(4
)
 
(12
)
Gross unrecognized tax benefits, end of period
 
$
1,056

 
$
598

 
$
263

The Company believes it is reasonably possible that its liability for unrecognized tax benefits will decrease in the next twelve months by $118 million as a result of audit settlements and the expiration of statutes of limitations.
The Company classifies interest and penalties associated with uncertain income tax positions as income taxes within its Consolidated Statements of Operations. During the years ended December 31, 2018 , 2017 and 2016 , the Company recognized $6 million , $14 million and $11 million of interest and penalties, respectively. The Company had $95 million and $84 million of accrued interest and penalties for uncertain tax positions as of December 31, 2018 and 2017 , respectively. These amounts are not included in the reconciliation above. As of December 31, 2018 , there were $716 million of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
The Company currently files income tax returns in the United States, various states and localities and non-U.S. jurisdictions. The U.S. Internal Revenue Service (IRS) has completed exams on the consolidated income tax returns for fiscal years 2016 and prior. The Company’s 2018 and 2017 tax years are under review by the IRS under its Compliance Assurance Program. With the exception of a few states, the Company is no longer subject to income tax examinations prior to the 2012 tax year. In general, the Company is subject to examination in non-U.S. jurisdictions for years 2013 and forward.
10.
Shareholders' Equity
Regulatory Capital and Dividend Restrictions
The Company’s regulated insurance and HMO subsidiaries in the United States are subject to regulations and standards in their respective jurisdictions. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital, as defined by each jurisdiction, and restrict the timing and amount of dividends and other distributions that may be paid to their parent companies. In the United States, most of these regulations and standards are generally consistent with model regulations established by the National Association of Insurance Commissioners. These standards generally permit dividends to be paid from statutory unassigned surplus of the regulated subsidiary and are limited based on the regulated subsidiary’s level of statutory net income and statutory capital and surplus. These dividends are referred to as “ordinary dividends” and generally may be paid without prior regulatory approval. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an “extraordinary dividend” and must receive prior regulatory approval.
For both the years ended December 31, 2018 and 2017 , the Company’s regulated subsidiaries paid their parent companies dividends of $3.7 billion , including $1.1 billion of extraordinary dividends.
The Company's regulated subsidiaries had estimated aggregate statutory capital and surplus of $23.7 billion as of December 31, 2018 . The estimated statutory capital and surplus necessary to satisfy regulatory requirements of the Company's regulated subsidiaries was approximately $10.3 billion as of December 31, 2018 .
Optum Bank must meet minimum capital requirements of the Federal Deposit Insurance Corporation (FDIC) to be considered “Well Capitalized” under the capital adequacy rules to which it is subject. At December 31, 2018 , the Company believes that Optum Bank met the FDIC requirements to be considered “Well Capitalized.”
Share Repurchase Program
Under its Board of Directors’ authorization, the Company maintains a share repurchase program. The objectives of the share repurchase program are to optimize the Company’s capital structure and cost of capital, thereby improving returns to shareholders, as well as to offset the dilutive impact of share-based awards. Repurchases may be made from time to time in

60

Table of Contents


open market purchases or other types of transactions (including prepaid or structured share repurchase programs), subject to certain Board restrictions. In June 2018, the Board renewed the Company’s share repurchase program with an authorization to
repurchase up to 100 million shares of its common stock.

A summary of common share repurchases for the years ended December 31, 2018 and 2017 is as follows:
 
 
Years Ended December 31,
(in millions, except per share data)
 
2018
 
2017
Common share repurchases, shares
 
19

 
9

Common share repurchases, average price per share
 
$
236.72

 
$
173.54

Common share repurchases, aggregate cost
 
$
4,500

 
$
1,500

Board authorized shares remaining
 
94

 
42

Dividends
In June 2018, the Company’s Board of Directors increased the Company’s annual dividend rate to shareholders to $3.60 per share compared to $3.00 per share, which the Company had paid since June 2017. Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.
11.
Share-Based Compensation
The Company’s outstanding share-based awards consist mainly of non-qualified stock options, SARs and restricted shares. As of December 31, 2018 , the Company had 42 million shares available for future grants of share-based awards under the Plan. As of December 31, 2018 , there were also 7 million shares of common stock available for issuance under the ESPP.
Stock Options and SARs
Stock option and SAR activity for the year ended December 31, 2018 is summarized in the table below:
 
Shares
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual Life
 
Aggregate
Intrinsic Value
 
(in millions)
 
 
 
(in years)
 
(in millions)
Outstanding at beginning of period
37

 
$
102

 
 
 
 
Granted
7

 
229

 
 
 
 
Exercised
(8
)
 
78

 
 
 
 
Forfeited
(1
)
 
162

 
 
 
 
Outstanding at end of period
35

 
131

 
6.5

 
$
4,114

Exercisable at end of period
16

 
87

 
5.0

 
2,560

Vested and expected to vest, end of period
34

 
129

 
6.5

 
4,072

Restricted Shares
Restricted share activity for the year ended December 31, 2018 is summarized in the table below:
(shares in millions)
 
Shares
 
Weighted-Average
Grant Date
Fair Value
per Share
Nonvested at beginning of period
 
7

 
$
128

Granted
 
2

 
229

Vested
 
(3
)
 
119

Nonvested at end of period
 
6

 
163


61

Table of Contents


Other Share-Based Compensation Data
(in millions, except per share amounts)
 
For the Years Ended December 31,
 
2018
 
2017
 
2016
Stock Options and SARs
 
 
 
 
 
 
Weighted-average grant date fair value of shares granted, per share
 
$
43

 
$
29

 
$
20

Total intrinsic value of stock options and SARs exercised
 
1,431

 
1,473

 
595

Restricted Shares
 
 
 
 
 
 
Weighted-average grant date fair value of shares granted, per share
 
229

 
163

 
115

Total fair value of restricted shares vested
 
$
521

 
$
460

 
$
274

Employee Stock Purchase Plan
 
 
 
 
 
 
Number of shares purchased
 
2

 
2

 
2

Share-Based Compensation Items
 
 
 
 
 
 
Share-based compensation expense, before tax
 
$
638

 
$
597

 
$
485

Share-based compensation expense, net of tax effects
 
587

 
531

 
417

Income tax benefit realized from share-based award exercises
 
239

 
431

 
236

(in millions, except years)
 
December 31, 2018
Unrecognized compensation expense related to share awards
 
$
628

Weighted-average years to recognize compensation expense
 
1.3

Share-Based Compensation Recognition and Estimates
The principal assumptions the Company used in calculating grant-date fair value for stock options and SARs were as follows:
 
 
For the Years Ended December 31,
 
 
2018
 
2017
 
2016
Risk-free interest rate
 
2.6% - 3.1%
 
1.9% - 2.1%
 
1.2% - 1.4%
Expected volatility
 
18.7% - 19.3%
 
18.5% - 20.7%
 
20.8% - 22.5%
Expected dividend yield
 
1.3% - 1.5%
 
1.4% - 1.6%
 
1.8%
Forfeiture rate
 
5.0%
 
5.0%
 
5.0%
Expected life in years
 
5.6
 
5.7
 
5.6 - 5.9
Risk-free interest rates are based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on the historical volatility of the Company’s common stock and the implied volatility from exchange-traded options on the Company’s common stock. Expected dividend yields are based on the per share cash dividend paid by the Company. The Company uses historical data to estimate option and SAR exercises and forfeitures within the valuation model. The expected lives of options and SARs granted represents the period of time that the awards granted are expected to be outstanding based on historical exercise patterns.
Other Employee Benefit Plans
The Company offers a 401(k) plan for its employees. Compensation expense related to this plan was not material for 2018, 2017 and 2016.
 
In addition, the Company maintains non-qualified, deferred compensation plans, which allow certain members of senior management and executives to defer portions of their salary or bonus and receive certain Company contributions on such deferrals, subject to plan limitations. The deferrals are recorded within long-term investments with an approximately equal amount in other liabilities in the Consolidated Balance Sheets. The total deferrals are distributable based upon termination of employment or other periods, as elected under each plan and were $988 million and $865 million as of December 31, 2018 and 2017 , respectively.


62

Table of Contents


12.
Commitments and Contingencies
The Company leases facilities and equipment under long-term operating leases that are non-cancelable and expire on various dates. Rent expense under all operating leases for the years ended December 31, 2018 , 2017 and 2016 was $751 million , $710 million and $608 million , respectively.
As of December 31, 2018 , future minimum annual lease payments, net of sublease income, under all non-cancelable operating leases were as follows:
(in millions)
 
Future Minimum Lease Payments
2019
 
$
669

2020
 
592

2021
 
511

2022
 
423

2023
 
338

Thereafter
 
1,343

The Company provides guarantees related to its service level under certain contracts. If minimum standards are not met, the Company may be financially at risk up to a stated percentage of the contracted fee or a stated dollar amount. None of the amounts accrued, paid or charged to income for service level guarantees were material as of December 31, 2018 , 2017 or 2016 .
As of December 31, 2018 , the Company had outstanding, undrawn letters of credit with financial institutions of $83 million and surety bonds outstanding with insurance companies of $1.3 billion , primarily to bond contractual performance.
Pending Acquisition
In December 2017, the Company entered into an agreement to acquire a company in the health care sector for a total of approximately $4.3 billion .
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.

63

Table of Contents


On February 14, 2017, the Department of Justice (DOJ) announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. Those motions were argued in September 2018. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.
13.
Segment Financial Information
Factors used to determine the Company’s reportable segments include the nature of operating activities, economic characteristics, existence of separate senior management teams and the type of information used by the Company’s chief operating decision maker to evaluate its results of operations. Reportable segments with similar economic characteristics, products and services, customers, distribution methods and operational processes that operate in a similar regulatory environment are combined.
The following is a description of the types of products and services from which each of the Company’s four reportable segments derives its revenues:
UnitedHealthcare includes the combined results of operations of UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, UnitedHealthcare Community & State and UnitedHealthcare Global. The U.S. businesses share significant common assets, including a contracted network of physicians, health care professionals, hospitals and other facilities, information technology and consumer engagement infrastructure and other resources. UnitedHealthcare Employer & Individual offers an array of consumer-oriented health benefit plans and services for large national employers, public sector employers, mid-sized employers, small businesses and individuals nationwide. UnitedHealthcare Medicare & Retirement provides health care coverage and health and well-being services to individuals age 50 and older, addressing their unique needs for preventive and acute health care services as well as services dealing with chronic disease and other specialized issues for older individuals. UnitedHealthcare Community & State’s primary customers oversee Medicaid plans, the Children’s Health Insurance Program and other federal, state and community health care programs. UnitedHealthcare Global is a diversified global health services business with a variety of offerings, including international commercial health and dental benefits and health care delivery.
OptumHealth focuses on care delivery, care management, wellness and consumer engagement, and health financial services. OptumHealth serves the physical, emotional and health-related financial needs of individuals, enabling population health through programs offered by employers, payers, government entities and directly with the care delivery system. OptumHealth offers access to networks of care provider specialists, health management services, care delivery, consumer engagement and financial services.
OptumInsight provides services, technology and health care expertise to major participants in the health care industry. Hospital systems, physicians, health plans, governments, life sciences companies and other organizations that comprise the health care industry depend on OptumInsight to help them improve performance, achieve efficiency, reduce costs, meet compliance mandates and modernize their core operating systems to meet the changing needs of the health system.
OptumRx offers pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy services, purchasing and clinical capabilities, and develops programs in areas such as step therapy, formulary management, drug adherence and disease/drug therapy management.
The Company’s accounting policies for reportable segment operations are consistent with those described in the Summary of Significant Accounting Policies (see Note 2 ). Transactions between reportable segments principally consist of sales of pharmacy care products and services to UnitedHealthcare customers by OptumRx, certain product offerings and care management and local care delivery services sold to UnitedHealthcare by OptumHealth, and health information and technology solutions, consulting and other services sold to UnitedHealthcare by OptumInsight. These transactions are recorded at management’s estimate of fair value. Intersegment transactions are eliminated in consolidation. Assets and liabilities that are jointly used are assigned to each reportable segment using estimates of pro-rata usage. Cash and investments are assigned such that each reportable segment has working capital and/or at least minimum specified levels of regulatory capital.
As a percentage of the Company’s total consolidated revenues, premium revenues from CMS were 30% , 28% and 25% for 2018 , 2017 and 2016 , respectively, most of which were generated by UnitedHealthcare Medicare & Retirement and included in the UnitedHealthcare segment. U.S. customer revenue represented approximately 96% , 96% and 97% of consolidated total revenues for 2018 , 2017 and 2016 , respectively. Long-lived fixed assets located in the United States represented approximately

64

Table of Contents


76% and 77% of the total long-lived fixed assets as of December 31, 2018 and 2017 , respectively. The non-U.S. revenues and fixed assets are primarily related to UnitedHealthcare Global.
The following table presents the reportable segment financial information:
 
 
 
 
Optum
 
 
 
 
(in millions)
 
UnitedHealthcare
 
OptumHealth
 
OptumInsight
 
OptumRx
 
Optum Eliminations
 
Optum
 
Corporate and
Eliminations
 
Consolidated
2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - unaffiliated customers:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
174,282

 
$
3,805

 
$

 
$

 
$

 
$
3,805

 
$

 
$
178,087

Products
 

 
52

 
111

 
29,438

 

 
29,601

 

 
29,601

Services
 
8,366

 
4,925

 
3,280

 
612

 

 
8,817

 

 
17,183

Total revenues - unaffiliated customers
 
182,648

 
8,782

 
3,391

 
30,050

 

 
42,223

 

 
224,871

Total revenues - affiliated customers
 

 
14,882

 
5,596

 
39,440

 
(1,409
)
 
58,509

 
(58,509
)
 

Investment and other income
 
828

 
481

 
21

 
46

 

 
548

 

 
1,376

Total revenues
 
$
183,476

 
$
24,145

 
$
9,008

 
$
69,536

 
$
(1,409
)
 
$
101,280

 
$
(58,509
)
 
$
226,247

Earnings from operations
 
$
9,113

 
$
2,430

 
$
2,243

 
$
3,558

 
$

 
$
8,231

 
$

 
$
17,344

Interest expense
 

 

 

 

 

 

 
(1,400
)
 
(1,400
)
Earnings before income taxes
 
$
9,113

 
$
2,430

 
$
2,243

 
$
3,558

 
$

 
$
8,231

 
$
(1,400
)
 
$
15,944

Total assets
 
$
82,938

 
$
29,837

 
$
11,039

 
$
33,912

 
$

 
$
74,788

 
$
(5,505
)
 
$
152,221

Purchases of property, equipment and capitalized software
 
761

 
593

 
517

 
192

 

 
1,302

 

 
2,063

Depreciation and amortization
 
845

 
439

 
654

 
490

 

 
1,583

 

 
2,428

2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - unaffiliated customers:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
154,709

 
$
3,744

 
$

 
$

 
$

 
$
3,744

 
$

 
$
158,453

Products
 

 
44

 
106

 
26,216

 

 
26,366

 

 
26,366

Services
 
7,890

 
4,013

 
2,849

 
565

 

 
7,427

 

 
15,317

Total revenues - unaffiliated customers
 
162,599

 
7,801

 
2,955

 
26,781

 

 
37,537

 

 
200,136

Total revenues - affiliated customers
 

 
12,429

 
5,127

 
36,954

 
(1,227
)
 
53,283

 
(53,283
)
 

Investment and other income
 
658

 
340

 
5

 
20

 

 
365

 

 
1,023

Total revenues
 
$
163,257

 
$
20,570

 
$
8,087

 
$
63,755

 
$
(1,227
)
 
$
91,185

 
$
(53,283
)
 
$
201,159

Earnings from operations
 
$
8,498

 
$
1,823

 
$
1,770

 
$
3,118

 
$

 
$
6,711

 
$

 
$
15,209

Interest expense
 

 

 

 

 

 

 
(1,186
)
 
(1,186
)
Earnings before income taxes
 
$
8,498

 
$
1,823

 
$
1,770

 
$
3,118

 
$

 
$
6,711

 
$
(1,186
)
 
$
14,023

Total assets
 
$
76,676

 
$
26,931

 
$
11,273

 
$
29,551

 
$

 
$
67,755

 
$
(5,373
)
 
$
139,058

Purchases of property, equipment and capitalized software
 
737

 
510

 
588

 
188

 

 
1,286

 

 
2,023

Depreciation and amortization
 
758

 
380

 
614

 
493

 

 
1,487

 

 
2,245

2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - unaffiliated customers:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Premiums
 
$
140,455

 
$
3,663

 
$

 
$

 
$

 
$
3,663

 
$

 
$
144,118

Products
 
1

 
48

 
103

 
26,506

 

 
26,657

 

 
26,658

Services
 
7,514

 
2,498

 
2,670

 
554

 

 
5,722

 

 
13,236

Total revenues - unaffiliated customers
 
147,970

 
6,209

 
2,773

 
27,060

 

 
36,042

 

 
184,012

Total revenues - affiliated customers
 

 
10,491

 
4,559

 
33,372

 
(1,088
)
 
47,334

 
(47,334
)
 

Investment and other income
 
611

 
208

 
1

 
8

 

 
217

 

 
828

Total revenues
 
$
148,581

 
$
16,908

 
$
7,333

 
$
60,440

 
$
(1,088
)
 
$
83,593

 
$
(47,334
)
 
$
184,840

Earnings from operations
 
$
7,307

 
$
1,428

 
$
1,513

 
$
2,682

 
$

 
$
5,623

 
$

 
$
12,930

Interest expense
 

 

 

 

 

 

 
(1,067
)
 
(1,067
)
Earnings before income taxes
 
$
7,307

 
$
1,428

 
$
1,513

 
$
2,682

 
$

 
$
5,623

 
$
(1,067
)
 
$
11,863

Total assets
 
$
70,505

 
$
18,656

 
$
9,017

 
$
29,066

 
$

 
$
56,739

 
$
(4,434
)
 
$
122,810

Purchases of property, equipment and capitalized software
 
640

 
345

 
571

 
149

 

 
1,065

 

 
1,705

Depreciation and amortization
 
724

 
297

 
559

 
475

 

 
1,331

 

 
2,055



65

Table of Contents


14.
Quarterly Financial Data (Unaudited)
Selected quarterly financial information for all quarters of 2018 and 2017 is as follows:  
 
 
For the Quarter Ended
(in millions, except per share data)
 
March 31
 
June 30
 
September 30
 
December 31
2018
 
 
 
 
 
 
 
 
Revenues
 
$
55,188

 
$
56,086

 
$
56,556

 
$
58,417

Operating costs
 
51,135

 
51,882

 
51,966

 
53,920

Earnings from operations
 
4,053

 
4,204

 
4,590

 
4,497

Net earnings
 
2,924

 
3,010

 
3,284

 
3,164

Net earnings attributable to UnitedHealth Group common shareholders
 
2,836

 
2,922

 
3,188

 
3,040

Net earnings per share attributable to UnitedHealth Group common shareholders:
 
 
 
 
 
 
 
 
Basic
 
2.94

 
3.04

 
3.31

 
3.16

Diluted
 
2.87

 
2.98

 
3.24

 
3.10

2017
 
 
 
 
 
 
 
 
Revenues
 
$
48,723

 
$
50,053

 
$
50,322

 
$
52,061

Operating costs
 
45,310

 
46,322

 
46,234

 
48,084

Earnings from operations
 
3,413

 
3,731

 
4,088

 
3,977

Net earnings
 
2,191

 
2,350

 
2,561

 
3,721

Net earnings attributable to UnitedHealth Group common shareholders
 
2,172

 
2,284

 
2,485

 
3,617

Net earnings per share attributable to UnitedHealth Group common shareholders:
 
 
 
 
 
 
 
 
Basic
 
2.28

 
2.37

 
2.57

 
3.73

Diluted
 
2.23

 
2.32

 
2.51

 
3.65


ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A.
CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this Annual Report on Form 10-K, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2018 . Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2018 .
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


66

Table of Contents


Report of Management on Internal Control Over Financial Reporting as of December 31, 2018
Management of UnitedHealth Group Incorporated and Subsidiaries (the Company) is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control system is designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. The Company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the consolidated financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018 . In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on our assessment and the COSO criteria, we believe that, as of December 31, 2018 , the Company maintained effective internal control over financial reporting.
The Company’s independent registered public accounting firm has audited the Company’s internal control over financial reporting as of December 31, 2018 , as stated in the Report of Independent Registered Public Accounting Firm , appearing under Item 9A.

67

Table of Contents



REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of UnitedHealth Group Incorporated and Subsidiaries:
Opinion on Internal Control over Financial Reporting
We have audited the internal control over financial reporting of UnitedHealth Group Incorporated and Subsidiaries (the “Company”) as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by COSO.
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2018, of the Company and our report dated February 12, 2019, expressed an unqualified opinion on those financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Report of Management on Internal Control Over Financial Reporting as of December 31, 2018. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ DELOITTE & TOUCHE LLP
 
Minneapolis, Minnesota
February 12, 2019



68

Table of Contents


ITEM 9B.
OTHER INFORMATION
None.
PART III
ITEM  10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
DIRECTORS OF THE REGISTRANT
The following sets forth certain information regarding our directors as of February 12, 2019 , including their name and principal occupation or employment:
William C. Ballard, Jr.
 
F. William McNabb III
Former Of Counsel
Bingham Greenebaum Doll LLP
 
Former Chairman and Chief Executive Officer
The Vanguard Group, Inc.
 
 
 
Richard T. Burke
 
Valerie Montgomery Rice, M.D
Lead Independent Director
UnitedHealth Group
 
President and Dean
Morehouse School of Medicine
 
 
 
 
Timothy P. Flynn
 
Glenn M. Renwick
Retired Chair
KPMG International
 
Chair
Fiserv, Inc.
 
 
 
 
Stephen J. Hemsley
 
David S. Wichmann
Executive Chair
UnitedHealth Group
 
Chief Executive Officer
UnitedHealth Group
 
 
 
 
Michele J. Hooper
 
Gail R. Wilensky, Ph.D.
President and Chief Executive Officer
The Directors’ Council
 
Senior Fellow
Project HOPE
 
Pursuant to General Instruction G(3) to Form 10-K and Instruction 3 to Item 401(b) of Regulation S-K, information regarding our executive officers is provided in Item 1 of Part I of this Annual Report on Form 10-K under the caption “Executive Officers of the Registrant.”
We have adopted a code of ethics applicable to our principal executive officer and other senior financial officers, who include our principal financial officer, principal accounting officer, controller and persons performing similar functions. The code of ethics, entitled Code of Conduct: Our Principles of Ethics and Integrity, is posted on our website at www.unitedhealthgroup.com . For information about how to obtain the Code of Conduct, see Part I, Item 1, “Business.” We intend to satisfy the SEC’s disclosure requirements regarding amendments to, or waivers of, the code of ethics for our senior financial officers by posting such information on our website indicated above.
The remaining information required by Items 401, 405, 406 and 407(c)(3), (d)(4) and (d)(5) of Regulation S-K will be included under the headings “Corporate Governance,” “Proposal 1-Election of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance” in our definitive proxy statement for our 2019 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.
ITEM  11.
EXECUTIVE COMPENSATION
The information required by Items 402, 407(e)(4) and (e)(5) of Regulation S-K will be included under the headings “Executive Compensation,” “Director Compensation,” “Corporate Governance - Risk Oversight” and “Compensation Committee Interlocks and Insider Participation” in our definitive proxy statement for our 2019 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.

69

Table of Contents


ITEM  12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS
Equity Compensation Plan Information
The following table sets forth certain information, as of December 31, 2018 , concerning shares of common stock authorized for issuance under all of our equity compensation plans:
Plan category  
 
(a)
Number of securities
to be issued upon
exercise of
outstanding
options, warrants
and rights  
 
(b)
Weighted-average
exercise
price of
outstanding
options, warrants
and rights   
 
(c)
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a))   
 
 
 
(in millions)
 
 
 
(in millions)
 
Equity compensation plans approved by shareholders (1)
 
33

 
$
135

 
49

(3)  
Equity compensation plans not approved by shareholders  (2)
 

 

 

 
Total (2)
 
33

 
$
135

 
49

 
(1)
Consists of the UnitedHealth Group Incorporated 2011 Stock Incentive Plan, as amended and the UnitedHealth Group 1993 Employee Stock Purchase Plan, as amended.
(2)
Excludes 1,676,000 shares underlying stock options assumed by us in connection with acquisitions. These options have a weighted-average exercise price of $59 and an average remaining term of approximately 5 years. These options are administered pursuant to the terms of the plans under which the options originally were granted. No future awards will be granted under these acquired plans.
(3)
Includes 7 million shares of common stock available for future issuance under the 1993 Employee Stock Purchase Plan as of December 31, 2018, and 42 million shares available under the 2011 Stock Incentive Plan as of December 31, 2018 . Shares available under the 2011 Stock Incentive Plan may become the subject of future awards in the form of stock options, SARs, restricted stock, restricted stock units, performance awards and other stock-based awards.
The information required by Item 403 of Regulation S-K will be included under the heading “Security Ownership of Certain Beneficial Owners and Management” in our definitive proxy statement for our 2019 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.
ITEM  13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by Items 404 and 407(a) of Regulation S-K will be included under the headings “Certain Relationships and Transactions” and “Corporate Governance” in our definitive proxy statement for our 2019 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.
ITEM  14.
PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by Item 9(e) of Schedule 14A will be included under the heading “Disclosure of Fees Paid to Independent Registered Public Accounting Firm” in our definitive proxy statement for our 2019 Annual Meeting of Shareholders, and such required information is incorporated herein by reference.

70

Table of Contents


PART IV
ITEM  15.
EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a)
1 . Financial Statements and Supplementary Data
The financial statements are included under Item 8 of this report:


2 . Financial Statement Schedules
The following financial statement schedule of the Company is included in Item 15(c):
Schedule I - Condensed Financial Information of Registrant (Parent Company Only).
All other schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions, are inapplicable, or the required information is included in the consolidated financial statements, and therefore have been omitted.
(b)
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1‑10864.
EXHIBIT INDEX**

 

 
4.1

 
Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)

 

 

 

 

 

 

 

71

Table of Contents



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

72

Table of Contents



 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

73

Table of Contents



 

 

 

 

 

 
11.1

 
Statement regarding computation of per share earnings (incorporated by reference to the information contained under the heading “ Net Earnings Per Common Share ” in Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data”)

 

 

 

 

 
101

 
The following materials from UnitedHealth Group Incorporated’s Annual Report on Form 10-K for the year ended December 31, 2018, filed on February 12, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Changes in Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to the Consolidated Financial Statements.
_______________________________________________ _
*
 
Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.
**
 
Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.
(c)
Financial Statement Schedule
Schedule I - Condensed Financial Information of Registrant (Parent Company Only).


74

Table of Contents


Schedule I

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and the Board of Directors of UnitedHealth Group Incorporated and Subsidiaries:
Opinion on the Financial Statement Schedule
We have audited the consolidated financial statements of UnitedHealth Group Incorporated and subsidiaries (the “Company”) as of December 31, 2018 and 2017, and for each of the three years in the period ended December 31, 2018, and the Company’s internal control over financial reporting as of December 31, 2018, and have issued our reports thereon dated February 12, 2019 ; such reports are included elsewhere in this Form 10-K. Our audits also included the financial statement schedule of the Company listed in the Index at Item 15. This financial statement schedule is the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statement schedule based on our audits. In our opinion, the financial statement schedule, when considered in relation to the consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.
/s/    DELOITTE & TOUCHE LLP
 
Minneapolis, Minnesota
February 12, 2019

75

Table of Contents


Schedule I
Condensed Financial Information of Registrant
(Parent Company Only)
UnitedHealth Group
Condensed Balance Sheets
 
(in millions, except per share data)
 
December 31,
2018
 
December 31,
2017
Assets
 
 
 
 
Current assets:
 
 
 
 
Cash and cash equivalents
 
$
434

 
$
359

Other current assets
 
197

 
575

Total current assets
 
631

 
934

Equity in net assets of subsidiaries
 
83,244

 
76,231

Long-term notes receivable from subsidiaries
 
4,461

 
4,278

Other assets
 
972

 
839

Total assets
 
$
89,308

 
$
82,282

 
 
 
 
 
Liabilities and shareholders’ equity
 
 
 
 
Current liabilities:
 
 
 
 
Accounts payable and accrued liabilities
 
$
618

 
$
502

Current portion of notes payable to subsidiaries
 
714

 
466

Commercial paper and current maturities of long-term debt
 
1,744

 
2,749

Total current liabilities
 
3,076

 
3,717

Long-term debt, less current maturities
 
33,490

 
28,318

Long-term notes payable to subsidiaries
 
560

 
1,518

Other liabilities
 
486

 
953

Total liabilities
 
37,612

 
34,506

Commitments and contingencies (Note 4)
 
 
 
 
Shareholders’ equity:
 
 
 
 
Preferred stock, $0.001 par value -10 shares authorized; no shares issued or outstanding
 

 

Common stock, $0.01 par value - 3,000 shares authorized; 960 and 969 issued and outstanding
 
10

 
10

Additional paid-in capital
 

 
1,703

Retained earnings
 
55,846

 
48,730

Accumulated other comprehensive loss
 
(4,160
)
 
(2,667
)
Total UnitedHealth Group shareholders’ equity
 
51,696

 
47,776

Total liabilities and shareholders’ equity
 
$
89,308

 
$
82,282

See Notes to the Condensed Financial Statements of Registrant

76

Table of Contents


Schedule I
Condensed Financial Information of Registrant
(Parent Company Only)
UnitedHealth Group
Condensed Statements of Comprehensive Income
 
 
 
For the Years Ended December 31,
(in millions)
 
2018
 
2017
 
2016
Revenues:
 
 
 
 
 
 
Investment and other income
 
$
194

 
$
527

 
$
522

Total revenues
 
194

 
527

 
522

Operating costs:
 
 
 
 
 
 
Operating costs
 
35

 

 
(22
)
Interest expense
 
1,285

 
1,114

 
995

Total operating costs
 
1,320

 
1,114

 
973

Loss before income taxes
 
(1,126
)
 
(587
)
 
(451
)
Benefit for income taxes
 
251

 
214

 
165

Loss of parent company
 
(875
)
 
(373
)
 
(286
)
Equity in undistributed income of subsidiaries
 
12,861

 
10,931

 
7,303

Net earnings
 
11,986

 
10,558

 
7,017

Other comprehensive (loss) income
 
(1,517
)
 
14

 
653

Comprehensive income
 
$
10,469

 
$
10,572

 
$
7,670

See Notes to the Condensed Financial Statements of Registrant

77

Table of Contents


Schedule I
Condensed Financial Information of Registrant
(Parent Company Only)
UnitedHealth Group
Condensed Statements of Cash Flows
 
 
 
For the Years Ended December 31,
(in millions)
 
2018
 
2017
 
2016
Operating activities
 
 
 
 
 
 
Cash flows from operating activities
 
$
6,099

 
$
2,021

 
$
4,294

Investing activities
 
 
 
 
 
 
Issuances of notes to subsidiaries
 
(1,420
)
 

 
(824
)
Repayments of notes to subsidiaries
 
1,419

 
2,071

 

Cash paid for acquisitions
 
(4,066
)
 
(2,313
)
 
(2,292
)
Return of capital to parent company
 
4,196

 
3,375

 
2,143

Capital contributions to subsidiaries
 
(1,259
)
 
(959
)
 
(765
)
Other, net
 
4

 

 
168

Cash flows (used for) from investing activities
 
(1,126
)
 
2,174

 
(1,570
)
Financing activities
 
 
 
 
 
 
Common stock repurchases
 
(4,500
)
 
(1,500
)
 
(1,280
)
Proceeds from common stock issuances
 
838

 
688

 
429

Cash dividends paid
 
(3,320
)
 
(2,773
)
 
(2,261
)
Repayments of commercial paper, net
 
(201
)
 
(3,508
)
 
(382
)
Proceeds from issuance of long-term debt
 
6,935

 
5,291

 
3,968

Repayments of long-term debt
 
(2,600
)
 
(3,472
)
 
(2,596
)
(Repayments) proceeds of notes from subsidiary
 
(1,127
)
 
1,704

 
(30
)
Other, net
 
(923
)
 
(446
)
 
(421
)
Cash flows used for financing activities
 
(4,898
)
 
(4,016
)
 
(2,573
)
Increase in cash and cash equivalents
 
75

 
179

 
151

Cash and cash equivalents, beginning of period
 
359

 
180

 
29

Cash and cash equivalents, end of period
 
$
434

 
$
359

 
$
180

 
 
 
 
 
 
 
Supplemental cash flow disclosures
 
 
 
 
 
 
Cash paid for interest
 
$
1,294

 
$
1,062

 
$
974

Cash paid for income taxes
 
2,379

 
3,455

 
4,557

 
 
 
 
 
 
 
Supplemental schedule of non-cash investing activities
 
 
 
 
 
 
Common stock issued for acquisitions
 
$

 
$
2,164

 
$

Conversion of note receivable from subsidiaries to equity
 

 
4,378

 

See Notes to the Condensed Financial Statements of Registrant









78

Table of Contents


Schedule I
Condensed Financial Information of Registrant
(Parent Company Only)
UnitedHealth Group
Notes to Condensed Financial Statements
1.    Basis of Presentation
UnitedHealth Group’s parent company financial information has been derived from its consolidated financial statements and should be read in conjunction with the consolidated financial statements included in this Form 10-K. The accounting policies for the registrant are the same as those described in Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”
2.    Subsidiary Transactions
Investment in Subsidiaries. UnitedHealth Group’s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries.
Dividends and Capital Distributions. Cash dividends received from subsidiaries and included in Cash Flows from Operating Activities in the Condensed Statements of Cash Flows were $5.6 billion , $3.4 billion and $3.7 billion in 2018, 2017 and 2016, respectively. Additionally, $4.2 billion , $3.4 billion and $2.1 billion in cash were received as a return of capital to the parent company during 2018, 2017 and 2016, respectively.
3.    Commercial Paper and Long-Term Debt
Discussion of commercial paper and long-term debt can be found in Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.” Long-term debt obligations of the parent company do not include other financing obligations at subsidiaries that totaled $1.3 billion and $625 million at December 31, 2018 and 2017, respectively.
Maturities of commercial paper and long-term debt for the years ending December 31 are as follows:
(in millions)
 
 
2019
 
$
1,750

2020
 
3,150

2021
 
3,150

2022
 
3,015

2023
 
2,125

Thereafter
 
22,477

4. Commitments and Contingencies
For a summary of commitments and contingencies, see Note 12 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data.”

ITEM  16.
FORM 10-K SUMMARY
None.


79

Table of Contents


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: February 12, 2019
 
UNITEDHEALTH GROUP INCORPORATED
 
 
By
/s/    DAVID S. WICHMANN
 
David S. Wichmann
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.  
Signature
 
Title
 
Date
/s/ D AVID  S. W ICHMANN
 
Director and Chief Executive Officer
(principal executive officer)
 
February 12, 2019
David S. Wichmann
 
 
 
/s/ J OHN  F. R EX
 
Executive Vice President and Chief Financial Officer
(principal financial officer)
 
February 12, 2019
John F. Rex
 
 
 
/s/ T HOMAS  E. R OOS
 
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
 
February 12, 2019
Thomas E. Roos
 
 
 
*
 
Director
 
February 12, 2019
William C. Ballard, Jr.
 
 
 
 
*
 
Director
 
February 12, 2019
Richard T. Burke
 
 
 
 
*
 
Director
 
February 12, 2019
Timothy P. Flynn
 
 
 
 
*
 
Director
 
February 12, 2019
Stephen J. Hemsley
 
 
 
 
*
 
Director
 
February 12, 2019
Michele J. Hooper
 
 
 
 
*
 
Director
 
February 12, 2019
F. William McNabb III
 
 
 
 
*
 
Director
 
February 12, 2019
Valerie Montgomery Rice
 
 
 
 
*
 
Director
 
February 12, 2019
Glenn M. Renwick
 
 
 
 
*
 
Director
 
February 12, 2019
Gail R. Wilensky
 
 
 
 
 
*By
/s/    MARIANNE D. SHORT
 
Marianne D. Short,
As Attorney-in-Fact

80

Exhibit 10.1

UNITEDHEALTH GROUP INCORPORATED 2011 STOCK INCENTIVE PLAN
(AS AMENDED AND RESTATED IN 2018)


Section 1. Purpose; Adoption; Effect on Prior Plans .
(a) Purpose . The purpose of the UnitedHealth Group Incorporated 2011 Stock Incentive Plan (as amended from time to time, the “Plan”) is to aid in attracting and retaining employees, management personnel and other personnel and members of the Board of Directors who are not also employees (“Non-Employee Directors”) of UnitedHealth Group Incorporated (the “Company”) capable of assuring the future success of the Company, to offer such personnel and Non-Employee Directors incentives to put forth maximum efforts for the success of the Company’s business and to afford such personnel and Non-Employee Directors an opportunity to acquire a proprietary interest in the Company.
(b) Adoption . The Company hereby adopts the Plan, subject to approval by the shareholders of the Company. As so established and approved, the Plan shall be known as the “2011 Stock Incentive Plan.”
(c) Effect on Prior Plans. On the effective date of the Plan determined in accordance with Section 11 of the Plan (the “Effective Date”), for purposes of administration and share accounting pursuant to Sections 3 and 4 of the Plan, the UnitedHealth Group Incorporated 2002 Stock Incentive Plan, as previously amended (the “Prior Plan”), shall be considered to be incorporated in the Plan. All outstanding options, restricted stock and other awards issued under the Prior Plan shall remain subject to the terms and conditions of the Prior Plan, but shares of stock relating to outstanding options, restricted stock or other awards issued under the Prior Plan are considered shares of stock subject to the Plan under Section 4 of the Plan. From and after the Effective Date of the Plan, no further awards shall be made under the Prior Plan.
Section 2. Definitions.
As used in the Plan, the following terms shall have the meanings set forth below:
(a) “Affiliate” shall mean (i) any entity that, directly or indirectly through one or more intermediaries, is controlled by the Company and (ii) any entity in which the Company has a significant equity interest, as determined by the Committee.
(b) “Award” shall mean any Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Performance Award, or Non-Employee Director Award granted under the Plan.
(c) “Award Agreement” shall mean any written certificate, agreement, contract or other instrument or document evidencing any Award granted under the Plan.
(d) “Change in Control” shall have the meaning ascribed to such term in any Award Agreement.
(e) “Code” shall mean the Internal Revenue Code of 1986, as amended from time to time, and any regulations promulgated thereunder.
(f) “Committee” shall mean the Compensation and Human Resources Committee of the Board of Directors or such other committee of the Board of Directors as is designated by such Board to administer the Plan and composed of not less than two directors.
(g) “Corporate Transaction” shall mean the effective date of any of the following transactions in which the Company does not survive (or does not survive as a public company in respect of its Common Stock): (1) any merger, combination, consolidation, or other reorganization; (2) any exchange of Common Stock or other securities of the Company; (3) a sale of all or substantially all the business, stock or assets of the Company; (4) a dissolution of the Company; or (5) any other similar event.
(h) “Eligible Person” shall mean, subject to applicable securities laws, any employee, officer or director (including any Non-Employee Director), or any individual consultant or independent contractor, providing services to the Company or any Affiliate whom the Committee determines to be an Eligible Person.
(i) “Fair Market Value” shall mean, with respect to any property (including, without limitation, any Shares or other securities), the fair market value of such property determined by such methods or procedures as shall be established from time to time by the Committee. Notwithstanding the foregoing, for purposes of the Plan, the Fair Market Value of Shares on a given date shall be, if the Shares are then traded on the New York Stock Exchange,




Exhibit 10.1

the closing price of the Shares as reported on the New York Stock Exchange on such date or, if the New York Stock Exchange is not open for trading on that date, the closing price on the immediately prior day on which the New York Stock Exchange was open for trading; provided that, (i) solely for the purposes of “cashless exercises” of Options permitted under Section 6(a)(iii) of this Plan, the Fair Market Value of a Share shall be the price at which a Share was last sold as reported on the New York Stock Exchange as of such valuation date and (ii) in the case of an Award granted to an Eligible Person subject to tax or legal requirements outside of the United States, the Committee may prescribe another method for determining Fair Market Value if the Committee determines such other method is advisable to satisfy local legal or regulatory requirements or to obtain more beneficial tax treatment.
(j) “Incentive Stock Option” shall mean an option granted under Section 6(a) of the Plan that is intended to meet the requirements of Section 422 of the Code or any successor provision.
(k) “Non-Employee Director Award” shall mean an Award granted under Section 6(f) of the Plan.
(l) “Non-Qualified Stock Option” shall mean an option granted under Section 6(a) of the Plan that is not an Incentive Stock Option.
(m) “Option” shall mean an Incentive Stock Option or a Non-Qualified Stock Option.
(n) “Participant” shall mean an Eligible Person designated to be granted an Award under the Plan.
(o) “Performance Award” shall mean any right granted under Section 6(d) of the Plan.
(p) “Person” shall mean any individual, corporation, limited liability company, partnership, association or trust.
(q) “Restricted Stock” shall mean any Share granted under Section 6(c) of the Plan.
(r) “Restricted Stock Unit” shall mean any unit granted under Section 6(c) of the Plan evidencing the right to receive a Share (or a cash payment equal to the Fair Market Value of a Share) at some future date.
(s) “Rule 16b-3” shall mean Rule 16b-3 promulgated by the Securities and Exchange Commission under the Securities Exchange Act of 1934.
(t) “Shares” shall mean shares of Common Stock, $.01 par value, of the Company or such other securities or property as may become subject to Awards pursuant to an adjustment made under Section 7(c) of the Plan.
(u) “Stock Appreciation Right” shall mean any right granted under Section 6(b) of the Plan.
Section 3. Administration.
(a) Power and Authority of the Committee . The Plan shall be administered by the Committee. Subject to the terms of the Plan and applicable law, the Committee shall have full power and authority to: (i) designate Participants; (ii) determine the type or types of Awards to be granted to each Participant under the Plan; (iii) determine the number of Shares to be covered by (or with respect to which payments, rights or other matters are to be calculated in connection with) each Award; (iv) determine the terms and conditions of any Award or Award Agreement; (v) subject to Section 7(b), amend the terms and conditions of any Award or Award Agreement and accelerate the exercisability or lapse of restrictions relating to Awards; (vi) determine whether, to what extent and under what circumstances Awards may be exercised in cash, Shares, other securities, other Awards or other property, or canceled, forfeited or suspended; (vii) determine whether, to what extent and under what circumstances cash, Shares, other securities, other Awards, other property and other amounts payable with respect to an Award under the Plan shall be deferred either automatically or at the election of the holder thereof or the Committee; (viii) interpret and administer the Plan and any instrument or agreement relating to, or Award made under, the Plan; (ix) establish, amend, suspend or waive such rules and regulations and appoint such agents as it shall deem appropriate for the proper administration of the Plan; and (x) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of the Plan. Unless otherwise expressly provided in the Plan, all designations, determinations, interpretations and other decisions under or with respect to the Plan or any Award shall be within the sole discretion of the Committee, may be made at any time and shall be final, conclusive and binding upon any Participant, any holder or beneficiary of any Award and any employee of the Company or any Affiliate.




Exhibit 10.1

(b) Delegation . The Committee may delegate to one or more officers of the Company or any Affiliate, or a committee of such officers, the authority, subject to such terms and limitations as the Committee shall determine, to grant Awards to Eligible Persons who are not officers or directors of the Company for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. The Committee shall not delegate its powers and duties under the Plan in any manner that would cause the Plan not to comply with the requirements of Section 162(m) of the Code.
Section 4. Shares Available for Awards .
(a) Shares Available . Subject to adjustment as provided in Sections 4(b) and 7(c), the total number of Shares available for granting Awards under the Plan shall be 238,103,375 (119,882,476 of which were previously authorized and subject to outstanding Awards under the Prior Plan). Shares that are subject to or underlie Awards granted under the Plan which expire, are cancelled or terminated, are forfeited, fail to vest, or for any other reason are not paid or delivered under the Plan, and Shares that are subject to any Awards that are settled in cash or a form other than Shares, shall again be available for subsequent Awards under the Plan based on the number of Shares counted at the time of grant pursuant to Section 4(b) of the Plan. Any Shares that are used by a Participant as full or partial payment to the Company of the purchase or exercise price relating to an Award, or in connection with satisfaction of tax obligations relating to an Award, (in each case, whether by actual delivery, attestation or having shares withheld from the Award) shall not be available for subsequent Awards under the Plan. To the extent that Shares are delivered pursuant to the exercise of a Stock Appreciation Right, the number of underlying Shares as to which the exercise related shall be counted against the foregoing Share limit, as opposed to only counting the shares issued. (For purposes of clarity, if a Stock Appreciation Right relates to 100,000 Shares and is exercised at a time when the payment due to the Participant is 15,000 Shares, 100,000 Shares shall be charged against the foregoing Share limit with respect to such exercise.) For purposes of the previous three sentences, the terms “Award” and “Stock Appreciation Right” shall explicitly include any Awards and Stock Appreciation Rights, respectively, granted under the Plan as well as any Awards or Stock Appreciation Rights, respectively, outstanding under the Prior Plan as of the Effective Date of the Plan.
(b) Accounting for Awards . For purposes of this Section 4, if an Award entitles the holder thereof to receive or purchase Shares, the number of Shares covered by such Award or to which such Award relates shall be counted, in accordance with this Section 4(b), on the date of grant of such Award against the aggregate number of Shares available for granting Awards under the Plan; provided, however, that the number of Shares covered by a Performance Award or to which such Performance Award relates shall be counted against the aggregate number of Shares available for granting Awards under the Plan on the date such Performance Awards vest. With respect to Options, Stock Appreciation Rights and any Awards other than Options and Stock Appreciation Rights that were granted prior to the Company’s 2015 Annual Meeting of Shareholders, the number of Shares available for Awards under the Plan shall be reduced by one Share for each Share covered by such Award or to which such Award relates. With respect to any Awards other than Options and Stock Appreciation Rights that were granted after the Company’s 2015 Annual Meeting of Shareholders, the number of Shares available for Awards under the Plan shall be reduced by 2.5 Shares for each Share covered by such Award or to which such Award relates. The number of Shares covered by any dividends and/or dividend equivalents paid or credited in respect of an Award shall be counted on the dividend payment date against the aggregate number of Shares available for granting Awards under the Plan. Such Shares may again become available for granting Awards under the Plan pursuant to the provisions of Section 4(a) of the Plan, subject to the limitations set forth in Section 4(d) of the Plan.
(c) Incentive Stock Options . Notwithstanding the foregoing, the number of Shares available for granting Incentive Stock Options under the Plan shall not exceed 25,000,000, subject to adjustment as provided in Section 7(c) of the Plan and Sections 422 or 424 of the Code or any successor provisions.
(d) Award Limitations Under the Plan . No Eligible Person may be granted any Options or Stock Appreciation Rights with respect to more than 5,000,000 Shares (subject to adjustment as provided in Section 7(c) of the Plan), in the aggregate, in any calendar year. In addition, no Eligible Person may be granted any Awards (other than Options or Stock Appreciation Rights subject to the limit of the preceding sentence) that qualify as “qualified performance-based” Awards within the meaning of Section 162(m) of the Code with respect to more than 5,000,000 Shares (subject to adjustment as provided in Section 7(c) of the Plan), in the aggregate, in any calendar year. Awards that are cancelled during the year shall be counted against these limits to the extent required by Section 162(m) of the Code.
(e) Minimum Vesting Requirements. No Award granted under the Plan shall become exercisable or vest until at least twelve (12) months following the date of grant of the Award; provided, however, that up to 5% of the aggregate number of Shares available for grant under the Plan may be subject to Awards that do not meet such exercisability or vesting requirements (as applicable), pursuant to Section 6(e) of the Plan.




Exhibit 10.1

Section 5. Eligibility.
Any Eligible Person, including any Eligible Person who is an officer or director of the Company or any Affiliate, shall be eligible to be designated a Participant; provided , however , that an Incentive Stock Option may be granted only to full-time or part-time employees (which term as used herein includes, without limitation, officers and directors who are also employees), and an Incentive Stock Option shall not be granted to an employee of an Affiliate unless the Affiliate is also a “subsidiary corporation” of the Company within the meaning of Section 424(f) of the Code or any successor provision.
Section 6. Awards.
(a) Options . The Committee is hereby authorized to grant Options to Participants with the following terms and conditions and with such additional terms and conditions not inconsistent with the provisions of the Plan as the Committee shall determine:
(i) Exercise Price . The purchase price per Share purchasable under an Option shall be determined by the Committee; provided , however , that such purchase price shall not be less than 100% of the Fair Market Value of a Share on the date of grant of such Option.
(ii) Option Term . The term of each Option shall be fixed by the Committee at the time of grant but in no event shall any Option have a term of more than 10 years.
(iii) Time and Method of Exercise . The Committee shall determine the time or times at which an Option may be exercised in whole or in part and the method or methods by which, and the form or forms in which, payment of the exercise price with respect thereto may be made or deemed to have been made (including, without limitation, cash, loans, Shares previously owned by the Participant (or a reduction in the number of Shares otherwise deliverable to the Participant on exercise of the Option), other securities, other Awards or other property, or any combination thereof, having a Fair Market Value on the exercise date equal to the relevant exercise price; or, subject to such procedures as the Committee may adopt, pursuant to a “cashless exercise” with a third party who provides financing for the purposes of (or who otherwise facilitates) such exercise). Such “cashless exercise” procedures with a third-party shall require (i) a valid exercise of the Awards and (ii) Participants to be legal owners of the shares subject to the Awards (even if the Participants do not pay the exercise price before the sale of the shares subject to the Awards).
(b) Stock Appreciation Rights . The Committee is hereby authorized to grant Stock Appreciation Rights to Participants subject to the terms of the Plan and any applicable Award Agreement. A Stock Appreciation Right granted under the Plan shall confer on the holder thereof a right to receive upon exercise thereof the excess of (i) the Fair Market Value of one Share on the date of exercise (or, if the Committee shall so determine, at any time during a specified period before or after the date of exercise) over (ii) the grant price of the Stock Appreciation Right as specified by the Committee, which price shall not be less than 100% of the Fair Market Value of one Share on the date of grant of the Stock Appreciation Right. The term of each Stock Appreciation Right shall be fixed by the Committee at the time of grant but in no event shall any Stock Appreciation Right have a term of more than 10 years. Subject to the terms of the Plan and any applicable Award Agreement, the methods of exercise, dates of exercisability, methods of settlement and any other terms and conditions of any Stock Appreciation Right shall be as determined by the Committee. The Committee may impose such conditions or restrictions on the exercise of any Stock Appreciation Right as it may deem appropriate.
(c) Restricted Stock and Restricted Stock Units . The Committee is hereby authorized to grant Awards of Restricted Stock and Restricted Stock Units to Participants with the following terms and conditions and with such additional terms and conditions not inconsistent with the provisions of the Plan as the Committee shall determine:
(i) Restrictions . Shares of Restricted Stock and Restricted Stock Units shall be subject to such restrictions as the Committee may impose (including, without limitation, any limitation on the right to vote a Share of Restricted Stock or the right to receive any dividend or other right or property with respect thereto), which restrictions may lapse separately or in combination at such time or times, in such installments or otherwise as the Committee may deem appropriate. Any dividends and/or dividend equivalents paid or credited in respect of an Award of Restricted Stock or Restricted Stock Units that is subject to performance-based or time-based vesting requirements will be subject to termination and forfeiture to the same extent as the corresponding portion of the Award to which they relate. Except as otherwise provided herein, Awards of Restricted Stock and Restricted Stock Units shall contain restrictions that lapse no sooner than over a period of three years following the date of grant or, in the case of Awards with performance-based vesting provisions, no sooner than over a period of one year




Exhibit 10.1

following the date of grant; provided , however , that no restriction as to any portion of such Awards may lapse sooner than 12 months from the date of grant.
(ii) Forfeiture; Delivery of Shares . Except as otherwise determined by the Committee, upon termination of employment (as determined under criteria established by the Committee) during the applicable restriction period, all Shares of Restricted Stock and all Restricted Stock Units at such time subject to restriction shall be forfeited and reacquired by the Company; provided , however , that the Committee may, when it finds that a waiver would be in the best interest of the Company, waive in whole or in part any or all remaining restrictions with respect to Shares of Restricted Stock or Restricted Stock Units. In the case of Restricted Stock, Shares shall be issued at the time such Awards are granted and may be certificated or uncertificated. Shares representing Restricted Stock that is no longer subject to restrictions shall be delivered to the holder thereof promptly after the applicable restrictions lapse or are waived. In the case of Restricted Stock Units, no Shares shall be issued at the time such Awards are granted. Unless a delayed payment date is provided under the terms of the Award, upon the lapse or waiver of restrictions and the restricted period relating to Restricted Stock Units evidencing the right to receive Shares, such Shares shall be issued and delivered to the holders of the Restricted Stock Units. The Committee may from time to time establish procedures pursuant to which a Participant may elect to defer, until a time or times later than the end of the restricted period relating to Restricted Stock Units, receipt of all or a portion of the Shares subject to such Restricted Stock Units, all on such terms and conditions as the Committee shall determine.
(d) Performance Awards . The Committee is hereby authorized to grant Performance Awards to Eligible Persons subject to the terms of the Plan and any applicable Award Agreement.
(i) A Performance Award granted under the Plan (1) may be denominated or payable in cash, Shares (including, without limitation, Restricted Stock or Restricted Stock Units), other securities, other Awards or other property and (2) shall confer on the holder thereof the right to receive payments, in whole or in part, upon the achievement of such performance goals during such performance periods as the Committee shall establish. Subject to the terms of the Plan and any applicable Award Agreement, the performance goals to be achieved during any performance period, the length of any performance period, the amount of any Performance Award granted, the amount of any payment or transfer to be made pursuant to any Performance Award and any other terms and conditions of any Performance Award shall be determined by the Committee. Notwithstanding the immediately preceding sentence, the length of a performance period shall not be less than three (3) months.
(ii) Performance Awards granted under this Section 6(d) may be intended to satisfy the requirements for “performance-based compensation” within the meaning of Section 162(m) of the Code. The specific performance goals for any such Performance Awards shall be, on an absolute or relative basis, established based on one or more of the following business criteria as selected by the Committee in its sole discretion: earnings per share, cash flow (which means cash and cash equivalents derived from either net cash flow from operations or net cash flow from operations, financing and investing activities), stock price, total stockholder return, net operating profit, margins (including gross or operating margins), gross revenue, revenue growth, operating income (before or after taxes), earnings or net earnings (before or after interest, taxes, depreciation and/or amortization), return measures (including, but not limited to, return on equity, assets, net investment, invested capital, sales or revenues), funds from operations, productivity ratios, performance against operating budget goals, operating efficiency, productivity ratios, economic value added, working capital target, expense targets, cost containment or reduction, market share, business pipeline, stewardship goals (including, but not limited to, customer, employee and provider satisfaction and engagement), or any combination thereof. These terms are used as applied under generally accepted accounting principles or in the financial reporting of the Company or one of its Affiliates. To qualify Performance Awards as performance-based under Section 162(m), the applicable business criteria and specific performance goals must be established and approved by the Committee during the first 90 days of the performance period (and, in the case of performance periods of less than one year, in no event after 25% or more of the performance period has elapsed) and while performance relating to such performance goals remains substantially uncertain within the meaning of Section 162(m) of the Code. The terms of any such Performance Award may specify the manner, if any, in which performance targets shall be adjusted to mitigate the unbudgeted impact of material, unusual or nonrecurring gains and losses, accounting changes or other extraordinary events not foreseen at the time the targets were set unless the Committee provides otherwise at the time of establishing the targets. The applicable performance measurement period may not be less than three months nor more than 10 years. To the extent that any Performance Award (other than an Option or Stock Appreciation Right) is intended to qualify as performance-based compensation under Section 162(m) of the Code, the Committee must certify in writing that the performance target(s) and any other material terms of the Performance Award were in fact timely satisfied prior to the payment of such Award. As required pursuant to Section 162(m) of the Code and the regulations promulgated thereunder, the Committee’s




Exhibit 10.1

authority to grant new Awards that are intended to qualify as performance-based compensation within the meaning of Section 162(m) of the Code (other than Options and Stock Appreciation Rights) shall terminate upon the first meeting of the Company’s shareholders that occurs in the fifth year following the year in which the Company’s shareholders first approve this Plan, subject to any subsequent extension that may be approved by shareholders.
(iii) The maximum number of Shares which may be delivered pursuant to Performance Awards intended to qualify as “performance-based compensation” under Section 162(m) (other than Options and Stock Appreciation Rights, and other than cash awards covered by the following sentence) that are granted to any one Participant in any one calendar year shall not exceed 5,000,000 shares, either individually or in the aggregate, subject to adjustment as provided in Section 7(c). The aggregate amount of compensation to be paid to any one Participant in respect of all Performance Awards intended to qualify as performance-based compensation under Section 162(m) that are payable only in cash and granted to that Participant in any one calendar year shall not exceed $10,000,000. Awards that are cancelled during the year shall be counted against these limits to the extent required by Section 162(m) of the Code.
(e) Special Share Limit . The Committee is hereby authorized to grant to Participants such other Awards that are denominated or payable in, valued in whole or in part by reference to, or otherwise based on or related to, Shares (including, without limitation, securities convertible into Shares), as are deemed by the Committee to be consistent with the purpose of the Plan; provided , however , that such grants must comply with applicable law. Subject to the terms of the Plan and any applicable Award Agreement, the Committee shall determine the terms and conditions of such Awards. In no event, however, may Shares issued in respect of Awards which do not meet the minimum vesting and exercisability requirements set forth in Section 4(e) exceed 5% of the aggregate number of Shares available for grant under the Plan. For purposes of clarity, Awards may be granted that do not satisfy the minimum vesting and exercisability requirements set forth in Section 4(e), but any Shares issued in respect of such Awards shall be counted against the Share limit of the immediately preceding sentence. Shares covered by an Award that are forfeited, as well as Shares that are subject to or underlie Awards which expire, are cancelled or terminated, are forfeited, fail to vest, or for any other reason are not paid or delivered under the Plan, and Shares that are subject to any Awards that are settled in cash or a form other than Shares, shall not count against the special Share limit of this Section 6(e).
(f) Non-Employee Director Awards . The Committee is authorized to grant to Non-Employee Director Awards denominated in Options, SARs, Restricted Stock, Restricted Stock Units, Shares or such other Share-based award as it shall determine is necessary and appropriate. Any such Award may have such vesting (or no vesting requirements) as the Committee may determine and may also be subject to any holding requirement as the Committee determines in its sole discretion. For the avoidance of doubt, Non-Employee Director Awards which do not meet the minimum vesting and exercisability requirements set forth in Section 4(e) shall count against and be subject to the special Share limitations of Section 6(e).
(g) General.
(i) Consideration for Awards . Awards may be granted for no cash consideration or for any cash or other consideration as may be determined by the Committee or required by applicable law.
(ii) Awards May Be Granted Separately or Together . Awards may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with or in substitution for any other Award or any award granted under any plan of the Company or any Affiliate other than the Plan. Awards granted in addition to or in tandem with other Awards or in addition to or in tandem with awards granted under any such other plan of the Company or any Affiliate may be granted either at the same time as or at a different time from the grant of such other Awards or awards.
(iii) Forms of Payment Under Awards . Subject to the terms of the Plan and of any applicable Award Agreement, payments or transfers to be made by the Company or an Affiliate upon the grant, exercise or payment of an Award may be made in such form or forms as the Committee shall determine (including, without limitation, cash, Shares, other securities, other Awards or other property or any combination thereof), and may be made in a single payment or transfer, in installments or on a deferred basis, in each case in accordance with rules and procedures established by the Committee. Such rules and procedures may include, without limitation, provisions for the payment or crediting of reasonable interest on installment or deferred payments.
(iv) Limits on Transfer of Awards . No Award and no right under any such Award shall be transferable by a Participant otherwise than by will or by the laws of descent and distribution or pursuant to a domestic relations order; provided , however , that, if so determined by the Committee, a Participant may, in the manner established by




Exhibit 10.1

the Committee, designate a beneficiary or beneficiaries to exercise the rights of the Participant and receive any property distributable with respect to any Award upon the death of the Participant; and provided , further , that except in the case of an Incentive Stock Option, Awards may be transferable as specifically provided in any applicable Award Agreement or amendment thereto pursuant to terms determined by the Committee and subject to all applicable laws (including, without limitation, applicable securities and tax laws). Except as otherwise provided in any applicable Award Agreement or amendment thereto (other than an Award Agreement relating to an Incentive Stock Option), pursuant to terms determined by the Committee, each Award or right under any Award shall be exercisable during the Participant’s lifetime only by the Participant or, if permissible under applicable law, by the Participant’s guardian or legal representative. Any Award which is transferred pursuant to a domestic relations order or as otherwise permitted by the Plan and the applicable Award Agreement shall remain subject to the terms and conditions set forth in the Award Agreement and the Plan. Except as otherwise provided in any applicable Award Agreement or amendment thereto (other than an Award Agreement relating to an Incentive Stock Option), no Award or right under any such Award may be pledged, alienated, attached or otherwise encumbered, and any purported pledge, alienation, attachment or encumbrance thereof shall be void and unenforceable against the Company or any Affiliate.
(v) Term of Awards . The term of each Award shall be for such period as may be determined by the Committee at the time of grant but in no event shall any Award have a term of more than 10 years.
(vi) Restrictions; Securities Exchange Listing . All certificates for Shares or other securities delivered under the Plan pursuant to any Award or the exercise thereof shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan or the rules, regulations and other requirements of the Securities and Exchange Commission and any applicable federal or state securities laws, and the Committee may cause a legend or legends to be placed on any such certificates to make appropriate reference to such restrictions. If the Shares or other securities are traded on a securities exchange, the Company shall not be required to deliver any Shares or other securities covered by an Award unless and until such Shares or other securities have been listed or admitted for trading on such securities exchange. The person acquiring any securities under this Plan will, if requested by the Company or one of its Affiliates, provide such assurances and representations to the Company or one of its Affiliates as the Committee may deem necessary or desirable to assure compliance with all applicable legal and accounting requirements.
Section 7. Amendment and Termination; Adjustments.
Except to the extent prohibited by applicable law and unless otherwise expressly provided in an Award Agreement or in the Plan:
(a) Amendments to the Plan . The Board of Directors of the Company may amend, alter, suspend, discontinue or terminate the Plan at any time and from time to time; provided , however , that, notwithstanding any other provision of the Plan or any Award Agreement, without the approval of the shareholders of the Company, no such amendment, alteration, suspension, discontinuation or termination shall be made that, absent such approval, would violate any rules or regulations of the New York Stock Exchange or any other national securities exchange that is applicable to the Company. Furthermore, shareholder approval shall be required for any amendments to the Plan which would (i) materially increase the benefits accruing to Participants; (ii) materially increase the number of securities which may be issued under the Plan; (iii) materially modify the requirements for participation under the Plan; or (iv) require shareholder approval under applicable law or any applicable listing agency or under Sections 162, 422 or 424 of the Code to preserve the intended tax consequences of the Plan.
(b) Amendments to Awards . Except as otherwise explicitly provided herein, the Committee may waive any conditions of or rights of the Company under any outstanding Award, prospectively or retroactively. The Committee may not amend, alter, suspend, discontinue or terminate any outstanding Award in any manner materially adverse to the Participant or holder or beneficiary thereof, prospectively or retroactively, without the consent of such Participant or holder or beneficiary. Adjustments and other actions contemplated by Section 7(c) shall not be deemed to constitute amendments of Awards for purposes of this Section 7(b). Notwithstanding any other provision herein and except as provided in Section 7(c) hereof or as may be approved by shareholders, no Option or Stock Appreciation Right may be amended to reduce its initial exercise price, canceled and replaced with an Option or Stock Appreciation Right having a lower exercise price, or canceled and exchanged for cash or another Award for the purpose of repricing the Award.
(c) Adjustments . In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase or exchange of Shares or other securities of the Company or other similar corporate




Exhibit 10.1

transaction or event affecting the Shares would be reasonably likely to result in the diminution or enlargement of any of the benefits or potential benefits intended to be made available under the Plan or under an Award (including, without limitation, the benefits or potential benefits of provisions relating to the term, vesting or exercisability of any Option, and any Change in Control or similar provisions of any Award), the Committee shall, in such manner as it shall deem equitable or appropriate in order to prevent such diminution or enlargement of any such benefits or potential benefits, adjust any or all of (i) the number and type of Shares (or other securities or other property) which thereafter may be made the subject of Awards, (ii) the number and type of Shares (or other securities or other property) subject to outstanding Awards and (iii) the purchase or exercise price with respect to any Award; provided , however , that the number of Shares covered by any Award or to which such Award relates shall always be a whole number.
(d) Correction of Defects, Omissions and Inconsistencies . The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem desirable to carry the Plan into effect.                            
Section 8. Corporate Transactions - Assumption and Termination of Awards .
Upon the occurrence of any Corporate Transaction, the Committee may make provision for a cash payment in settlement of, or for the assumption, substitution or exchange of any or all outstanding share-based Awards or the cash, securities or property deliverable to the holder of any or all outstanding share-based Awards, based upon, to the extent relevant under the circumstances, the distribution or consideration payable to holders of the Common Stock upon or in respect of such event. The Board of Directors or the Committee may also terminate each Award upon the effective date of a Corporate Transaction, subject to the following provisions:
unless otherwise provided in the applicable Award Agreement, each Option and Stock Appreciation Right outstanding at the effective date of the Corporate Transaction shall become fully vested, each then-outstanding Award of Restricted Stock and Restricted Stock Units shall fully vest free of restrictions, and each other then-outstanding Award granted under the Plan shall become payable to the holder of such Award; and
to the extent provision has not been made for the cash settlement of any outstanding Options and Stock Appreciation Rights, the holder of each Option or Stock Appreciation Right shall be given reasonable advance notice of the impending termination and a reasonable opportunity to exercise his or her outstanding vested Options and Stock Appreciation Rights (after giving effect to any accelerated vesting required in the circumstances) in accordance with their terms before the termination of such Awards (except that in no case shall more than ten days’ notice of the impending termination be required and any acceleration of vesting and any exercise of any portion of an Award that is so accelerated may be made contingent upon the closing of the transaction).
The Committee may adopt such valuation methodologies for outstanding Awards as it deems reasonable in the event of a cash or property settlement and, in the case of Options and Stock Appreciation Rights, may base such settlement solely upon the excess (if any) of the per share amount payable for the Common Stock in respect of such transaction over the exercise price of the Award. The Committee may take the actions contemplated by this Section 8 immediately prior to the transaction (as opposed to on the occurrence of the transaction) to the extent that the Committee deems the action necessary to permit the Participant to realize the benefits intended to be conveyed with respect to the underlying Shares.




Exhibit 10.1

Section 9. Income Tax Withholding .
In order to comply with all applicable federal, state or local income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that all applicable federal, state or local payroll, withholding, income or other taxes, which are the sole and absolute responsibility of a Participant, are withheld or collected from such Participant (including, without limitation, deducting the minimum amount of such withholding obligation from any amount otherwise payable in cash (whether related to the Award or otherwise) to the Participant). In order to provide for such tax withholding in connection with an Award, the Committee, in its discretion and subject to such additional terms and conditions as it may adopt, may (i) require that, or permit the Participant to satisfy such tax obligation by electing to have, the Company withhold a portion of the Shares otherwise to be delivered upon exercise or receipt of (or the lapse of restrictions relating to) such Award with a Fair Market Value equal to the amount of such taxes (but only to the extent of the minimum amount required to be withheld under applicable laws or regulations) or (ii) permit the Participant to deliver to the Company Shares other than Shares issuable upon exercise or receipt of (or the lapse of restrictions relating to) such Award with a Fair Market Value equal to the amount of such taxes (but only to the extent of the minimum amount required to be withheld under applicable laws or regulations). The election, if any, must be made on or before the date that the amount of tax to be withheld is determined in accordance with the rules and regulations of the agent selected by the Committee to administer such aspect of the Plan.
Section 10. General Provisions.
(a) No Rights to Awards . No Eligible Person, Participant or other Person shall have any claim to be granted any Award under the Plan, and there is no obligation for uniformity of treatment of Eligible Persons, Participants or holders or beneficiaries of Awards under the Plan. The terms and conditions of Awards need not be the same with respect to different Participants.
(b) Award Agreements . To the extent that the Company provides for a written Award Agreement to be executed by the recipient of the Award or other procedures for the Participant to accept his or her Award, the Participant will have no rights under the Award unless and until the Award Agreement shall have been duly delivered by the Company and executed or accepted, as the case may be, by the Participant in accordance with any procedures and within any applicable time limits prescribed by the Company.
(c) No Limit on Other Compensation Arrangements . Nothing contained in the Plan shall prevent the Company or any Affiliate from adopting or continuing in effect other or additional compensation arrangements, and such arrangements may be either generally applicable or applicable only in specific cases.
(d) No Right to Employment, etc . The grant of an Award shall not be construed as giving a Participant the right to be retained in the employ, or as giving a Non-Employee Director the right to continue as a director, of the Company or any Affiliate. In addition, the Company or an Affiliate may at any time dismiss a Participant from employment, or terminate the term of a Non-Employee Director, free from any liability or any claim under the Plan, unless otherwise expressly provided in the Plan or in any Award Agreement.
(e) Governing Law . The validity, construction and effect of the Plan and any rules and regulations relating to the Plan shall be determined in accordance with the laws of the State of Delaware without regard to its conflicts of laws provisions.
(f) Severability . If any provision of the Plan or any Award is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the purpose or intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction or Award, and the remainder of the Plan or any such Award shall remain in full force and effect.
(g) No Trust or Fund Created . Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate and a Participant or any other Person. To the extent that any Person acquires a right to receive payments from the Company or any Affiliate pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Company or any Affiliate.
(h) Headings . Headings are given to the Sections and subsections of the Plan solely as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof.




Exhibit 10.1

(i) Section 16 Compliance . The Plan is intended to comply in all respects with Rule 16b-3 or any successor provision, as in effect from time to time, and in all events the Plan shall be construed in accordance with the requirements of Rule 16b-3. If any Plan provision does not comply with Rule 16b-3 as hereafter amended or interpreted, the provision shall be deemed inoperative. The Board of Directors, in its absolute discretion, may bifurcate the Plan so as to restrict, limit or condition the use of any provision of the Plan with respect to persons who are officers or directors subject to Section 16 of the Securities Exchange Act of 1934, as amended, without so restricting, limiting or conditioning the Plan with respect to other Participants.
(j) Section 409A Requirements . Notwithstanding anything to the contrary in this Plan or any Award agreement, the following provisions shall apply to any payments and benefits otherwise payable to or provided to a Participant under this Plan and any Award:
(i) For purposes of Code Section 409A, each “payment” (as defined by Code Section 409A) made under this Plan or an Award shall be considered a “separate payment.” In addition, for purposes of Code Section 409A, payments shall be deemed exempt from the definition of deferred compensation under Code Section 409A to the fullest extent possible under the “short-term deferral” exemption of Treasury Regulation § 1.409A-1(b)(4).
(ii) If the Participant is a “specified employee” (within the meaning of Section 409A and determined pursuant to procedures adopted by the Company) at the time of Participant’s “separation from service” (as defined in Section 409A of the Code and Treasury Regulations Section 1.409A-1(h) without regard to the optional alternative definitions available thereunder) and any amount that would be paid to the Participant during the six-month period following such separation from service constitutes a deferral of compensation (within the meaning of Section 409A), such amount shall not be paid to the Participant until the later of (i) six months after the date of Participant’s separation from service, and (ii) the payment date or commencement date specified in the Plan for such payment(s). On the first regular payroll date following the expiration of such six-month period (or if Participant dies during the 6-month period, the first payroll date following the death), any payments that were delayed pursuant to the preceding sentence shall be paid to Participant in a single lump sum and thereafter all payments shall be made as if there had been no such delay. The provisions of this Section 10(k)(ii) shall only apply if, and to the extent, required to avoid the imputation of any tax, penalty or interest pursuant to Code Section 409A.
(iii) It is intended that any amounts payable under this Plan shall either be exempt from Section 409A of the Code or shall comply with Section 409A of the Code (including Treasury Regulations and other published guidance related thereto) so as not to subject Participants to payment of any additional tax, penalty, or interest imposed under Section 409A of the Code. The Plan shall be construed in a manner to give effect to such intention. In no event whatsoever shall the Company and/or any of its Affiliates be liable for any tax, interest or penalties that may be imposed on any Participant (or any Participant’s estate) under Section 409A of the Code. Neither the Company and/or any of its affiliates shall have any obligation to indemnify or otherwise hold a Participant (or any Participant’s estate) harmless from any or all such taxes, interest or penalties, or liability for any damages related thereto.
(k) Stock-Based Awards in Substitution for Stock Options or Awards Granted by Other Corporation . Awards may be granted to Eligible Persons in substitution for or in connection with an assumption of employee stock options, stock appreciation rights, restricted stock or other stock-based awards granted by other entities to persons who are or who will become Eligible Persons in respect of the Company or one of its Affiliates, in connection with a distribution, merger or other reorganization by or with the granting entity or an affiliated entity, or the acquisition by the Company or one of its Affiliates, directly or indirectly, of all or a substantial part of the stock or assets of the employing entity. The Awards so granted need not comply with other specific terms of the Plan, provided the Awards reflect only adjustments giving effect to the assumption or substitution consistent with the conversion applicable to the Company’s Common Stock in the transaction and any change in the issuer of the security. Any Shares that are delivered and any Awards that are granted by, or become obligations of, the Company, as a result of the assumption by the Company of, or in substitution for, outstanding awards previously granted by an acquired company (or previously granted by a predecessor employer (or direct or indirect parent thereof) in the case of persons that become employed by the Company or one of its Affiliates in connection with a business or asset acquisition or similar transaction) shall not be counted against the share limits in Section 4 or any other limits on the number of Shares available for issuance under the Plan.




Exhibit 10.1


(l) Clawback Policy . The Awards granted under the Plan are subject to the terms of the Company’s recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of Awards or any Shares or other cash or property received with respect to the Awards (including any value received from a disposition of the Shares or other property acquired upon payment of the Awards).
Section 11. Effective Date of the Plan.
The Plan shall be effective as of the date of approval by the shareholders of the Company in accordance with applicable law.
Section 12. Term of the Plan.
New Awards shall be granted under the Plan only during a 10-year period beginning on the date on which the Board of Directors of the Company approves the Plan. However, unless otherwise expressly provided in the Plan or in an applicable Award Agreement, any Award theretofore granted may extend beyond the end of such 10-year period, and the authority of the Committee provided for hereunder with respect to the Plan and any Awards, and the authority of the Board of Directors of the Company to amend the Plan, shall extend beyond the end of such period.


Adopted by Board February 9, 2011, subject to and effective upon shareholder approval Approved by shareholders on May 23, 2011
Amended by Board February 10, 2015, subject to and effective upon shareholder approval
Approved by shareholders on June 1, 2015
Amended by Board November 8, 2018







Exhibit 10.26

UHGDIRECTORCOMPSUMMARY.JPG
Our compensation and benefit program is designed to compensate our non-employee directors fairly for work required for a company of our size and scope, and align their interests with the long-term interests of our shareholders. Director compensation reflects our desire to attract, retain and use the expertise of highly qualified people serving on the Company’s Board of Directors. The Compensation and Human Resources Committee reviews the compensation level of our non-employee directors on an annual basis and makes recommendations to the Board of Directors.
The Company uses annual retainers, equity-based compensation, expense reimbursement and other forms of compensation, as appropriate, to attract and retain non-employee directors.
Cash Compensation
Non-employee directors receive an annual cash retainer of $125,000. We pay an additional annual cash retainer of $75,000 to the Lead Independent Director, an additional annual cash retainer of $25,000 to the Chair of the Audit Committee, and additional annual cash retainers of $20,000 to the Chair of the Compensation and Human Resources Committee, the Chair of the Nominating and Corporate Governance Committee and the Chair of the Public Policy Strategies and Responsibility Committee.
Cash retainers are payable on a quarterly basis in arrears on the first business day following the end of each fiscal quarter, and subject to pro-rata adjustment if the director did not serve the entire quarter. Directors may elect to receive deferred stock units (“DSUs”) or common stock (if the director has met the stock ownership guidelines) in lieu of their cash compensation or may defer receipt of their cash compensation to a later date pursuant to the Directors' Compensation Deferral Plan ("Director Deferral Plan").
Equity-Based Compensation
Non-employee directors receive annual grants of DSUs under the 2011 Stock Incentive Plan, as amended, having an annual aggregate fair value of $205,000, subject to rounding adjustments described below. The grants are issued quarterly in arrears on the first business day following the end of each fiscal quarter and prorated if the director did not serve the entire quarter. The number of DSUs granted is determined by dividing $51,250 (the quarterly value of the annual equity award) by the closing stock price on the grant date, rounded up to the nearest share.
The DSUs immediately vest upon grant and must be retained until completion of the director’s service on the Board of Directors. Upon completion of service, the DSUs convert into an equal number of shares of the Company’s common stock. A director may defer receipt of the shares for up to ten years after completion of service pursuant to the Director Deferral Plan. Non-employee directors who have met their stock ownership requirement may elect to receive common stock in lieu of DSUs and/or in-service distributions on pre-selected dates.
If a director elects to convert his or her cash compensation into DSUs, such conversion grants are made on the day the eligible cash compensation becomes payable to the director and immediately vest upon grant. The director receives the number of DSUs equal to the cash compensation foregone, divided by the closing price of our common stock on the date of grant, rounded up to the nearest share. A director may only elect to receive common stock if he or she has met the stock ownership guidelines.
The Company pays dividend equivalents in the form of additional DSUs on all outstanding DSUs. Dividend equivalents are paid at the same rate and at the same time that dividends are paid to Company shareholders and are subject to the same vesting conditions as the underlying grant.
Director Deferral Plan
Under the Director Deferral Plan, subject to compliance with applicable laws, non-employee directors may elect annually to defer receipt of all or a percentage of their compensation. Amounts deferred are credited to a bookkeeping account maintained for each director participant that uses a collection of unaffiliated mutual funds as measuring investments. Subject to certain additional rules set forth in the Director Deferral Plan, a participating director may elect to receive the distribution in one of the following ways:

Effective October 1, 2018


Exhibit 10.26

a series of five or ten annual installments following the completion of his or her service on the Board of Directors;
a delayed lump sum following either the fifth or tenth anniversary of the completion of his or her service on the Board of Directors;
for cash deferrals, an immediate lump sum upon the completion of his or her service on the Board of Directors; or
pre-selected amounts to be distributed on pre-selected dates while the director remains a member of the Board of Directors.
The Director Deferral Plan does not provide for matching contributions by the Company, but our Board of Directors may determine, in its discretion, to supplement the accounts of participating directors with additional amounts.
Other Compensation
We reimburse directors for any out-of-pocket expenses incurred in connection with service as a director. We also provide health care coverage to directors but only if the director is not eligible for coverage under another group health care benefit program. Health care coverage is provided generally on the same terms and conditions as current employees. Upon retirement from the Board of Directors, directors may continue to obtain health care coverage under benefit continuation coverage, and after the lapse of such coverage, under the Company’s post-employment medical plan for up to a total of 96 months if they are otherwise eligible.
The Company maintains a program through which it will match up to $15,000 of charitable donations made by each director for each calendar year. The directors do not receive any financial benefit from this program because the charitable income tax deductions accrue solely to the Company. Donations under the program may not be made to family trusts, partnerships or similar organizations.


Effective October 1, 2018

Exhibit 10.50

EMPLOYMENT AGREEMENT

This Agreement is between Andrew Witty (“Executive”) and United HealthCare Services, Inc. (“UnitedHealth Group”), and is effective as of Executive’s first day of employment with UnitedHealth Group (the “Effective Date”). This Agreement’s purposes are to set forth certain terms of Executive’s employment by UnitedHealth Group or one of its affiliates and to protect UnitedHealth Group’s knowledge, expertise, customer relationships, and confidential information. Unless the context otherwise requires, “UnitedHealth Group” includes all its affiliated entities.
1.     Employment and Duties .
A.
Employment .    UnitedHealth Group hereby employs Executive, and Executive accepts employment, under this Agreement’s terms.
B.
Title and Duties . Executive will be employed as Chief Executive Officer of Optum. Executive will perform such duties, and exercise such supervision and control, as are commonly associated with Executive’s position, as well as perform such other duties as are reasonably assigned to Executive. Executive will devote substantially all of Executive’s business time and energy to Executive’s duties. Executive will maintain operations in Executive’s area of responsibility, and make every reasonable effort to ensure that the employees within that area of responsibility act, in compliance with applicable law and UnitedHealth Group’s Code of Conduct, as amended from time to time. Executive is subject to all of UnitedHealth Group’s employment policies and procedures (except as specifically superseded by this Agreement).
2.      Compensation and Benefits .
A.
Base Salary . Executive’s initial annual base salary will be $1,100,000, less applicable withholdings and deductions, payable according to UnitedHealth Group’s regular payroll schedule. Periodic increases to Executive’s base salary may be made in UnitedHealth Group’s sole discretion.
B.
Incentive Compensation . Executive will be eligible to participate in UnitedHealth Group’s incentive compensation plans in UnitedHealth Group’s discretion and in accordance with the plans’ terms and conditions. Executive’s initial target bonus potential will be 200% of annual base salary, subject to periodic adjustments in UnitedHealth Group’s discretion.
C.
Sign-On Equity Award. Executive will be eligible for stock-based awards in UnitedHealth Group’s discretion. In accordance with guideline amounts authorized by UnitedHealth Group’s Compensation and Human Resources Committee, management will recommend that Executive be awarded an initial sign-on grant of $10,000,000 in the form of Restricted Stock Units. Subject to the terms of the applicable equity award certificate and UnitedHealth Group’s applicable equity incentive plan, as amended, the Restricted Stock Units will vest 20% on each anniversary date of the grant, over a five-year period.
UnitedHealth Group’s governance policy stipulates that its Compensation and Human Resources Committee can only grant equity awards at regularly scheduled quarterly committee meetings. Accordingly, Executive’s recommended grant will be reviewed by the Committee at its next regularly scheduled quarterly meeting following the Effective Date.    
D.
Annual Equity Awards . Executive will be eligible for annual stock-based awards in accordance with UnitedHealth Group’s governance policy and guideline amounts authorized by UnitedHealth Group’s Compensation and Human Resources Committee. For 2018, management will recommend that Executive be awarded an annual equity grant of $8,400,000 in the form of (i) Performance-Based Restricted Stock Units with a value of $4,200,000 for the performance period January 1, 2018 through December 31, 2020, (ii) Restricted Stock Units with a value of $2,100,000, and (iii) Options with a FAS value of $2,100,000. Subject to the terms of the applicable equity award certificate and UnitedHealth Group’s applicable equity incentive plan, as amended, the Restricted Stock Units (other than the Performance-Based Restricted Stock Units) and Options will vest 25% on each anniversary date of the grant, over a four-year period.
Recommended annual grants will be reviewed by the Committee at a regularly scheduled quarterly meeting. The number of shares comprising any Options award will be calculated the day of the Committee meeting using the closing price of UnitedHealth Group stock on that day that the calculation is made. The actual grant




Exhibit 10.50

price of any Options award will be the closing price of UnitedHealth Group stock on the day of the Committee meeting.
E.
Employee Benefits . Executive will be eligible to participate in UnitedHealth Group’s employee welfare, retirement, and stock incentive plans on the same basis as other similarly situated executives, in accordance with the terms of the plans. Executive will be eligible for Paid Time Off in accordance with UnitedHealth Group’s policies. UnitedHealth Group reserves the right to amend or discontinue any plan or policy at any time in its sole discretion. In addition to the Company’s generally available benefits, UnitedHealth Group shall provide Executive, at UnitedHealth Group’s expense during the term of Executive’s employment, a $2 million face value term life insurance policy and a long term disability policy which covers 60% of base salary in the event of a qualifying long term disability, subject to the policy terms.
3.      Termination of Employment .
A.
By Mutual Agreement . The parties may terminate Executive’s employment at any time by mutual agreement.

B.
By UnitedHealth Group without Cause . UnitedHealth Group may terminate Executive’s employment without Cause upon 90 days’ prior written notice.

C.
By UnitedHealth Group with Cause . UnitedHealth Group may terminate Executive’s employment at any time for Cause. “Cause” means Executive’s (a) material failure to follow UnitedHealth Group’s reasonable direction or to perform any duties reasonably required on material matters, (b) material violation of, or failure to act upon or report known or suspected violations of, UnitedHealth Group’s Code of Conduct, as amended from time to time, (c) conviction of any felony, (d) commission of any criminal, fraudulent, or dishonest act in connection with Executive’s employment, (e) material breach of this Agreement, or (f) conduct that is materially detrimental to UnitedHealth Group’s interests. UnitedHealth Group will, within 120 days of discovery of the conduct, give Executive written notice specifying the conduct constituting Cause in reasonable detail and Executive will have 60 days to remedy such conduct, if such conduct is reasonably capable of being remedied. In any instance where the Company may have grounds for Cause, failure by the Company to provide written notice of the grounds for Cause within 120 days of discovery shall be a waiver of its right to assert the subject conduct as a basis for termination for Cause.

D.
By Executive without Good Reason . Executive may terminate Executive’s employment at any time for any reason, including due to Executive’s retirement.

E.
By Executive for Good Reason . Executive may terminate Executive’s employment for Good Reason, as defined below. Executive must give UnitedHealth Group written notice specifying in reasonable detail the circumstances constituting Good Reason, within 120 days of becoming aware of such circumstances, or such circumstances will not constitute Good Reason. If the circumstances constituting Good Reason are reasonably capable of being remedied, UnitedHealth Group will have 60 days to remedy such circumstances. “Good Reason” will exist if UnitedHealth Group takes any of the following actions, without Executive’s consent: (a) reduces Executive’s base salary or target bonus percentage other than in connection with a general reduction affecting a group of employees; (b) moves Executive’s primary work location more than 50 miles; or (c) makes changes that substantially diminish Executive’s duties or responsibilities.
    
F.
Due to Executive’s Death or Disability . Executive’s employment will terminate automatically if Executive dies, effective as of the date of Executive’s death. UnitedHealth Group may terminate Executive’s employment due to Executive’s disability that renders Executive incapable of performing the essential functions of Executive’s job, with or without reasonable accommodation. Executive will not be entitled to Severance Benefits under Section 4 in the event of termination due to Executive’s death or disability.




Exhibit 10.50


4.
Severance Benefits .
A.
Circumstances under Which Severance Benefits Payable . Executive will be entitled to Severance Benefits only if Executive’s employment is terminated by UnitedHealth Group without Cause or if Executive terminates employment for Good Reason. Whether Executive has had a termination of employment will be determined in a manner consistent with the definition of “Separation from Service” under Section 409A of the Internal Revenue Code of 1986 and its accompanying regulations (“Section 409A”) and will be referred to herein as a “Termination.” For purposes of this Agreement, Executive will be considered to have experienced a Termination as of the date that the facts and circumstances indicate that it is reasonably anticipated that Executive will provide no further services after such date or that the level of bona fide services that Executive is expected to perform permanently decreases to no more than 20% of the average level of bona fide services that Executive performed over the immediately preceding 36-month period In consideration of the Severance Benefits in this Agreement, Executive waives any payments or benefits to which Executive otherwise might be or become entitled under any UnitedHealth Group severance plan or program.
B.
Severance Benefits . Subject to Section 4.C, Executive shall be entitled to the following Severance Benefits if Executive experiences a Termination under the circumstances described in Section 4.A above:
(i) Two times Executive’s annualized base salary as of Executive’s Termination.
(ii) Any bonus or incentive compensation paid or payable to Executive for the two most recent calendar years (excluding equity-related awards, payments under any long-term or similar benefit plan, or any other special or one-time bonus or incentive compensation payments); provided, however, that if termination occurs within two years following the Effective Date, the amount payable under this paragraph will be two times Executive’s target incentive.
(iii) $12,000 lump sum payment, minus applicable deductions, to offset costs of COBRA, which amount will be paid within 60 days following Termination.
(iv) Outplacement services consistent with those provided to similarly situated executives provided by an outplacement firm selected by UnitedHealth Group.
The Severance Benefits in Sections 4.B.(i)-(ii) will be paid out, minus applicable deductions, including deductions for tax withholding, in equal bi-weekly payments on the regular payroll cycle over the 24-month period following Executive’s Termination. Commencement of payments shall begin on the first payroll date that is at least 60 days after the date of Executive’s Termination (the “Starting Date”), provided that Executive has satisfied the requirement in Section 4.C. The first payment on the Starting Date shall include those payments that would have been previously paid if the payments of the severance compensation had begun on the first payroll date following the date of Executive’s Termination. Executive’s entitlement to the payments of the severance compensation described in Sections 4.B(i)-(ii) shall be treated as the entitlement to a series of separate payments for purposes of Section 409A.
If Executive is a “Specified Employee” (within the meaning of Section 409A and determined pursuant to procedures adopted by UnitedHealth Group) at the time of Executive’s Termination and any amount that would be paid to Executive during the six-month period following Termination constitutes “Deferred Compensation” (within the meaning of Section 409A), such amount shall not be paid to Executive until the later of (i) six months after the date of Executive’s Termination, and (ii) the payment date or commencement date specified in this Agreement for such payment(s). On the first regular payroll date following the expiration of such six-month period (or if Executive dies during the six-month period, the first payroll date following the death), all payments that were delayed pursuant to the preceding sentence shall be paid to Executive in a single lump sum and thereafter all payments shall be made as if there had been no such delay. All Severance Benefits described in Section 4.B shall be paid by, and no further severance compensation shall be paid or payable after, December 31 of the second calendar year following the year in which Executive’s Termination occurs.
C.
Separation Agreement and Release Required . In order to receive any Severance Benefits under this Agreement, Executive must timely sign a separation agreement and release of claims in a form determined by UnitedHealth




Exhibit 10.50

Group in its discretion. UnitedHealth Group shall provide to Executive a form of separation agreement and release of claims no later than three (3) days following Executive’s date of Termination. If Executive does not timely execute and deliver to UnitedHealth Group such separation agreement and release, or if Executive does so, but then revokes it if permitted by and within the time required by applicable law, UnitedHealth Group will have no obligation to pay severance compensation to Executive.
5.
Property Rights, Confidentiality, Non-Disparagement, and Restrictive Covenants .
A. UnitedHealth Group’s Property .

i.
Assignment of Property Rights . Executive must promptly disclose in writing to UnitedHealth Group all inventions, discoveries, processes, procedures, methods and works of authorship, whether or not patentable or copyrightable, that Executive alone or jointly conceives, makes, discovers, writes or creates, during working hours or on Executive’s own time, during this Agreement’s term (the “Works”). Executive hereby assigns to UnitedHealth Group all Executive’s rights, including copyrights and patent rights, to all Works. Executive must assist UnitedHealth Group as it reasonably requires to perfect, protect, and use its rights to the Works. This provision does not apply to any Work for which no UnitedHealth Group equipment, supplies, facility or trade secret information was used and: (1) which does not relate directly to UnitedHealth Group’s business or actual or demonstrably anticipated research or development, or (2) which does not result from any work performed for UnitedHealth Group.

ii.
No Removal of Property . Executive may not remove from UnitedHealth Group’s premises any UnitedHealth Group records, documents, data or other property, in either original or duplicate form, except as necessary in the ordinary course of UnitedHealth Group’s business.
iii.
Return of Property . Executive must immediately deliver to UnitedHealth Group, upon termination of employment, or at any other time at UnitedHealth Group’s request, all UnitedHealth Group property, including records, documents, data, and equipment, and all copies of any such property, including any records or data Executive prepared during employment.
B.
Confidential Information . Executive will be given access to and provided with sensitive, confidential, proprietary and trade secret information (“Confidential Information”) in the course of Executive’s employment. Examples of Confidential Information include: inventions; new product or marketing plans; business strategies and plans; merger and acquisition targets; financial and pricing information; computer programs, source codes, models and databases; analytical models; customer lists and information; and supplier and vendor lists and other information which is not generally available to the public. Executive agrees not to disclose or use Confidential Information, either during or after Executive’s employment with UnitedHealth Group, except as necessary to perform Executive’s UnitedHealth Group duties or as UnitedHealth Group may consent in writing.
 
C.
Non-Disparagement . Executive agrees not to criticize, make any negative comments about or otherwise disparage UnitedHealth Group or those associated with it, whether orally, in writing or otherwise, directly or by implication, to any person or entity, including UnitedHealth Group customers or agents.

D.
Restrictive Covenants . Executive agrees to the restrictive covenants in this Section in consideration of Executive’s employment and UnitedHealth Group’s promises in this Agreement, including providing Executive access to Confidential Information. The restrictive covenants in this Section apply during Executive’s employment and for 24 months following termination of employment for any reason. Executive agrees that he/she will not, without UnitedHealth Group's prior written consent, directly or indirectly, for Executive or for any other person or entity, as agent, employee, officer, director, consultant, owner, principal, partner or shareholder, or in any other individual or representative capacity, engage in any of the following activities:    
i.
Non-Solicitation . Executive will not:
(a)
Solicit or conduct business with any business competitive with UnitedHealth Group from any person or entity: (1) who was a UnitedHealth Group provider or customer within the 12 months before Executive’s employment termination and with whom Executive had contact regarding UnitedHealth Group’s activity, products or services, or for whom Executive provided services or supervised employees who provided those services, or about




Exhibit 10.50

whom Executive learned Confidential Information during employment related to UnitedHealth Group’s provision of products and services to such person or entity, or (2) was a prospective provider or customer UnitedHealth Group solicited within the 12 months before Executive’s employment termination and with whom Executive had contact for the purposes of soliciting the person or entity to become a provider or customer of UnitedHealth Group, or supervised employees who had those contacts, or about whom Executive learned Confidential Information during employment related to UnitedHealth Group’s provision of products and services to such person or entity;
(b)
Raid, hire, employ, recruit or solicit any UnitedHealth Group employee or consultant who possesses Confidential Information of UnitedHealth Group to leave UnitedHealth Group to join a competitor;
(c)
Induce or influence any UnitedHealth Group employee, consultant, or provider who possesses Confidential Information of UnitedHealth Group to terminate his, her or its employment or other relationship with UnitedHealth Group; or
(d)
Assist anyone in any of the activities listed above.
ii.
Non-Competition . Executive will not:
(a)
Engage in or participate in any activity that competes, directly or indirectly, with any UnitedHealth Group activity, product or service that Executive engaged in, participated in, or had Confidential Information about during Executive’s last 36 months of employment with UnitedHealth Group; or
(b)
Assist anyone in any of the activities listed above.
iii.
Because UnitedHealth Group’s business competes on a nationwide basis, the Executive’s obligations under this “Restrictive Covenants” section shall apply on a nationwide basis anywhere in the United States.
iv.
To the extent Executive and UnitedHealth Group agree at any time to enter into separate agreements containing restrictive covenants with different or inconsistent terms than those contained herein, Executive and UnitedHealth Group acknowledge and agree that such different or inconsistent terms shall not in any way affect or have relevance to the Restrictive Covenants contained herein.
Executive agrees that the provisions of this Section 5 are reasonable and necessary to protect the legitimate interests of UnitedHealth Group.
E.
Cooperation and Indemnification . Executive agrees to cooperate fully (i) with UnitedHealth Group in the investigation, prosecution or defense of any potential claims or concerns regarding UnitedHealth Group’s business about which Executive has relevant knowledge, including by providing truthful information and testimony as reasonably requested by UnitedHealth Group, and (ii) with all government authorities on matters pertaining to any investigation, litigation or administrative proceeding concerning UnitedHealth Group. UnitedHealth Group will reimburse Executive for any reasonable travel and out-of-pocket expenses incurred by Executive in providing such cooperation. UnitedHealth Group will indemnify Executive, in accordance with the Minnesota Business Corporation Act, for all claims and other covered matters arising in connection with Executive’s employment.
F.
Injunctive Relief . Executive agrees that (a) legal remedies (money damages) for any breach of Section 5 will be inadequate, (b) UnitedHealth Group will suffer immediate and irreparable harm from any such breach, and (c) UnitedHealth Group will be entitled to injunctive relief from a court in addition to any legal remedies UnitedHealth Group may seek in arbitration. If an arbitrator or court determines that Executive has breached any provision of Section 5, Executive agrees to pay to UnitedHealth Group its reasonable costs and attorney’s fees incurred in enforcing that provision




Exhibit 10.50


6.
Miscellaneous .
A.
Tax Withholding . All compensation payable under this Agreement will be subject to applicable tax withholding and other required or authorized deductions.

B.
Assignment . Executive may not assign this Agreement. UnitedHealth Group may assign this Agreement. Any successor to UnitedHealth Group will be deemed to be UnitedHealth Group under this Agreement.

C.
Entire Agreement; Amendment . This Agreement contains the parties’ entire agreement regarding its subject matter and may only be amended in a writing signed by the parties. This Agreement supersedes any and all prior oral or written employment agreements (including letters and memoranda) between Executive and UnitedHealth Group or its predecessors. This Agreement does not supersede the terms of any stock option, restricted stock, or stock appreciation rights plan or award.

D.
Choice of Law . Minnesota law governs this Agreement.

E.
Waivers; Other Rights .  No party’s failure to exercise, or delay in exercising, any right or remedy under this Agreement will be a waiver of such right or remedy, nor will any single or partial exercise of any right or remedy preclude any other or further exercise of such right or remedy.  Nothing in this Agreement prohibits Executive from making disclosures that are protected under law or reporting violations of state or federal law or regulation to governmental agencies or entities.

F.
Narrowed Enforcement and Severability . If a court or arbitrator decides that any provision of this Agreement is invalid or overbroad, the parties agree that the court or arbitrator should narrow such provision so that it is enforceable or, if narrowing is not possible or permissible, such provision should be considered severed and the other provisions of this Agreement should be unaffected.

G.
Dispute Resolution and Remedies . Except for injunctive relief under Section 5.F, any dispute between the parties relating to this Agreement or to Executive’s employment will be resolved by binding arbitration under UnitedHealth Group’s Employment Arbitration Policy, as it may be amended from time to time. The arbitrator(s) may not vary this Agreement’s terms and must apply applicable law.
H.
Payment of Deferred Compensation - Section 409A . To the extent applicable, it is intended that the compensation arrangements under this Agreement be in full compliance with Section 409A. This Agreement shall be construed in a manner to give effect to such intention. In no event whatsoever shall UnitedHealth Group be liable for any tax, interest or penalties that may be imposed on Executive under Section 409A. UnitedHealth Group shall have no obligation to indemnify or otherwise hold Executive harmless from any such taxes, interest or penalties, or from liability for any damages related thereto.
I.
Electronic Transmission/Counterparts . The executed version of this Agreement may be delivered by facsimile or email, and upon receipt, such transmission shall be deemed delivery of an original. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, and all of which together will constitute one document.


United HealthCare Services, Inc.
 
Executive
 
 
 
 
 
 
 
By:    /s/ D. Ellen Wilson
 
By: /s/ Andrew P. Witty
 
 
 
 
 
 
 
Its:    Executive Vice President, Human Capital
 
 
 
 
 
 
 
 
 
 
 
Date: March 9, 2018
 
 




Exhibit 21.1
Subsidiaries of the Company

Listed below are subsidiaries of UnitedHealth Group Incorporated as of December 31, 2018. Those subsidiaries not listed would not, in the aggregate, constitute a “significant subsidiary” of UnitedHealth Group Incorporated, as that term is defined in Rule 1-02(w) of Regulation S-X.
Name of Entity
State of Jurisdiction or Domicile
Doing Business As
1070715 B.C. Unlimited Liability Company
British Columbia
 
310 Canyon Medical, LLC
California
 
5995 Minnetonka, LLC
Delaware
 
ABCO India Private Limited
India
 
ABCO International Holdings, LLC
Delaware
 
ACN Group IPA of New York, Inc.
New York
 
ACN Group of California, Inc.
California
OptumHealth Physical Health of California
Administradora Clínica La Colina S.A.S.
Colombia
 
Administradora Country S.A.
Colombia
 
Administradora deTransacciones Electrónicas
Chile
 
Administradora Médica Centromed S.A.
Chile
 
Advanced Pharma, Inc.
Texas
Avella of Houston
Advanced Surgical Hospital, LLC
Pennsylvania
 
Advocate Condell Ambulatory Surgery Center, LLC
Illinois
 
Advocate Sherman Ambulatory Surgery Center, LLC
Illinois
 
Advocate Southwest Ambulatory Surgery Center, LLC
Illinois
 
Advocate-SCA Partners, LLC
Delaware
 
AHN Accountable Care Organization, LLC
Indiana
 
AHN Central Services, LLC
Indiana
 
AHN Target Holdings, LLC
Delaware
 
Alaska Surgery Center, Inc.
Alaska
 
Aliansalud Entidad Promotora de Salud S.A.
Colombia
 
All Savers Insurance Company
Indiana
 
All Savers Life Insurance Company of California
California
 
Alliance Surgical Center, LLC
Florida
 
Aloha Surgical Center, LLC
Tennessee
 
Ambient Healthcare, Inc.
Florida
 
Ambient Holdings, Inc.
Delaware
 
Ambulatory Surgery Center of Mt. Pleasant, LLC
South Carolina
 
American Health Network of Indiana Care Organization, LLC
Indiana
 
American Health Network of Indiana II, LLC
Indiana
Healthcare Network
American Health Network of Indiana, LLC
Indiana
EXPRESS CARE
American Health Network of Ohio Care Organization, LLC
Ohio
 
American Health Network of Ohio II, LLC
Ohio
 
American Health Network of Ohio, LLC
Ohio
 
AmeriChoice Corporation
Delaware
 
AmeriChoice Health Services, Inc.
Delaware
 
AmeriChoice of New Jersey, Inc.
New Jersey
UnitedHealthcare Community Plan





Amico Saúde Ltda.
Brazil
 
Amil Assistência Médica Internacional S.A.
Brazil
 
Amil Clinical Research Participações Ltda.
Brazil
 
AMIL International
Luxembourg
 
Análisis Clínicos ML S.A.C.
Peru
 
Antelope Valley Surgery Center, L.P.
California
 
Apothecary Holdings, Inc.
Delaware
 
Apothecary Shop of Phoenix, Inc.
Arizona
 
AppleCare Medical Management, LLC
Delaware
 
APS – Assistência Personalizada à Saúde Ltda.
Brazil
 
Aquitania Chilean Holding SpA
Chile
 
Aquitania Holding SpA
Chile
 
Arise Physician Group
Texas
 
Arizona Physicians IPA, Inc.
Arizona
UnitedHealthcare Community Plan
ASC Holdings of New Jersey, LLC
New Jersey
 
ASC Network, LLC
Delaware
 
ASI Global, LLC
Texas
 
AssuranceRx, LLC
Alabama
 
Athens ASC Holdings, LLC
Georgia
 
Audax Health Solutions, LLC
Delaware
 
Austin Center for Outpatient Surgery, L.P.
Georgia
 
Avella of Austin, Inc.
Arizona
 
Avella of Columbus, Inc.
Arizona
 
Avella of Deer Valley, Inc.
Arizona
Avella of Deer Valley, Inc. #038
Avella Specialty Pharmacy
Avella of Denver, Inc.
Arizona
 
Avella of Gilbert, Inc.
Arizona
 
Avella of Las Vegas II, Inc.
Arizona
 
Avella of Orlando, Inc.
Arizona
 
Avella of Phoenix III, Inc.
Arizona
 
Avella of Sacramento, Inc.
California
 
Avella of Scottsdale, Inc.
Arizona
 
Avella of St. Louis, Inc.
Arizona
 
Avella of Tampa, LLC
Florida
 
Avella of Tucson II, Inc.
Arizona
 
Avella of Tucson, Inc.
Arizona
 
Avella Patient Access Program, Inc.
Arizona
 
Aveta Inc.
Delaware
 
AxelaCare Intermediate Holdings, LLC
Delaware
 
AxelaCare, LLC
Delaware
 
B.R.A.S.S. Partnership in Commendam
Louisiana
 
Bakersfield-SC, LLC
Delaware
 
Banmédica Colombia SpA
Colombia
 
Banmédica Internacional SpA
Chile
 
Banmédica S.A.
Chile
 
Beach Surgical Holdings III, LLC
California
 
Behavioral Healthcare Options, Inc.
Nevada
 





Belleville Surgical Center, Ltd., an Illinois Limited Partnership
Illinois
 
Birmingham Outpatient Surgical Center, LLC
Delaware
 
Blackstone Valley Surgicare GP, LLC
Delaware
 
Blue Ridge GP, LLC
North Carolina
 
Bordeaux (Barbados) Holdings I, SRL
Barbados
 
Bordeaux (Barbados) Holdings II, SRL
Barbados
 
Bordeaux (Barbados) Holdings III, SRL
Barbados
 
Bordeaux Holding SpA
Chile
 
Bordeaux International Holdings, Inc.
Delaware
 
Bordeaux UK Holdings I Limited
United Kingdom
 
Bordeaux UK Holdings II Limited
United Kingdom
 
Bordeaux UK Holdings III Limited
United Kingdom
 
Bosque Medical Center Ltda.
Brazil
 
Brandon Ambulatory Surgery Center, LLC
Florida
 
BriovaRx Infusion Services 100, Inc.
New York
Advanced Care of New Jersey Inc.
BriovaRx Infusion Services 101, Inc.
New York
 
BriovaRx Infusion Services 102, LLC
Delaware
 
BriovaRx Infusion Services 103, LLC
Delaware
AxelaCare
Equinox Healthcare
BriovaRx Infusion Services 200, Inc.
South Carolina
 
BriovaRx Infusion Services 201, Inc.
Florida
 
BriovaRx Infusion Services 202, Inc.
Florida
 
BriovaRx Infusion Services 203, Inc.
Florida
 
BriovaRx Infusion Services 204, Inc.
Florida
 
BriovaRx Infusion Services 205, Inc.
Florida
 
BriovaRx Infusion Services 206, Inc.
Alabama
 
BriovaRx Infusion Services 207, Inc.
Alabama
 
BriovaRx Infusion Services 208, Inc.
North Carolina
AxelaCare
BriovaRx Infusion Services 209, Inc.
Georgia
AxelaCare
BriovaRx Infusion Services 301, LP
Oklahoma
AxelaCare
BriovaRx Infusion Services 302, LLC
Nebraska
AxelaCare
BriovaRx Infusion Services 305, LLC
Delaware
 
BriovaRx Infusion Services 308, LLC
Arizona
AxelaCare
BriovaRx Infusion Services 401, LLC
California
 
BriovaRx Infusion Services 402, LLC
California
 
BriovaRx Infusion Services 403, LLC
California
 
BriovaRx Infusion Services 404, LLC
Oregon
 
BriovaRx Infusion Services, Inc.
Delaware
BriovaRx Infusion Services
BriovaRx of California, Inc.
California
BriovaRx MRP
BriovaRx of Los Angeles
Mission Road Pharmacy
MRP
BriovaRx of Florida, Inc.
Delaware
BriovaRx of Florida
BriovaRx of Georgia, LLC
Alabama
 
BriovaRx of Indiana, LLC
Indiana
BriovaRx
BriovaRx of Louisiana, L.L.C.
Louisiana
 
BriovaRx of Maine, Inc.
Maine
BriovaRx





BriovaRx of Massachusetts, LLC
Massachusetts
BriovaRx
BriovaRx of Nevada, LLC
Nevada
BriovaRx
BriovaRx of Nevada
BriovaRx of New York, Inc.
New York
BriovaRx of New York
BriovaRx of Texas, Inc.
Texas
BriovaRx of Texas
BriovaRx Specialty, LLC
Delaware
BriovaRx Specialty
BriovaRx, LLC
Alabama
BriovaRx
Cabin Enterprises, LLC
Delaware
 
Cabin Holdings, LLC
Delaware
 
California MedTrans Network IPA LLC
California
 
California MedTrans Network MSO LLC
California
 
Camp Hill-SCA Centers, LLC
Delaware
 
Capital City Medical Group, L.L.C.
Louisiana
Peoples Health Clinical
Cardio Management, Inc.
Delaware
 
Care Improvement Plus Group Management, LLC
Maryland
 
Care Improvement Plus of Texas Insurance Company
Texas
Care Improvement Plan
Care Improvement Plus South Central Insurance Company
Arkansas
 
Care Improvement Plus Wisconsin Insurance Company
Wisconsin
 
Casa de Saúde Santa Therezinha S.A.
Brazil
 
Castle Rock SurgiCenter, LLC
Colorado
 
Catalyst360, LLC
Delaware
 
Catamaran Finance (Ireland) Unlimited Company
Dublin
 
Catamaran S.á.r.l.
Luxembourg
 
CDC Holdings Colombia S.A.S.
Colombia
 
Cedar Park Surgery Center, LLC
Texas
 
Cemed Care – Empresa de Atendimento Clínico Geral Ltda.
Brazil
 
Central de Compras SpA
Chile
 
Central Indiana Care Organization, LLC
Indiana
 
Central Ohio Care Organization, LLC
Ohio
 
CentrifyHealth, LLC
Delaware
 
CentriHealth Corporation
Ontario
 
CentriHealth UK Limited
United Kingdom
 
Centro de Entrenamiento en Reanimación y Prevención Limitada (CERP)
Chile
 
Centro de Servicios Compartidos Banmédica S.A.
Chile
 
Centro Médico Hospitalar Pitangueiras Ltda.
Brazil
 
Centro Médico Odontológico Americano S.A.C.
Peru
 
Centro Médico PJ Ltda.
Brazil
 
Centromed Quilpué S.A.
Chile
 
Centros Médicos y Dentales Multimed Ltda.
Chile
 
Channel Islands Surgicenter Properties, LLC
Delaware
 
Channel Islands Surgicenter, L.P.
California
 
Charleston Surgery Properties, LLC
Delaware
 
Charlotte-SC, LLC
Delaware
 
Childrens Surgery Center, LLC
Florida
 
ChinaGate (Hong Kong) Limited
Hong Kong
OptumInsight





Citrus Regional Surgery Center, L.P.
Tennessee
 
Clínica Alameda S.A.
Chile
 
Clínica Bío Bío S.A.
Chile
 
Clínica Ciudad del Mar S.A.
Chile
 
Clínica Dávila y Servicios Médicos S.A.
Chile
 
Clínica del Country S.A.
Colombia
 
Clínica Médico Cirúrgica de Santa Tecla, S.A.
Portugal
 
Clinica Oftalmologica Danilo de Castro Sociedade Simples
Brazil
 
Clínica San Borja (La Esperanza del Perú S.A.)
Peru
 
Clínica San Felipe S.A.
Peru
 
Clínica Sánchez Ferrer S.A.
Peru
 
Clínica Santa María S.A.
Chile
 
Clínica Vespucio S.A.
Chile
 
CLISA – Clínica de Santo António, S.A.
Portugal
 
CMO – Centro Médico de Oftalmologia S/S Ltda.
Brazil
 
CMS – Central de Manipulação e Serviços Farmacêuticos S.A.
Brazil
 
CNIC Health Solutions, Inc.
Colorado
Rocky Mountain Health Administrators, Inc.
Specialty Claims Solutions
Coachella Valley Physicians of PrimeCare, Inc.
California
 
Coalition for Advanced Pharmacy Services, Inc.
Delaware
 
COI – Clínicas Oncológicas Integradas S.A.
Brazil
 
COI Participações S.A.
Brazil
 
Collaborative Care Holdings, LLC
Delaware
 
Collaborative Care Services, Inc.
Delaware
 
Collaborative Realty, LLC
New York
 
Colmedica Medicina Prepagada
Colombia
 
Colorado Springs Surgery Center, Ltd.
Colorado
 
Comfort Care Transportation, LLC
Texas
 
Connecticut Surgery Center, Limited Partnership
Connecticut
 
Connecticut Surgery Properties, LLC
Delaware
 
Connecticut Surgical Center, LLC
Delaware
 
Constructora e Inmobiliaria Magapoq S.A.
Chile
 
Consumer Wellness Solutions, Inc.
Delaware
 
Country Scan Ltda.
Colombia
 
Cypress Care, Inc.
Delaware
Optum Workers Compensation Services of Georgia
Danbury Surgical Center, L.P.
Georgia
 
Day-Op Surgery Consulting Company, LLC
Delaware
 
DBP Services of New York IPA, Inc.
New York
 
Dental Benefit Providers of California, Inc.
California
OptumHealth Dental of California
Dental Benefit Providers of Illinois, Inc.
Illinois
 
Dental Benefit Providers, Inc.
Delaware
DBP Services
DBP Services Inc.
Derry Surgical Center, LLC
New Hampshire
 
Diagnóstico Ecotomográfico Centromed Ltda.
Chile
 





Diasnóstico por Imágenes Centromed Ltda.
Chile
 
Dilab Medicina Nuclear Ltda.
Brazil
 
Distance Learning Network, Inc.
Delaware
i3CME
OptumHealth Education
Doctor + S.A.C.
Peru
 
Dry Creek Surgery Center, LLC
Colorado
 
DTC Surgery Center, LLC
Colorado
 
Dublin Surgery Center, LLC
Ohio
 
Duncan Printing Services, LLC
South Carolina
 
DWIC of Tampa Bay, Inc.
Florida
Doctor's Walk-In Clinics
MedExpress
MedExpress Urgent Care - Brandon
MedExpress Urgent Care - Cape Coral, SW Pine Island Rd
MedExpress Urgent Care - Carrollwood
MedExpress Urgent Care - Clearwater
MedExpress Urgent Care - Clewiston, W Sugarland Hwy
MedExpress Urgent Care - Deland, N Woodland Blvd
MedExpress Urgent Care - Estero, S Tamiami Trl
MedExpress Urgent Care - Fort Meyers, S Cleveland Ave
MedExpress Urgent Care - Golden Gate, Collier Blvd.
MedExpress Urgent Care - Hudson, State Road 52
MedExpress Urgent Care - Jacksonville, Atlantic Blvd.
MedExpress Urgent Care - Jacksonville, Merrill Rd
MedExpress Urgent Care - Lakeland, N Road 98
MedExpress Urgent Care - Largo
MedExpress Urgent Care - Lehigh Acres, Homestead Rd N
MedExpress Urgent Care - Lutz
MedExpress Urgent Care - New Tampa
MedExpress Urgent Care - North Port, Tuscola Blvd
MedExpress Urgent Care - Northside
MedExpress Urgent Care - Palm Beach Gardens
MedExpress Urgent Care - Port Charlotte, Tamiami Trl
MedExpress Urgent Care - Seffner
MedExpress Urgent Care - Vero Beach, US Highway 1
MedExpress Urgent Care - West Tampa
E Street Endoscopy, LLC
Florida
 
Ear Professionals International Corporation
Delaware
EPIC Hearing Healthcare
East Brunswick Surgery Center, LLC
New Jersey
 
eCode Solutions, LLC
Delaware
 
Electronic Network Systems, Inc.
Delaware
 
Elual Participações S.A.
Brazil
 
Emmaus Holdings, LLC
New Jersey
 
Empire Physician Management Company, LLC
California
 
Empremédica S. A.
Peru
 
Endoscopy Center Affiliates, Inc.
Delaware
 





EP Campus I, LLC
Delaware
 
Esho – Empresa de Serviços Hospitalares S.A.
Brazil
 
Etho – Empresa de Tecnologia Hospitalar Ltda.
Brazil
 
Evercare Collaborative Solutions, Inc.
Delaware
 
Excellion Serviços Biomédicos Ltda.
Brazil
 
Executive Health Resources, Inc.
Pennsylvania
 
Executive Surgery Center, LLC
Texas
 
Family Health Care Services
Nevada
Southwest Medical Associates Home Health
Family Home Hospice, Inc.
Nevada
Family Home Hospice and Palliative Care
Southwest Medical Associates Hospice and Palliative Care
Florida MedTrans Network LLC
Florida
 
Florida MedTrans Network MSO LLC
Florida
 
FMG Holdings, LLC
Delaware
 
For Health of Arizona, Inc.
Arizona
Geriatrix of Arizona
INSPIRIS of Arizona
For Health, Inc.
Delaware
 
Fortify Technologies Asia, LLC
Phillipines
 
Fortify Technologies, LLC
Minnesota
 
Franklin Surgical Center, LLC
New Jersey
 
Freeway Surgicenter of Houston, LLC
Texas
 
Frontier Medex Tanzania Limited
Tanzania
 
FrontierMEDEX (RMS), Inc.
Delaware
 
FrontierMEDEX Government Services, LLC
Delaware
 
FrontierMEDEX Kenya Limited
Nairobi
 
FrontierMEDEX US, Inc.
Delaware
 
FrontierMEDEX, Inc.
Minnesota
UnitedHealthcare Global
Fundación Banmédica
Chile
 
Gadsden Surgery Center, LLC
Delaware
 
Gadsden Surgery Center, Ltd.
Alabama
 
Gainesville Surgery Center, L.P.
Tennessee
 
Gainesville Surgery Properties, LLC
Delaware
 
Genoa Healthcare LLC
Pennsylvania
 
Genoa Healthcare, Inc.
Delaware
 
Genoa of Arkansas, LLC
Arkansas
 
Genoa Technology (Canada) Inc.
Canada
 
Genoa Technology, Inc.
Delaware
 
Genoa Telepsychiatry, Inc.
Delaware
1DocWay, Inc.
Genoa, QoL Wholesale, LLC
Delaware
 
gethealthinsurance.com Agency Inc.
Indiana
UnitedOne Insurance Agency
Glenwood Surgical Center, L.P.
California
 
Glenwood-SC, Inc.
Tennessee
 
Golden Outlook, Inc.
California
Golden Outlook
Golden Outlook Insurance Services
Golden Rule Financial Corporation
Delaware
 
Golden Rule Insurance Company
Indiana
UnitedHealthOne
Golden Triangle Surgicenter, L.P.
California
 





GRANTS PASS SURGERY CENTER, LLC
Oregon
 
Greater Hartford ASC, LLC
Connecticut
 
Grove Place Surgery Center, L.L.C.
Florida
 
H&W Indemnity (SPC), Ltd.
Grand Cayman
 
H.I. Investments Holding Company, LLC
Delaware
 
Handles Merger Sub, Inc.
Delaware
 
Harken Health Insurance Company
Wisconsin
 
Hayes-Strub, LLC
Ohio
 
hCentive, Inc.
Delaware
 
Health Inventures Employment Solutions, LLC
Delaware
 
Health Inventures, LLC
Delaware
 
Health Net Services (Cayman) PIC
Grand Cayman
 
Health Plan of Nevada, Inc.
Nevada
 
HealthAllies, Inc.
Delaware
OptumHealth Allies
Healthcare Solutions, Inc.
Delaware
Optum Healthcare Solutions of Georgia
HealthFirst IPA, Inc.
Colorado
 
Help S.A.
Chile
 
Help Service S.A.
Chile
 
Highlands Ranch Healthcare, LLC
Colorado
 
Home Medical S.A.
Chile
 
Hospice Inspiris Holdings, Inc.
Tennessee
 
Hospitais Associados de Pernambuco Ltda.
Brazil
 
Hospital Alvorada de Taguatinga Ltda.
Brazil
 
Hospital Ana Costa S.A.
Brazil
 
Hospital de Clínicas de Jacarepaguá Ltda.
Brazil
 
Hospital Samaritano de São Paulo Ltda.
Brazil
 
Hospital Santa Helena S.A.
Brazil
 
Humedica, Inc.
Delaware
 
Hygeia Corporation
Delaware
 
Hygeia Corporation (Ontario)
Ontario
 
Illinois Independent Care Network
Delaware
 
Imed Star – Serviços de Desempenho Organizacional Ltda.
Brazil
 
Impel Consulting Experts, L.L.C.
Texas
 
Impel Management Services, L.L.C.
Texas
Impel Consulting Experts
Indian River Surgery Center, Ltd.
Florida
 
Indian River Surgery Properties, LLC
Florida
 
Indiana Care Organization, LLC
Indiana
 
Ingram & Associates, LLC
Tennessee
Ingram & Associates, LLC (Tennessee)
Ingram & Associates,(Tennessee) LLC
Ingram BPO Services, LLC
Inmobiliaria Apoquindo 3001 S.A.
Chile
 
Inmobiliaria Apoquindo 3600 Ltda.
Chile
 
Inmobiliaria Apoquindo S.A.
Chile
 
Inmobiliaria Clínica Santa María S.A.
Chile
 
Inmobiliaria e Inversiones Alameda S.A.
Chile
 
Inmobiliaria Viñamed Ltda.
Chile
 





INOV8 Surgical at Memorial City, LLC
Texas
 
inPharmative, Inc.
Nevada
 
INSPIRIS of New York IPA, Inc.
New York
Care Level Management of New York
OptumCare Network IPA
INSPIRIS of New York Management, Inc.
New York
INSPIRIS of New York Management
INSPIRIS of Texas Physician Group
Texas
Optum Clinic
Optum Clinic + Medical Spa
Optum Clinic + Urgent Care
Inspiris, Inc.
Delaware
 
Inversiones Clínicas Santa María S.A.
Chile
 
Isapre Banmédica S.A.
Chile
 
Isapre Vida Tres S.A.
Chile
 
Johnston Surgicare, L.P.
Rhode Island
 
Joliet Surgery Center Limited Partnership
Illinois
 
Laboratorio ROE S.A.
Peru
 
Laboratorios Médicos Amed Quilpué S.A.
Chile
 
Liberty Anesthesia Services, LLC
Illinois
 
Lifeprint Accountable Care Organization, LLC
Delaware
Optum Accountable Care, Arizona
Lifeprint East, Inc.
Delaware
OptumCare Network of Connecticut
LifePrint Health, Inc.
Delaware
Optum Medical Network
OptumCare Medical Network
Optumcare Network of Indiana
Logistics Health, Inc.
Wisconsin
 
Lotten-Eyes Oftalmologia Clinica e Cirurgica Ltda.
Brazil
 
Louisville S.C., Ltd.
Kentucky
 
Louisville-SC Properties, Inc.
Kentucky
 
Loyola Ambulatory Surgery Center at Oakbrook, Inc.
Illinois
 
Lusíadas - Parcerias Cascais, S.A.
Portugal
 
Lusíadas A.C.E.
Portugal
 
Lusíadas, S.A.
Portugal
 
Lusíadas, SGPS, S.A.
Portugal
 
MAMSI Insurance Resources, LLC
Maryland
 
MAMSI Life and Health Insurance Company
Maryland
 
Managed Physical Network, Inc.
New York
 
March Holdings, Inc.
California
 
March Vision Care, Inc.
California
 
Marin Surgery Holdings, Inc.
Delaware
 
Maryland Ambulatory Centers
Maryland
 
Maryland-SCA Centers, LLC
Delaware
 
Massachusetts Assurance Co., Ltd.
Grand Cayman
 
Massachusetts Avenue Surgery Center, LLC
Maryland
 
McKenzie Surgery Center, L.P.
Tennessee
 
MD Ops, Inc.
California
CHIEF
Community Health Information Exchange Foundation
MD-Individual Practice Association, Inc.
Maryland
M.D. IPA
M.D. IPA HEALTH
M.D. IPA PREFERRED
ME AHS UC LLC
Delaware
 





Medalliance Net Ltda.
Brazil
 
MEDEX Insurance Services, Inc.
Maryland
MEDEX Insurance Agency
MGG Insurance Services
MedExpress Development, LLC
Florida
 
MedExpress Urgent Care Alabama, LLC
Alabama
 
MedExpress Urgent Care Maine, Inc.
Maine
 
MedExpress Urgent Care New Hampshire, Inc.
New Hampshire
 
MedExpress Urgent Care of Boynton Beach, LLC
Florida
MedExpress Urgent Care - Boca Raton
MedExpress Urgent Care - Coral Springs
MedExpress Urgent Care - Palm Beach Gardens
MedExpress Urgent Care - Royal Palm Beach
MedExpress Urgent Care, Inc. - Ohio
Ohio
 
Medica Health Plans of Florida, Inc.
Florida
 
Medica HealthCare Plans, Inc.
Florida
 
Medical Hilfe S.A.
Chile
 
Medical Surgical Centers of America, Inc.
Delaware
 
Medical Transportation Services, LLC
Florida
MTS
Medication Management Systems, Inc.
Minnesota
 
MedSynergies, LLC
Delaware
 
Melbourne Surgery Center, LLC
Georgia
 
Memorial City Holdings, LLC
Delaware
 
Memorial City Partners, LLC
Delaware
 
Memphis-SC, LLC
Tennessee
 
Memphis-SP, LLC
Tennessee
 
Mesquite Liberty, LLC
Nevada
 
Metropolitan Medical Partners, LLC
Maryland
 
Metropolitan Medical Transportation IPA, LLC
New York
 
MHC Real Estate Holdings, LLC
California
 
MIAMI SURGERY CENTER, LLC
Delaware
 
Midwest Center for Day Surgery, LLC
Illinois
 
Mile High SurgiCenter, LLC
Colorado
 
Mississippi Surgery Holdings, LLC
Delaware
 
Mississippi Surgical Center Limited Partnership
Mississippi
 
Modern Medical, Inc.
Ohio
MMI of Ohio, Inc.
Modern Medical of Ohio, Inc.
Optum Workers Compensation Medical Services
Optum Workers Compensation Services
Optum WorkersCompensation Medical Services
Monarch Management Services, Inc.
Delaware
 
Montgomery Surgery Center Limited Partnership
Maryland
 
MSLA Management LLC
Delaware
 
Mt. Pleasant Surgery Center, L.P.
Tennessee
 
Multiangio Ltda.
Brazil
 
Muskogee Surgical Investors, LLC
Oklahoma
 
Mustang Razorback Holdings, Inc.
Delaware
 
My Wellness Solutions, LLC
Delaware
 





NAMM Holdings, Inc.
Delaware
 
Nashville-SCA Surgery Centers, Inc.
Tennessee
 
National MedTrans, LLC
New York
 
National Pacific Dental, Inc.
Texas
 
National Surgery Centers, LLC
Delaware
 
Neighborhood Health Partnership, Inc.
Florida
 
Netwerkes, LLC
Tennessee
 
Nevada Pacific Dental
Nevada
 
New Orleans Regional Physician Hospital Organization, L.L.C.
Louisiana
Peoples Health
Peoples Health Network
New West Physicians, Inc.
Colorado
Elk Ridge Family Medicine
HEALTHFIRST PHYSICIANS
New West Physicians
Physician Alliance of the Rockies
Newton Holdings, LLC
Delaware
 
North American Medical Management California, Inc.
Tennessee
 
Northern Nevada Health Network, Inc.
Nevada
 
Northern Rockies Surgery Center, L.P.
Tennessee
 
Northern Rockies Surgicenter, Inc.
Montana
 
Northwest Surgicare, LLC
Delaware
 
Northwest Surgicare, Ltd., an Illinois Limited Partnership
Illinois
 
NSC Fayetteville, LLC
Delaware
 
NSC Greensboro, LLC
Delaware
 
NSC Lancaster, LLC
Delaware
 
NSC Seattle, Inc.
Washington
 
NSC Upland, LLC
Delaware
 
Omesa S.A.
Chile
 
Oncocare S.A.C.
Peru
 
OneNet PPO, LLC
Maryland
 
Optimum Choice, Inc.
Maryland
 
Optum Bank, Inc.
Utah
Exante Bank, Inc.
OptumHealth Bank, Inc.
Optum Biometrics, Inc.
Illinois
Wellness, Inc.
Wellness, Inc., which will do business in California as Illinois Wellness, Inc.
Optum Care Services Company
Tennessee
Care Level Management of Florida
Inspiris of Florida
Optum Care, Inc.
Delaware
 
Optum Clinics Holdings, Inc.
Delaware
 
Optum Clinics Intermediate Holdings, Inc.
Delaware
 
Optum Digital Health Holdings, LLC
Delaware
 
Optum Finance (Ireland) Unlimited Company
Dublin
 
Optum Global Solutions (India) Private Limited
India
 
Optum Global Solutions (Philippines), Inc.
Phillipines
 
Optum Global Solutions International B.V.
Netherlands
 
Optum Government Solutions, Inc.
Delaware
 
Optum Health & Technology (Hong Kong) Limited
Hong Kong
 
Optum Health & Technology (India) Private Limited
India
 





Optum Health & Technology (Singapore) Pte. Ltd.
Singapore
 
Optum Health & Technology (UK) Limited
United Kingdom
 
Optum Health & Technology (US), LLC
Missouri
 
Optum Health & Technology Holdings (US), Inc.
Missouri
 
Optum Health & Technology Serviços do Brasil Ltda.
Brazil
 
Optum Health and Technology FZ-LLC
Dubai
 
Optum Health Services (Canada) Ltd.
British Columbia
Interlock Employee and Family Assistance
Optum Health Solutions (Australia) Pty Ltd
Australia
 
Optum Health Solutions (UK) Limited
United Kingdom
 
Optum Healthcare of Illinois, Inc.
Georgia
 
Optum Hospice Pharmacy Services, LLC
Delaware
HospiScript Services
Optum Hospice Pharmacy Services
Optum Hospice Pharmacy Services Administrator
Optum Insurance of Ohio, Inc.
Ohio
 
Optum Labs Dimensions, Inc.
Delaware
 
Optum Labs International (UK) Ltd.
United Kingdom
 
Optum Labs, Inc.
Delaware
 
Optum Life Sciences (Canada) Inc.
Ontario
 
Optum Management Consulting (Shanghai) Co., Ltd.
China
 
Optum Nevada Accountable Care Organization LLC
Delaware
 
Optum of New York, Inc.
New York
 
Optum Palliative and Hospice Care of Pennsylvania, Inc.
Tennessee
Evercare Hospice & Palliative Care
Optum Palliative and Hospice Care of Texas, Inc.
Tennessee
Evercare Hospice & Palliative Care
Optum Palliative and Hospice Care, Inc.
Delaware
Evercare Hospice
Evercare Hospice and Palliative Care
Evercare Hospice and Palliative Care of Colorado Springs
Evercare Hospice and Palliative Care of Denver
Evercare Palliative Care
Evercare Palliative Services
Evercare Palliative Services of Colorado Springs
Evercare Palliative Services of Denver
Evercare Palliative Services of Dover
Evercare Palliative Services of Vienna
Optum Public Sector Solutions, Inc.
Delaware
Ingenix Public Sector Solutions
Ingenix Public Sector Solutions, Inc.
Optum Rocket, Inc.
Delaware
 
Optum Senior Services, LLC
Alabama
SeniorScript
Optum Services (Ireland) Limited
Dublin
 
Optum Services (Puerto Rico) LLC
Puerto Rico
 
Optum Services, Inc.
Delaware
 
Optum Solutions do Brasil – Tecnologia e Serviços de Suporte Ltda.
Brazil
 
Optum Solutions UK Holdings Limited
United Kingdom
 
Optum Technology, Inc.
Delaware
 
Optum UK Solutions Group Limited
United Kingdom
 
Optum Women's and Children's Health, LLC
Delaware
 
Optum, Inc.
Delaware
 
Optum360 Services, Inc.
Delaware
 





Optum360 Solutions, LLC
Delaware
 
Optum360, LLC
Delaware
 
OptumHealth Care Solutions, LLC
Delaware
 
OptumHealth Financial Services, Inc.
Delaware
 
OptumHealth Holdings, LLC
Delaware
 
OptumHealth International B.V.
Netherlands
 
OptumInsight Holdings, LLC
Delaware
 
OptumInsight Life Sciences, Inc.
Delaware
Innovus
QualityMetric
QualityMetric Incorporated
OptumInsight, Inc.
Delaware
Ingenix
Ingenix, Inc.
Optum
OptumRx Administrative Services, LLC
Texas
 
OptumRx Discount Card Services, LLC
Delaware
 
OptumRx Group Holdings, Inc.
Delaware
 
OptumRx Health Solutions, LLC
Delaware
 
OptumRx Holdings I, LLC
Delaware
 
OptumRx Holdings, LLC
Delaware
 
OptumRx Home Delivery of Ohio, LLC
Ohio
OptumRx at Nationwide
OptumRx of Ohio
OptumRx IPA III, Inc.
New York
 
OptumRx NY IPA, Inc.
New York
 
OptumRx of Pennsylvania, LLC
Delaware
FutureScripts Secure
OptumRx PBM of Illinois, Inc.
Delaware
 
OptumRx PBM of Maryland, LLC
Nevada
 
OptumRx PBM of Pennsylvania, LLC
Pennsylvania
FutureScripts
OptumRx PBM of Puerto Rico, LLC
Nevada
 
OptumRx PBM of Wisconsin, LLC
Wisconsin
OptumRx PBM Administrator of Wisconsin
OptumRx PD of Pennsylvania, LLC
Pennsylvania
 
OptumRx Pharmacy of Nevada, Inc.
Nevada
Culinary
Culinary Pharmacy
OptumRx Pharmacy, Inc.
Delaware
 
OptumRx, Inc.
California
hi HealthInnovations
OptumRx
OptumRx Pharmacy at Collins Aerospace
OptumRx Pharmacy at Rockwell Collins
Orlando Center for Outpatient Surgery, L.P.
Georgia
 
OrthoNet Holdings, Inc.
Delaware
 
OrthoNet LLC
New York
OrthoNet of New York
OrthoNet New York IPA, Inc.
New York
 
OrthoNet of the Mid-Atlantic, Inc.
Delaware
 
OrthoNet of the South, Inc.
Delaware
 
OrthoNet Services, Inc.
Delaware
 
OrthoNet West, Inc.
Delaware
 
Ovations, Inc.
Delaware
 
Oxford Benefit Management, Inc.
Connecticut
 
Oxford Health Insurance, Inc.
New York
 
Oxford Health Plans (CT), Inc.
Connecticut
 





Oxford Health Plans (NJ), Inc.
New Jersey
 
Oxford Health Plans (NY), Inc.
New York
 
Oxford Health Plans LLC
Delaware
Oxford Agency - Oxford Health Plans Inc.
P2P Link, LLC
Delaware
 
PacifiCare Life and Health Insurance Company
Indiana
UnitedHealthOne
PacifiCare Life Assurance Company
Colorado
UnitedHealthOne
PacifiCare of Arizona, Inc.
Arizona
PacifiCare
Secure Horizons
PacifiCare of Colorado, Inc.
Colorado
Comprecare, Inc.
Secure Horizons
PacifiCare of Nevada, Inc.
Nevada
PacifiCare
Pacífico S.A. Entidad Prestadora de Salud
Peru
 
Paoli Ambulatory Surgery Center
Pennsylvania
 
Paoli Surgery Center, L.P.
Tennessee
 
Parkway Surgery Center, LLC
Delaware
 
Pasteur Plaza Surgery Center GP, Inc.
Delaware
 
Patrimonio Autónomo Clínica del Country (Colombia)
Colombia
 
Patrimonio Autónomo Clínica la Colina (Colombia)
Colombia
 
Patrimonio Autónomo Nueva Clínica - PANC.
Colombia
 
Payment Resolution Services, LLC
Tennessee
 
PCCCV, Inc.
California
 
Peoples Health, Inc.
Louisiana
 
Pharmacy Software Holdco, Inc.
Pennsylvania
 
PHC Subsidiary Holdings, LLC
Texas
 
Physician Alliance of the Rockies, LLC
Colorado
 
PHYSICIANS DAY SURGERY CENTER, LLC
Florida
 
Physicians Health Choice of Texas, LLC
Texas
Physicians Health Choice
Physicians Health Plan of Maryland, Inc.
Maryland
 
Physicians Plaza Holdings, LLC
California
 
Plano de Saúde Ana Costa Ltda.
Brazil
 
Plus One Health Management Puerto Rico, Inc.
Puerto Rico
 
Plus One Holdings, Inc.
Delaware
 
PMI Acquisition, LLC
Delaware
 
PMSI Holdings, LLC
Delaware
 
PMSI Settlement Solutions, LLC
Florida
Helios
Optum Settlement Solutions
PMSI, LLC
Florida
Helioscomp, LLC
Optum
Optum Workers Compensation Services of Florida
Polar II Fundo de Investimento em Participações Multiestrategia
Brazil
 
Polo Holdco, LLC
Delaware
 
POMCO Network, Inc.
New York
 
POMCO of Florida Ltd., Inc.
Florida
 
POMCO West, Inc.
Delaware
 
POMCO, Inc.
New York
EM Risk Management
Pomco
Pomco Group Benefit Administrators





Pomcoplus, LLC
New York
AllMed Audit Services
Recovery Resource Specialist
Pomerado Outpatient Surgical Center, Inc.
California
 
Pomerado Outpatient Surgical Center, L.P.
California
 
Preferred Care Partners Holding, Corp.
Florida
UnitedHealthcare
Preferred Care Partners Medical Group, Inc.
Florida
 
Preferred Care Partners, Inc.
Florida
 
Premier Choice ACO, Inc.
California
 
Premier Surgery Center of Louisville, L.P.
Tennessee
 
Prime Health, Inc.
Nevada
Med One Works
PrimeCare Medical Network, Inc.
California
 
PrimeCare of Citrus Valley, Inc.
California
 
PrimeCare of Corona, Inc.
California
 
PrimeCare of Hemet Valley, Inc.
California
 
PrimeCare of Inland Valley, Inc.
California
 
PrimeCare of Moreno Valley, Inc.
California
 
PrimeCare of Redlands, Inc.
California
 
PrimeCare of Riverside, Inc.
California
 
PrimeCare of San Bernardino, Inc.
California
 
PrimeCare of Sun City, Inc.
California
 
PrimeCare of Temecula, Inc.
California
 
Procura Management, Inc.
Delaware
Optum Managed Care Services
Progressive Enterprises Holdings, Inc.
Delaware
 
Progressive Medical, LLC
Ohio
Automed Solutions
Helios
Optum Workers Compensation Services of Ohio
PMI Medical Solutions, LLC
PMI Solutions, LLC
Progressive Medical Solutions, LLC
Progressive Medical, LLC of Ohio
ProHEALTH Fitness of Lake Success, LLC
New York
 
ProHEALTH Medical Management, LLC
Delaware
 
ProHealth Physicians ACO, LLC
Connecticut
 
ProHealth Physicians, Inc.
Connecticut
 
ProHealth Proton Center Management, LLC
Delaware
 
Promotora Country S.A.
Colombia
 
Pronounced Health Solutions, Inc.
Delaware
 
Prosemedic S.A.C.
Peru
 
Pueblo Ambulatory Surgery Center, LLC
Colorado
 
Pueblo-SCA Surgery Center, LLC
Delaware
 
Pulse Platform, LLC
Delaware
 
QoL Acquisition Holdings Corp.
Delaware
 
Quality Software Services, Inc.
Maryland
Optum
Optum, Inc.
Q.S.S., Inc.
QSSI
Rally Health, Inc.
Delaware
 
Real Appeal, Inc.
Delaware
 
Recaudación y Cobranzas Honodav Ltda.
Chile
 





Redlands Ambulatory Surgery Center
California
 
Redlands-SCA Surgery Centers, Inc.
California
 
Reliant MSO, LLC
Delaware
 
River Valley ASC, LLC
Connecticut
 
Riverside Medical Management, LLC
Delaware
 
Rocky Mountain Health Maintenance Organization, Incorporated
Colorado
Rocky Mountain Health Plans
Rocky Mountain HMO
Rocky Mountain Health Management Corporation
Colorado
Rocky Mountain Health Advantage
Rocky Mountain HMC
Western Health Plans, Inc.
Rocky Mountain HealthCare Options, Inc.
Colorado
HealthCare Options, Inc.
Rocky Mountain HCO
Saden S.A.
Chile
 
Salem Surgery Center, LLC
Oregon
 
Salveo Specialty Pharmacy, Inc.
Delaware
 
Sand Lake SurgiCenter, LLC
Florida
 
Santa Cruz Endoscopy Center, LLC
California
 
Santa Helena Assistência Médica S.A.
Brazil
 
Santos Administração e Participações S.A.
Brazil
 
Savvysherpa Administrative Services, LLC
Minnesota
 
Savvysherpa Asia, Inc.
Phillipines
 
Savvysherpa, LLC
Delaware
 
SC Affiliates, LLC
Delaware
 
SCA Athens, LLC
Delaware
 
SCA Austin Holdings, LLC
Delaware
 
SCA BOSC Holdings, LLC
Delaware
 
SCA California Surgical Holdings, LLC
Delaware
 
SCA Capital, LLC
Delaware
 
SCA Cedar Park Holdings, LLC
Delaware
 
SCA Danbury Surgical Center, LLC
Delaware
 
SCA Development, LLC
Delaware
 
SCA eCode Solutions Private Limited
India
 
SCA EHSC Holdings, LLC
Delaware
 
SCA EWASC Holdings, LLC
Delaware
 
SCA Hays Holdings, LLC
Delaware
 
SCA Heartland Holdings, LLC
Delaware
 
SCA HoldCo, Inc.
Delaware
 
SCA Holding Company, Inc.
Delaware
 
SCA Holdings, Inc.
California
 
SCA IEC Holdings, LLC
Delaware
 
SCA Indiana Holdings, LLC
Delaware
 
SCA Nashville ASC, LLC
Tennessee
 
SCA of Clarksville, Inc.
Tennessee
 
SCA Pacific Holdings, Inc.
California
 
SCA Pennsylvania Holdings, LLC
Delaware
 
SCA Premier Surgery Center of Louisville, LLC
Delaware
 
SCA Rockledge JV, LLC
Delaware
 
SCA ROCS Holdings, LLC
Delaware
 





SCA Southwestern PA, LLC
Delaware
 
SCA Specialists of Florida, LLC
Delaware
 
SCA SSC Holdings, LLC
Delaware
 
SCA SSSC Holdings, LLC
Delaware
 
SCA Stonegate Holdings, LLC
Delaware
 
SCA Surgery Center of Cullman, LLC
Delaware
 
SCA Surgery Holdings, LLC
Delaware
 
SCA Surgery Partners, LLC
Delaware
 
SCA Surgicare of Laguna Hills, LLC
Delaware
 
SCA Teammate Support Network
Alabama
 
SCA-Albuquerque Surgery Properties, Inc.
New Mexico
 
SCA-Alliance, LLC
Delaware
 
SCA-Anne Arundel, LLC
Delaware
 
SCA-Bethesda, LLC
Delaware
 
SCA-Blue Ridge, LLC
Delaware
 
SCA-Bonita Springs, LLC
Delaware
 
SCA-Brandon, LLC
Delaware
 
SCA-Brazil, LLC
Delaware
 
SCA-Castle Rock, LLC
Delaware
 
SCA-Central Florida, LLC
Florida
 
SCA-Charleston, LLC
Delaware
 
SCA-Chatham, LLC
Delaware
 
SCA-Cherry Creek, LLC
Delaware
 
SCA-Chevy Chase, LLC
Delaware
 
SCA-Citrus, Inc.
Tennessee
 
SCA-Colorado Springs, LLC
Delaware
 
SCA-Connecticut Partners, LLC
Delaware
 
SCA-Davenport, LLC
Delaware
 
SCA-Derry, LLC
Delaware
 
SCA-Doral, LLC
Delaware
 
SCA-DRY CREEK, LLC
Delaware
 
SCA-DTC Holdings, LLC
Delaware
 
SCA-Dublin, LLC
Delaware
 
SCA-Encinitas, Inc.
Delaware
 
SCA-Eugene, Inc.
Tennessee
 
SCA-First Coast, LLC
Delaware
 
SCA-Florence, LLC
Delaware
 
SCA-Fort Collins, Inc.
Colorado
 
SCA-Fort Walton, Inc.
Tennessee
 
SCA-Franklin, LLC
Delaware
 
SCA-Frederick, LLC
Delaware
 
SCA-Freeway Holdings, LLC
Delaware
 
SCA-Ft. Myers, LLC
Delaware
 
SCA-Gainesville, LLC
Delaware
 
SCA-Gladiolus, LLC
Delaware
 
SCA-GRANTS PASS, LLC
Delaware
 





SCA-Grove Place, LLC
Delaware
 
SCA-Hagerstown, LLC
Delaware
 
SCA-Hamden, LLC
Delaware
 
SCA-Hilton Head, LLC
Delaware
 
SCA-Honolulu, LLC
Delaware
 
SCA-Houston Executive, LLC
Delaware
 
SCAI Holdings, LLC
Delaware
 
SCA-Illinois, LLC
Delaware
 
SCA-IT Holdings, LLC
Delaware
 
SCA-Kissing Camels Holdings, LLC
Delaware
 
SCA-Main Street, LLC
Delaware
 
SCA-Marina del Rey, LLC
California
 
SCA-MC VBP, Inc.
Delaware
 
SCA-Mecklenburg Development Corp.
North Carolina
 
SCA-Memorial City, LLC
Delaware
 
SCA-Merritt, LLC
Delaware
 
SCA-Midlands, LLC
Delaware
 
SCA-Midway Management, LLC
Illinois
 
SCA-Mile High Holdings, LLC
Delaware
 
SCA-Mobile, LLC
Delaware
 
SCA-Mokena Properties, LLC
Delaware
 
SCA-Mokena, LLC
Delaware
 
SCA-Mt. Pleasant, LLC
Delaware
 
SCA-Naperville, LLC
Delaware
 
SCA-Naples, LLC
Delaware
 
SCA-ND VBP, Inc.
Delaware
 
SCA-New Jersey, LLC
Delaware
 
SCA-Newport Beach, LLC
California
 
Scanner Centromed S.A.
Chile
 
SCA-Northeast Georgia Health, LLC
Tennessee
 
SCA-Ortho Holdings, LLC
Delaware
 
SCA-Palm Beach MSO Holdings, LLC
Delaware
 
SCA-Palm Beach, LLC
Delaware
 
SCA-Paoli, LLC
Delaware
 
SCA-Phoenix, LLC
Delaware
 
SCA-Pocono, LLC
Delaware
 
SCA-PORTLAND, LLC
Delaware
 
SCA-River Valley, LLC
Delaware
 
SCA-Rockville, LLC
Florida
 
SCA-San Diego, Inc.
Delaware
 
SCA-San Luis Obispo, LLC
Delaware
 
SCA-Sand Lake, LLC
Florida
 
SCA-Santa Rosa, Inc.
Nevada
 
SCA-Shelby Development Corp.
Tennessee
 
SCA-Somerset, LLC
Delaware
 
SCA-South Jersey, LLC
Delaware
 





SCA-Sovereign Santa Monica, LLC
Delaware
 
SCA-Sparta, LLC
Delaware
 
SCA-Spartanburg Holdings, LLC
Delaware
 
SCA-St. Louis, LLC
Delaware
 
SCA-St. Lucie, LLC
Delaware
 
SCA-SurgiCare, LLC
Delaware
 
SCA-Swiftpath, LLC
Delaware
 
SCA-VERTA, LLC
Delaware
 
SCA-Wake Forest, LLC
Delaware
 
SCA-Western Connecticut, LLC
Delaware
 
SCA-Westover Hills, LLC
Delaware
 
SCA-Wilmington, LLC
Delaware
 
SCA-Wilson, LLC
Delaware
 
SCA-Winchester, LLC
Delaware
 
SCA-Winter Park, Inc.
Tennessee
 
SCA-Woodlands Holdings, LLC
Delaware
 
SCP Specialty Infusion, LLC
Delaware
 
ScriptSwitch Limited
United Kingdom
 
Seisa Serviços Integrados de Saúde Ltda.
Brazil
 
Senate Street Surgery Center, LLC
Indiana
 
Serquinox Holdings LLC
Delaware
 
Servicios de Entrenamiento en Competencias Clínicas Ltda.
Chile
 
Servicios Integrados de Salud Ltda.
Chile
 
Servicios Médicos Amed Quilpué S.A.
Chile
 
Servicios Médicos Bío Bío Limitada
Chile
 
Servicios Médicos Ciudad del Mar Ltda.
Chile
 
Servicios Médicos Santa María Limitada
Chile
 
Servicios Médicos Vespucio Ltda.
Chile
 
SharedClarity LLC
Delaware
 
SHC Atlanta, LLC
Delaware
 
SHC Austin, Inc.
Georgia
 
SHC Hawthorn, Inc.
Georgia
 
SHC Melbourne, Inc.
Georgia
 
Shelby Surgery Properties, Inc.
Tennessee
 
Sierra Health and Life Insurance Company, Inc.
Nevada
 
Sierra Health Services, Inc.
Nevada
 
Sierra Health-Care Options, Inc.
Nevada
 
Sierra Home Medical Products, Inc.
Nevada
THC of Nevada
THC of Nevada Pharmacy
Sierra Nevada Administrators, Inc.
Nevada
 
Sistema de Administración Hospitalaria S.A.C.
Peru
 
Sobam – Centro Médico Hospitalar S.A.
Brazil
 
Sociedad de Inversiones Santa María S.A.
Chile
 
Sociedad Editorial para la Ciencia Limitada.
Colombia
 
Somerset Outpatient Surgery, L.L.C.
New Jersey
 





Southwest Medical Associates, Inc.
Nevada
Optum Nevada Medical Partners
OptumCare Medical Group
Sierra Home Medical Products, Inc.
SMA Lifestyle Center
Soutwest Medical Pharmacy & Home Medical Equipment
Southwest Michigan Health Network Inc.
Michigan
 
Southwest Surgery Center, LLC
Illinois
 
Southwest Surgical Center of Bakersfield, L.P.
California
 
Space Coast Surgical Center, Ltd.
Florida
 
Specialists in Urology Surgery Center, LLC
Florida
 
Specialized Pharmaceuticals, Inc.
Pennsylvania
 
Specialty Benefits, LLC
Delaware
EyeFit
EyeFit Vision Center
EyeFit Vision Centers
Specialty Surgical Center, LLC
New Jersey
 
Spectera of New York, IPA, Inc.
New York
 
Spectera, Inc.
Maryland
CARE Programs, a division of Spectera, Inc
Health Benefit Sevices, Inc.
Spectera
United Optical
SPINETRACK 20/20, Inc.
California
 
Spotlite, Inc.
Delaware
 
SRPS, LLC
Delaware
 
St. Cloud Surgical Center, LLC
Delaware
 
Stonegate Surgery Center, L.P.
Texas
 
Streamlines Health, LLC
Minnesota
 
SunSurgery, LLC
Delaware
 
Surgery Center at Cherry Creek, LLC
Colorado
 
Surgery Center at Kissing Camels, LLC
Colorado
 
Surgery Center Holding, LLC
Delaware
 
Surgery Center of Athens, LLC
Georgia
 
Surgery Center of Boca Raton, Inc.
Florida
 
Surgery Center of Clarksville, L.P.
Tennessee
 
Surgery Center of Colorado Springs, LLC
Delaware
 
Surgery Center of Des Moines, LLC
Delaware
 
Surgery Center of Easton, LLC
Delaware
 
Surgery Center of Ellicott City, Inc.
Delaware
 
Surgery Center of Lexington, LLC
Delaware
 
Surgery Center of Louisville, LLC
Delaware
 
Surgery Center of Maui, LLC
Delaware
 
Surgery Center of Muskogee, LLC
Delaware
 
Surgery Center of Rockville, L.L.C.
Maryland
 
Surgery Center of Southern Pines, LLC
Delaware
 
Surgery Center of Spokane, LLC
Delaware
 
Surgery Center of Summerlin, LLC
Delaware
 
Surgery Center of The Woodlands, LLC
Texas
 
Surgery Center of Vero Beach, Inc.
Tennessee
 
Surgery Center of Wilmington Properties, LLC
North Carolina
 





Surgery Center of Wilmington, LLC
North Carolina
 
Surgery Center of Wilson, LLC
North Carolina
 
Surgery Centers of Des Moines, Ltd., an Iowa Limited Partnership
Iowa
 
Surgery Centers-West Holdings, LLC
Delaware
 
Surgical Care Affiliates Political Action Committee
Alabama
 
Surgical Care Affiliates, LLC
Delaware
 
Surgical Care Partners of Melbourne, LLC
Delaware
 
Surgical Center of South Jersey, Limited Partnership
New Jersey
 
Surgical Center of Tuscaloosa Holdings, LLC
Alabama
 
Surgical Health of Orlando, Inc.
Florida
 
Surgical Health, LLC
Delaware
 
Surgical Hospital Holdings of Oklahoma, LLC
Delaware
 
Surgical Hospital of Oklahoma, L.L.C.
Oklahoma
 
Surgicare of Belleville, LLC
Delaware
 
Surgicare of Jackson, LLC
Delaware
 
Surgicare of Joliet, Inc.
Illinois
 
Surgicare of La Veta, Inc.
California
 
Surgicare of La Veta, Ltd., a California Limited Partnership
California
 
Surgicare of Minneapolis, LLC
Delaware
 
Surgicare of Mobile, LLC
Delaware
 
Surgicare of Oceanside, Inc.
California
 
Surgicare of Owensboro, LLC
Delaware
 
Surgicare of Salem, LLC
Delaware
 
Surgicare, LLC
Indiana
 
Surgicenters of Southern California, Inc.
California
 
Symphonix Health Holdings, LLC
Delaware
 
Symphonix Health Insurance, Inc.
Illinois
 
TeamMD Holdings, Inc.
Delaware
 
TeamMD Iowa, Inc.
Delaware
 
TeamMD Physicians of Texas, Inc.
Texas
 
Tecnologías de Información en Salud S.A.
Chile
 
The Advisory Board (Chile) SpA
Chile
 
The Advisory Board Company
Delaware
The Delaware Advisory Board Company
The Lewin Group, Inc.
North Carolina
Lewin
The Outpatient Surgery Center of Hilton Head, LLC
South Carolina
 
The Surgery Center of Easton, L.P.
Tennessee
 
THE SURGICAL CENTER OF THE TREASURE COAST, L.L.C.
Florida
 
Thomas Johnson Surgery Center, LLC
Maryland
 
Thousand Oaks Endoscopy Center, LLC
California
 
Three Rivers Holdings, Inc.
Delaware
 
Three Rivers Surgical Care, L.P.
Tennessee
 
Tmesys, LLC
Florida
 
Topimagem Diagnóstico por Imagem Ltda.
Brazil
 
Trails Edge Surgery Center, LLC
Florida
 





Travel Express Incorporated
Maryland
 
TriMed, LLC
Utah
 
Trio Motion, LLC
Delaware
 
Tucson Arizona Surgical Center, LLC
Arizona
 
U.S. Behavioral Health Plan, California
California
OptumHealth Behavioral Solutions of California
UHC Finance (Ireland) Unlimited Company
Dublin
 
UHC Global Health Services BC Ltd.
British Columbia
 
UHC International Services, Inc.
Delaware
 
UHC of California
California
PacifiCare
PacifiCare of California
Secure Horizons
UnitedHealthcare of California
UHCFI LLC
Delaware
 
UHCG – FZE
Dubai
 
UHCG Holdings (Ireland) Limited
Ireland
 
UHCG Services (Ireland) Limited
Ireland
 
UHG Brasil Participações S.A.
Brazil
 
UHIC Holdings, Inc.
Delaware
 
UMR, Inc.
Delaware
Fiserv Health - Wausau Benefits
UMR
Unidad Médica Diagnóstico S.A.
Colombia
 
Unimerica Insurance Company
Wisconsin
Unimerica Life Insurance Company
Unimerica Life Insurance Company of New York
New York
 
Unison Administrative Services, LLC
Pennsylvania
 
Unison Health Plan of Delaware, Inc.
Delaware
UnitedHealthcare Community Plan
United Behavioral Health
California
Life Strategies
Optum Idaho
OptumHealth Behavioral Solutions
Plan 21, Incorporated
Plan 21, INCORPORATED
United Behavioral Health (Inc.)
United Behavioral Health, Inc.
United Behavioral Health of New York, I.P.A., Inc.
New York
 
United Health Foundation
Minnesota
United Health Hospice Foundation
United HealthCare Services, Inc.
Minnesota
AmeriChoice
Center for Health Care Policy and Evaluation
EverCare
Health Professionals Review
Healthmarc
HealthPro
Institute for Human Resources
Optum
UHC Management Company
UHC Management Company, Inc.
United HealthCare Corporation
United HealthCare Management Company, Inc.
United HealthCare Management Services
United HealthCare Services of Minnesota
United HealthCare Services of Minnesota, Inc.
United Resource Networks
United Resource Networks, Inc.
UnitedHealthcare MedicareStore
United Resource Networks IPA of New York, Inc.
New York
 





UnitedHealth Advisors, LLC
Maine
UnitedHealthcare
UnitedHealth Group Incorporated
Delaware
UnitedHealth Group
UnitedHealth Group International Finance (Ireland) Unlimited Company
Ireland
 
UnitedHealth Group International GP
Grand Cayman
 
UnitedHealth Group International L.P.
Grand Cayman
 
UnitedHealth International, Inc.
Delaware
 
UnitedHealth Military & Veterans Services, LLC
Delaware
 
UnitedHealth UK Limited
United Kingdom
 
UnitedHealthcare Benefits of Texas, Inc.
Texas
PacifiCare
Secure Horizons
UnitedHealthcare Benefits Plan of California
California
 
UnitedHealthcare Children's Foundation, Inc.
Maryland
 
UnitedHealthcare Community Plan of California, Inc.
California
 
UnitedHealthcare Community Plan of Georgia, Inc.
Georgia
 
UnitedHealthcare Community Plan of Ohio, Inc.
Ohio
 
UnitedHealthcare Community Plan of Texas, L.L.C.
Texas
United Healthcare - Texas
UnitedHealthcare Comminity Plan
UnitedHealthcare Community Plan, Inc.
Michigan
 
UnitedHealthcare Consulting & Assistance Service (Beijing) Co., Ltd.
China
 
UnitedHealthcare Europe S.á r.l.
Luxembourg
 
UnitedHealthcare Global Canada Limited
Alberta
UnitedHealthcare Global
UnitedHealthcare Global Medical (UK) Limited
United Kingdom
 
UnitedHealthcare India Private Limited
India
 
UnitedHealthcare Insurance Company
Connecticut
UnitedHealthcare Community Plan
UnitedHealthOne
UnitedHealthcare Insurance Company of Illinois
Illinois
 
UnitedHealthcare Insurance Company of New York
New York
 
UnitedHealthcare Insurance Company of the River Valley
Illinois
 
UnitedHealthcare Insurance Designated Activity Company
Ireland
 
UnitedHealthcare Integrated Services, Inc.
Arizona
UnitedHealthcare Community Plan
UnitedHealthcare International Asia, LLC
Delaware
 
UnitedHealthcare International I B.V.
Netherlands
 
UnitedHealthcare International II S.á r.l.
Luxembourg
 
UnitedHealthcare International III B.V.
Netherlands
 
UnitedHealthcare International III S.á r.l.
Luxembourg
 
UnitedHealthcare International IV B.V.
Netherlands
 
UnitedHealthcare International IV S.á r.l.
Luxembourg
 
UnitedHealthcare International VI S.à r.l.
Luxembourg
 
UnitedHealthcare International VII S.à r.l.
Luxembourg
 
UnitedHealthcare International VIII S.à r.l.
Luxembourg
 
UnitedHealthcare International X S.à r.l.
Luxembourg
 
UnitedHealthcare Life Insurance Company
Wisconsin
UnitedHealthOne
UnitedHealthcare of Alabama, Inc.
Alabama
 
UnitedHealthcare of Arizona, Inc.
Arizona
 
UnitedHealthcare of Arkansas, Inc.
Arkansas
Complete Health





UnitedHealthcare of Colorado, Inc.
Colorado
MetraHealth Care Plan
UnitedHealthcare of Florida, Inc.
Florida
Community and State Plan of Florida
UnitedHealthcare Community Plan
UnitedHealthcare Community Plan of Florida
UnitedHealthcare of Georgia, Inc.
Georgia
United HealthCare of Georgia
UnitedHealthcare of Illinois, Inc.
Illinois
 
UnitedHealthcare of Kentucky, Ltd.
Kentucky
United HealthCare of Kentucky, L.P.
UnitedHealthcare of Louisiana, Inc.
Louisiana
UnitedHealthcare Community Plan
UnitedHealthcare of Mississippi, Inc.
Mississippi
 
UnitedHealthcare of New England, Inc.
Rhode Island
 
UnitedHealthcare of New Mexico, Inc.
New Mexico
 
UnitedHealthcare of New York, Inc.
New York
UnitedHealthcare Community Plan
UnitedHealthcare of North Carolina, Inc.
North Carolina
 
UnitedHealthcare of Ohio, Inc.
Ohio
 
UnitedHealthcare of Oklahoma, Inc.
Oklahoma
PacifiCare
PacifiCare Health Options
PacifiCare of Oklahoma
Secure Horizons
UnitedHealthcare of Oregon, Inc.
Oregon
 
UnitedHealthcare of Pennsylvania, Inc.
Pennsylvania
UnitedHealthcare Community Plan
UnitedHealthcare Community Plan for Families
UnitedHealthcare Community Plan for Kids
UnitedHealthcare Community Plan of Pennsylvania
UnitedHealthcare Dual Complete
UnitedHealthcare of Texas, Inc.
Texas
 
UnitedHealthcare of the Mid-Atlantic, Inc.
Maryland
 
UnitedHealthcare of the Midlands, Inc.
Nebraska
 
UnitedHealthcare of the Midwest, Inc.
Missouri
 
UnitedHealthcare of Utah, Inc.
Utah
UnitedHealthcare of Idaho, Inc.
UnitedHealthcare of Washington, Inc.
Washington
PacifiCare
Secure Horizons
UnitedHealthcare
UnitedHealthcare Community Plan
UnitedHealthcare of Wisconsin, Inc.
Wisconsin
UnitedHealthcare of Wisconsin - Personal Care Plus
UnitedHealthcare Plan of the River Valley, Inc.
Illinois
 
UnitedHealthcare Service LLC
Delaware
 
UnitedHealthcare Services Company of the River Valley, Inc.
Delaware
 
UnitedHealthcare Specialty Benefits, LLC
Maine
UnitedHealthcare Specialty Benefits
WorkUp, LLC
UnitedHealthcare, Inc.
Delaware
 
UpFront Insurance Agency, LLC
Minnesota
 
Upland Holdings, LLC
California
 
Upland Outpatient Surgical Center, L.P.
California
 
Urgent Care Holdings, Inc.
Delaware
 
Urgent Care MSO, LLC
Delaware
 
Urology Associates of North Texas, P.L.L.C.
Texas
 
USMD Administrative Services, L.L.C.
Texas
 





USMD Affiliated Services
Texas
USMD Physician Services
USMD Holdings, Inc.
Delaware
 
USMD Inc.
Texas
 
USMD PPM, LLC
Texas
 
Valley Hospital, L.L.C.
Washington
 
Valley Physicians Network, Inc.
California
 
VERTA MANAGEMENT SERVICES, LLC
Delaware
 
Vida Tres Internacional S.A.
Chile
 
Vidaintegra S.A.
Chile
 
Virtual Therapeutics Corporation
Delaware
 
Wauwatosa Outpatient Surgery Center, LLC
Delaware
 
Wauwatosa Surgery Center, Limited Partnership
Wisconsin
 
Wayland Square Surgicare Acquisition, L.P.
Rhode Island
 
Wayland Square Surgicare GP, Inc.
Rhode Island
 
WebInsure Benefits, LLC
Delaware
 
WellMed Medical Management of Florida, Inc.
Florida
Preferred Care Partners Medical Group of Hialeah
Preferred Care Partners Medical Group of Little Havana
Preferred Care Partners Medical Group of Red Road
Preferred Care Partners Medical Group of West Hialeah
Preferred Care Partners Medical Group of Westchester
WellMed at 9th Ave. North
WellMed at Bartow
WellMed at Downtown Clearwater
WellMed at Fort Pierce
WellMed at Haines City
WellMed at Haverford Ave.
WellMed at Lake Copeland
WellMed at Longwood
WellMed at Oak Commons
WellMed at Plant City - Family Practice Center
WellMed at Port St. Lucie West
WellMed at Saint Isabel
WellMed at SE Lakeland
WellMed at Sebastian
WellMed at South Parsons
WellMed at South Stuart
WellMed at Southwest Orlando
WellMed at Stonerock Lake
WellMed Medical Group
WellMed Medical Management, Inc.
Texas
DataRaps, Inc.
HealthRight / ITC Rosa Verde
Silver Life Fitness
WellMed Networks - DFW, Inc.
Texas
WNI-DFW
West Coast Endoscopy Holdings, LLC
Delaware
 
Western Connecticut Orthopedic Surgical Center, LLC
Connecticut
 
WESTMED Practice Partners LLC
Delaware
 
WillowB Labs LLC
Delaware
 
Wilmington ASC, LLC
North Carolina
 
Winchester Endoscopy, LLC
Illinois
 
Winter Park, LLC
Tennessee
 
XLHealth Corporation
Maryland
XLHealth





XLHealth Corporation India Private Limited
India
 
Your Health Options Insurance Services, Inc.
California
 





Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-216150 on Form S-3, No. 333-105877 on Form S-4, Nos. 333-174436, 333-174437, 333-193962, 333-205824, 333-205826, 333-221642, 333-224253, and 333-224254 on Form S-8 and Post-Effective Amendment on Form S-8 to Registration Statement File No. 333-216153 on Form S-4 of our reports dated February 12, 2019, relating to the consolidated financial statements and financial statement schedules of UnitedHealth Group Incorporated and subsidiaries, and the effectiveness of UnitedHealth Group Incorporated Group's internal control over financial reporting, appearing in this Annual Report on Form 10-K of UnitedHealth Group Incorporated for the year ended December 31, 2018.

 
/S/ DELOITTE & TOUCHE LLP
 
Minneapolis, Minnesota
February 12, 2019



Exhibit 24.1

FORM 10-K POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marianne D. Short, Dannette L. Smith and Faraz A. Choudhry, and each of them, his or her true and lawful attorneys-in-fact and agents, each acting alone, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign an Annual Report on Form 10-K for the year ended December 31, 2018 for UnitedHealth Group Incorporated, and any and all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, each acting alone, or each of their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, the undersigned have executed this Power of Attorney as of the date set forth below.
/s/ William C. Ballard, Jr.
 
/s/ F. William McNabb III
William C. Ballard, Jr.
 
F. William McNabb III
Director
 
Director
Dated: February 12, 2019
 
Dated: February 12, 2019
 
 
 
/s/ Richard T. Burke
 
/s/ Valerie Montgomery Rice, M.D.
Richard T. Burke
 
Valerie Montgomery Rice, M.D.
Director
 
Director
Dated: February 12, 2019
 
Dated: February 12, 2019
 
 
 
/s/ Timothy P. Flynn
 
/s/ Glenn M. Renwick
Timothy P. Flynn
 
Glenn M. Renwick
Director
 
Director
Dated: February 12, 2019
 
Dated: February 12, 2019
 
 
 
/s/ Stephen J. Hemsley
 
/s/ Gail R. Wilensky, Ph.D.
Stephen J. Hemsley
 
Gail R. Wilensky, Ph.D.
Director
 
Director
Dated: February 12, 2019
 
Dated: February 12, 2019
 
 
 
/s/ Michele J. Hooper
 
 
Michele J. Hooper
 
 
Director
 
 
Dated: February 12, 2019
 
 






EXHIBIT 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
Certification of Principal Executive Officer

 I, David S. Wichmann, certify that:

1.
I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”);
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 
February 12, 2019
/s/    DAVID S. WICHMANN
 
David S. Wichmann
Chief Executive Officer
 
 






Certification of Principal Financial Officer

I, John F. Rex certify that:

1.
I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”);
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


 
February 12, 2019
/s/ JOHN F. REX
 
John F. Rex
Executive Vice President and Chief Financial Officer






EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Certification of Principal Executive Officer
In connection with the report of UnitedHealth Group Incorporated (the “Company”) on Form 10-K for the period ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David S. Wichmann, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
February 12, 2019
/s/    DAVID S. WICHMANN
 
David S. Wichmann
Chief Executive Officer

Certification of Principal Financial Officer
In connection with the report of UnitedHealth Group Incorporated (the “Company”) on Form 10-K for the period ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John F. Rex, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
February 12, 2019
/s/ JOHN F. REX
 
John F. Rex
Executive Vice President and Chief Financial Officer